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Summary 
 Hereditary haemophilia A (HA), an X-linked bleeding disorder, is caused by 
mutations in the coagulation factor VIII gene  (FVIII abbreviates protein, gene 
symbol F8). The aim of this study was (1) to characterise F8 mutations in HA 
cohort from Pakistan, (2) to investigate whether in vitro thrombin generation (TG) 
differs according to mutation type, and (3) to compare haemophilia joint health 
score (HJHS) and Gilbert score with severity, age, TG and underlying mutation in 
HA cohort which had minimal access to haemostatic replacement therapy.  
Methods: One hundred HA individuals and 100 healthy controls were recruited; 
clinical details were recorded. Results: Phenotypic measurements were re-evaulated 
in Cardiff; the essential regions of F8 were screened. Ninty two individuals were 
diagnosed with HA, 7 with haemophilia B and 1 was normal. The F8 defects were 
characterised and comprised point mutations, inversions and frameshifts. Thirty 
novel variants were identified. No significant difference was observed in vitro TG 
between severes with null mutation and those with a missense change. HJHS was 
strongly correlated with Gilbert score (r =0.98), both were siginificantly higher in 
severe compared with nonsevere before the age of 12 years (P≤0.01) but not 
thereafter. According to developmental age (<12 years, 12-16 years and > 16 years), 
both scores were significantly lower in the youngest group (P≤0.001). In severes 
there was no correlation between in vitro TG and joint score, no significant 
difference was observed for either joint score according to the underlying mutation 
type. Whereas in nonseveres, negative correlation between in vitro TG and joint 
score was observed. Conclusions:  F8 defects in Pakistan is heterogenous; in severe 
HA in vitro TG are not influenced by underlying mutation. Haemophilic arthropathy 
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is correlated with severity and age; among severes, joint health scores did not relate 
to either the underlying mutation or in vitro TG. 
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Chapter 1 
Introduction 
 
 Haemostasis is the process by which blood loss is prevented. Three 
major stages of haemostasis comprise primary haemostasis (formation of the 
platelet rich soft clot), secondary haemostasis (fibrin formation) and tertiary 
haemostasis (fibrinolysis, breakdown of the clot). In primary haemostasis 
platelets adhere, activate and aggregate, the activation brought about by 
various agonists. Secondary haemostasis involves a series of reactions that 
ultimately generate thrombin which converts soluble fibrinogen into insoluble 
fibrin, the structural component of a blood clot. Tertiary haemostasis is the 
formation of plasmin (clot lysis enzyme), which is responsible for fibrinolysis 
(1). 
 
1.1.  Primary Haemostasis 
 
1.1.1. Platelet Adhesion   
 When a blood vessel is damaged, the sub-endothelial structures are 
exposed and platelets adhere to the vessel wall. Adhesion molecules are present 
in the vessel wall which causes the binding of platelets to the sub-endothelium. 
These include fibronectin, von Willebrand factor (VWF), laminin and nidogen. 
Several platelet glycoprotein (GP) receptors are involved in binding to these 
adhesion molecules. Platelet GP receptors include GPIb-IX-V, GPIIb/IIIa 
(αIIbβ3), GPIa/GPIIa (α2β1) and GPVI (2).  
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 One of the most important interactions for platelet adhesion to the vessel 
wall is that involving VWF, a multimeric protein synthesized by endothelial 
cells and megakaryocytes. It is stored in the Weibel-Palade bodies of endothelial 
cells and α-granules of platelets. The latter bind to VWF via the GPIb-IX-V 
complex which consists of four subunits, GPIbα, GPIbβ, GPIX and GPV at a 
ratio of 2:2:2:1. VWF interacts with the GPIbα of the complex and this leads to 
platelet activation, resulting in cytoskeleton rearrangement, tyrosine 
phosphorylation and calcium mobilisation (3-5). 
 The interaction between platelets and VWF initiates signal transduction 
events that lead to activation of platelet GPIIb/IIIa, which becomes competent to 
bind VWF or fibrinogen to mediate platelet aggregation. Like other platelet GP 
receptors, GPIIb/IIIa is a heterodimer with an alpha (αIIb) and a beta (β3) subunit; 
it binds to fibrinogen, VWF, fibronectin and vitronectin through the beta 
subunit. 
 Platelet adhesion and aggregation are dependent upon shear, a measure of 
gradient of flow velocity relative to the distance from the vessel wall. There are 
two important mechanisms that give rise to adhesion and aggregation at the low 
and very high shear rates found respectively in veins and in stenosed arteries. At 
shear rates of 500/s, which are found in venules and larger veins, platelets are 
able to adhere directly to exposed sub-endothelial matrix proteins and maintain 
stable adhesion independent of VWF and GPIb-IX-V. At shear rates of 
100,000/s and above, which are found in stenosed vessels, adhesion and 
aggregation are facilitated entirely by the interaction of soluble and immobilized 
VWF with GPIb-IX-V and GPIIb/IIIa respectively (6, 7). 
3 
 
 Collagen is an important thrombogenic component of the sub-endothelial 
matrix. Nine forms of collagen have been described within the vessel wall (types 
I and III are more predominant in the deeper layer and type VI in the more 
superficial region of the vessel wall). GPIa/GPIIa and GPVI are the primary 
receptors for collagen; both play a prominent role in platelet adhesion. Platelet 
adhesion promoted by GPIa/GPIIa is a further interaction leading to the 
activation of GPIIb/IIIa. When platelets are activated, the surface expression of 
GPVI is increased. GPVI mainly binds to collagen type III and has an essential 
role in platelet adhesion to the vessel wall. 
 Application of high-resolution imaging technology has revealed that 
platelets translocate in a stop-start manner through sliding rather than rolling and 
this assists to minimize the drag forces on adhesive bonds. This stop-start 
phenomenon involves many of the interactions discussed above. Once platelets 
adhere to the vessel wall, they activate and spread (8). 
 
1.1.2. Platelet spreading 
  
 When platelets come into contact with a surface, they undergo a 
characteristic set of morphological changes known as spreading. The initial 
shape change of platelets involves the generation of finger-like projections 
known as filopodia. Filopodia grow from the periphery of the platelets and then 
there is subsequent formation of lamellipodia which fill the areas between 
adjacent filopodia. Actin-myosin stress fibres then serve to strengthen the spread 
of platelets. As these events progress, granules and organelles are squeezed into 
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the centre of the platelet, resulting in a characteristic “fried egg” appearance. In 
combination, the formation of actin-myosin stress fibres and platelet spreading 
reinforce and secure the growing thrombus against flow and shear forces of the 
vascular system (9). 
 
1.1.3. Granule secretion, thromboxane A2 formation and platelet aggregation 
 
 Adhesion of platelets to collagen is followed by aggregation.  Platelet 
aggregation can be initiated by a variety of biological agonists in vivo, including 
adenosine diphosphate (ADP), thrombin, collagen and thromboxane A2 (TxA2). 
 There are two pathways for platelet aggregation, one involving TxA2 and 
the other an increase in the concentration of free calcium in the cytoplasm.  An 
important enzyme in the later pathway is phospholipase C (PLC), an enzyme 
that hydrolyses fatty acid off phospholipids. PLC is further classified into PLCβ, 
γ and δ. PLCγ hydrolyses phosphatidylinositol (PI) yielding water soluble 
inositol-1, 4, 5-triphosphate (Ins-1, 4, 5- P3) and diacylglycerol.  Ins-1, 4, 5-P3 
binds to intracellular calcium channels, as the result of this binding the channels 
open and allow an influx of calcium into the cytoplasm. This leads to an increase 
in the level of free cytoplasmic calcium.
 
The elevated calcium level allows 
different processes to accelerate, including calmodulin-dependent activation 
kinase, activation of protein kinase C (PKC) and activation of phospholipase A2 
(PLA2). 
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 When PLA2 is activated, arachidonic acid (AA) is released, and within the 
platelet this acts as a substrate for cyclooxygenase-1 and also lipooxygenases 12 
and 15. Cyclooxygenase-1 transforms AA into the prostaglandin (PG) G2 and 
PGH2, which is converted to the active TxA2 within the platelet. TxA2 is released 
and acts as a powerful platelet aggregator and vasoconstrictor.  
 Platelets contain several types of granules in which bioactive constituents 
are sequestered. These include dense bodies (containing serotonin, adenosine 
triphosphate, ADP, and calcium), α-granules (containing fibrinogen, α1-
antitrypsin, VWF, FV, high molecular weight kininogen (HMWK), fibronectin, 
platelet factor 4, thromboglobin, protein S, tissue factor pathway inhibitor 
(TFPI) and platelet derived growth factor), lysosomes and peroxisome, although 
the significance of the latter two is unclear. Fusion of α-granules with the 
platelet plasma membrane has the potential to increase the expression of 
GPIIb/IIIa as well as P-selectin on its surface. 
 Additional changes in platelet phospholipids bring about a reorientation of 
the lipid bilayer, a mechanism called flip-flop. This translocates procoagulant 
phospholipids in the intact platelet from inside to outside.  As the result of this 
translocation, platelets become procoagulant. All of the above mentioned 
mechanisms ultimately trigger the cross linking of platelets through bivalent and 
multivalent ligands and produce platelet aggregation.  
 The processes of platelet adhesion to sub-endothelium, discharge of 
granular contents, and platelet aggregation all overlap and can rapidly produce a 
platelet plug and cessation of bleeding. However, fibrin is necessary for the 
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longer term prevention of bleeding and its formation occurs in parallel with 
platelet plug development (10-13). 
 
1.2.   Secondary Haemostasis 
 
 The coagulation system is composed of a series of serine proteases and their 
cofactors which interact on the phospholipid surface of activated platelets to form a 
stable fibrin clot. Historically, coagulation was divided into extrinsic and intrinsic 
pathways respectively involving tissue factor (TF)-factor VII (FVII) and surface-
contact factors. The penultimate step of both pathways is the conversion of 
prothrombin (FII) to thrombin (FIIa) which subsequently converts fibrinogen to 
fibrin. 
 
1.2.1. Extrinsic Pathway 
 
 The coagulation cascade is activated when blood comes into contact with TF 
that is either constitutively presents in tissues surrounding blood vessels or that is 
exposed on damaged or stimulated cells such as monocytes. TF is a lipoprotein 
present in almost all tissues in different concentrations, particularly high in lung, 
brain, bone marrow, kidney and placenta. 
 When there is a disruption of vascular integrity, blood is immediately 
exposed to cells expressing TF, leading to initiation of coagulation. Circulating 
zymogen FVII is exposed to membrane bound TF, becomes activated to the active 
serine protease (FVIIa) by an unknown mechanism, leading to the formation of a 
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high affinity TF-FVIIa complex. This complex then converts coagulation factors IX 
(FIX) and X (FX) to their activated forms (FIXa and FXa respectively).  FXa, in 
combination with its cofactor, activated coagulation factor V (FVa), converts 
prothrombin to thrombin (14). 
 
1.2.2. Intrinsic Pathway 
 
 The intrinsic pathway is initiated by activation of coagulation factor XII 
(FXII) to FXIIa by the HMWK-kallikrein complex. FXIIa then activates 
coagulation factor XI (FXI) to FXIa and this converts factor IX (FIX) to FIXa. The 
latter forms an activation complex (tenase complex) with its cofactor, activated 
factor VIII (FVIIIa), that binds with FX at the phospholipid surface of activated 
platelets. The tenase complex converts FX to its activated form FXa, which itself 
takes part in another activation complex, the prothrombinase complex. The latter 
comprises FXa and FVa, and converts prothrombin to thrombin. FV and FVIII 
circulate as inactive procofactors, and are activated to functional cofactors by the 
proteolytic action of thrombin. 
 Thrombin cleaves fibrinogen in the N terminal regions of its alpha and beta 
chains, releasing fibrinogen peptides A and B and producing fibrin monomers. 
These monomers polymerise to form long strands of fibrin and become cross-linked 
by activated coagulation factor XIII (FXIIIa), to give a stable blood clot. This 
crosslinking increases the strength of the clot and helps to prevent its removal by 
flowing blood. FXIII itself is activated by thrombin  
(15, 16). 
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1.2.3. The Cell Based Model of Haemostasis 
 
 The cell based model proposes that secondary haemostasis occurs in three 
overlapping steps – initiation, amplification, and propagation – and takes place on 
different cell surfaces, leading to the formation of thrombin.  
 
1.2.3.1.  Initiation Phase  
 
 During initiation, the TF pathway remains constantly active in a basal state 
and generates low levels of activated coagulation factors. The generation of a small 
amount of thrombin continues to take place outside the vasculature even in a healthy 
individual. In effect, the initial step of coagulation is happening all of the time, but 
clot formation does not proceed until injury or inflammation occurs to the blood 
vessel. The TF pathway is regulated by tissue factor pathway inhibitor (TFPI) which 
binds to any factor Xa and the TFPI/FXa complex inhibits TF/FVIIa.  
 
1.2.3.2.  Amplification Phase 
  
 Following vessel damage, important components of the haemostatic system 
(platelets, FVIII and VWF) come into contact with the limited amount of thrombin 
that is generated on TF-bearing cells in the initiation phase. Platelets attach to the 
site of injury, make a plug and become fully activated by thrombin and also by 
contact with VWF and collagen. The thrombin produced in the initiation phase also 
plays an important role in activating other coagulation factors. It activates FV and is 
also responsible for both the activation of FVIII and its release from VWF. 
Thrombin also activates FXI which binds to the surface of activated platelets. At the 
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end of the amplification phase, activated platelets are coated with active coagulation 
factors, and the process moves to the propagation phase. 
 
1.2.3.3.  Propagation Phase 
 
 On the surface of activated platelets, FIXa combines with its cofactor FVIIIa 
to give the tenase complex that activates FX. FXa immediately combines with its 
cofactor FVa, forming the prothrombinase complex that converts prothrombin to 
thrombin. These reactions are extremely efficient on the surface of activated 
platelets and lead to a rapid production of a large amount of thrombin (the thrombin 
burst). Thrombin causes the cleavage of fibrinogen to fibrin monomers, which 
polymerise to reinforce the initial platelet plug and give a stable clot (17-19). 
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Figure 1.1: A cell-based model of coagulation. The three phases of coagulation 
(initiation, amplification and propagation) occur on different cell surfaces. Initiation 
phase occurs on the tissue factor bearing cell, amplification phase on the platelet as 
it becomes activated and propagation phase occur on the activated platelet surface.  
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1.3. Fibrinolysis 
 
 The principal function of the fibrinolytic system is to ensure that excess 
fibrin deposition does not occur. Fibrinolysis is a vital, localized, surface-bound 
phenomenon in which fibrin choreographs its own destruction. The fibrinolytic 
system is composed of plasminogen (PLG), its activated form plasmin, several 
endogenous PLG activators (tissue and plasma derived) and a number of inhibitors.  
 PLG activation is a two-step process, in which tissue plasminogen activator 
(t-PA) converts it into Glu-plasmin. Glu-plasmin is functionally ineffective and it 
converts auto- catalytically to Lys-plasmin, the latter interacts with fibrin more 
efficiently. The major physiological targets of plasmin are fibrin and fibrinogen, 
which give a series of fragments of gradually decreasing molecular size, fibrin 
degradation product (FDP) (20, 21). 
1.4.  Anticoagulation 
 
 Physiological anticoagulants are divided into two main groups; one inhibits 
the serine proteases of coagulation and the other targets the destruction of FVa and 
FVIIIa. Physiological inhibitors include TFPI, α2-macroglobulin, antithrombin 
(AT), heparin cofactor II, α1-antitrypsin, nexin 2, C1-esterase inhibitor, α2-
antitrypsin.  Protein C and protein S are engaged in the destruction of FVa and 
FVIIIa (22). 
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1.5.   Haemophilia A and B 
 
 Haemophilia A and B are bleeding disorders caused by a deficiency of FVIII 
and FIX respectively, and are classified into inherited and acquired types. Inherited 
haemophilia A and B are X-linked, respectively with a frequency of 1 in 10,000 and 
1 in 50,000 per capita in the general population (23). Haemophilia A is 
characterised as mild (>0.05 IU/mL), moderate (0.01-0.05 IU/mL) and severe 
(<0.01 IU/mL) according to the residual amount of FVIII coagulant activity (FVIII: 
C) present in the blood of the affected individual. Acquired haemophilia A and B 
are characterised by the production of autoantibodies against the relevant 
coagulation factor. The annual incidence of acquired haemophilia A is 1.5 per 
million and unknown in haemophilia B (23). 
 
1.5.1. Structure of the Gene Encoding FVIII  
 
The human gene encoding FVIII (official gene symbol F8) is approximately 
186 kilobases (kb) long, located towards the telomere of the long arm of the X 
chromosome (Xq28). The gene contains 26 exons, 24 of which vary in length from 
69 to 262 base pairs (bp), the remaining two larger exons (14 and 26) contain 3,106 
and 1,958 bp respectively. The F8 mRNA is approximately 9 kb in length, 
comprises a short 5-untranslated region (5'-UTR), an open reading frame (ORF) 
plus stop codon, and a long 3'-UTR (150, 7056, 1806 bp respectively) (24, 25). 
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1.5.2. Structure and Function of FVIII 
 
 Following translation, the signal peptide is proteolytically removed to give a 
mature FVIII molecule of 2332 amino acids (molecular weight 264,763 Daltons). 
Mature FVIII has a domain structure arising from internal homologies and unique 
regions within the protein: NH2-A1-a1-A2-a2-B-a3-A3-C1-C2-COOH (25). 
Activated FVIII comprises two chains, heavy chain (HCh) and light chain (LCh). 
The HCh consists of the A1, A2 and B domains (amino acids 1-336, 373-719 and 
741-1648 respectively). The LCh contains the A3, C1 and C2 domains (residues 
1690-2019, 2020-2172 and 2173-2332 respectively). The C-terminal region of the 
A1 and A2 domains and the N-terminal portion of the A3 domain contain a high 
proportion of negatively charged residues and are called acidic region a1, a2 and a3 
respectively (26, 27). Non-activated FVIII is a multidomain structure in which A1 
and A3 domains are non-covalently linked via a metal ion-mediated interaction. The 
C2 domain of FVIII is responsible for its attachment with activated platelet surface, 
thrombin, FXa. The a3 and A3 domains are respectively involved with the binding 
VWF and FIXa. The B domain is not directly involved in FVIII procoagulant 
activity but it has an important role in intracellar processing and trafficking (28, 29). 
 Immediately after release into the circulation, FVIII as an inactive precursor 
forms a tight noncovlant complex with VWF. This interaction is mediated by the 
LCh with contributions from the a3 region (the major binding site) and parts of the 
C2 and C1 domains. The HCh does not directly bind to VWF, however in its 
presence, the interaction of FVIII with VWF is increased 10-fold. This interaction 
results in significant stabilization and survival of FVIII in the circulation (30).  
 Activation of FVIII is required for its cofactor function in the tenase 
complex; it has no detectable cofactor activity in the inactivated form. In the tenase 
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complex, FVIIIa acts as a cofactor for FIXa in the conversion of FX to FXa. In the 
absence of cofactor, FIXa has a very low catalytic activity. Thrombin and FX are 
two major physiological activators of FVIII, both proteases cleave the cofactor 
within the HCh at Arg372 (between the A1 and A2 domains), at Arg740 (between 
the A2 and B domains) and also within the LCh at Arg1689. This results in a 
heterotrimer (A1/A2/A3-C1-C2) which is the active form of the cofactor (31). 
Cleavage at Arg1689 results in the removal of a3, which is vital for the release of 
FVIIIa from VWF. After this dissociation, FVIIIa effectively binds to the 
phospholipid (PL) surface and to FIXa during assembly of the tenase complex. 
 The cofactor activity of FVIIIa in the tenase complex requires three 
important interactions: binding to the PL membrane, FIXa and FX. There are high 
and low-affinity interactions between FVIIIa and FIXa which are conferred 
respectively by the A3 domain in the LCh and the A2 domain in the HCh. These 
interactions stabilize FVIIIa within the tenase complex.  
 The activated heterotrimeric FVIII is highly unstable, there is a tendency for 
spontaneous dissociation of the A2 subunit. There is a rapid loss of the A2 subunit 
because it is weakly associated with the A1/A3-C1-C2 dimer through low affinity 
electrostatic interaction and loss of this domain is concomitant with the loss of 
FVIII activity. In addition FVIIIa is susceptible to proteolytic inactivation by 
activated protein C (APC) (32, 33).  
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Figure 1.2: Structure of coagulation FVIII. Mature FVIII molecule consists of 2332 
amino acids. Activated FVIII constitute of two chains, heavy chain (A1, A2 and B 
domains) and light chain (A3, C1 and C2 domains). The C2 domain of FVIII is 
involved for its attachment with FXa, activated platelet surface and thrombin, the a3 
and A3 domains are respectively involved with the binding VWF and FIXa. The B 
domain of FVIII is not directly involved in its procoagulant activity.  Two major 
physiological activators of FVIII are thrombin and FX, both proteases cleave the 
cofactor within the heavy chain at Arg372, at Arg740 and also within the light 
chain. 
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1.5.3. Clearance of FVIII 
 
 Removal of FVIII from the circulation involves a receptor mediated 
catabolic pathway. FVIII is bound and catabolized by low-density lipoprotein 
receptor-related protein (LRP). LRP is a multiligand hepatic receptor that belongs to 
the low-density lipoprotein (LDL) receptor superfamily (34). These are endocytic 
receptors involved in removal and clearance of diverse molecules. LRP-mediated 
clearance of FVIII is facilitated by cell-surface heparan sulphate proteoglycans 
(HSPGs), which are one of the major glycoprotein components of the extracellular 
matrix. The A2 domain of the HCh, and the C2 and A3 domains of the LCh are 
involved in the interaction of FVIII with LRP (35). 
 
1.5.4. Pathophysiology 
 
 F8 defects associated with haemophilia A are divided into several 
categories: gross gene rearrangements, deletions or insertions of genetic sequence of 
a size varying from one base pair to entire gene, single DNA base substitutions 
(point mutations) resulting in either an amino acid replacement (missense) or a 
premature termination codon (non-sense) and RNA splicing defects.   
1.5.4.1.  Intron 22 Inversion 
 
 About 50 % of severe haemophilia A individuals have an inversion 
involving intron 22 of F8 (Inv22).  Intron 22 is extremely large (approximately 32 
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kb), contains a GC-rich region and two transcribed genes (F8A and F8B). A 9.5 kb 
sequence (int22h-1) within the intron 22 GC-rich region is replicated at two 
positions approximately 300 kb (proximal, int22h-2) and 400 kb (distal, int22h-3) 
telomeric to F8. Inv22 involves homologous recombination between the intragenic 
int22h-1 and one of the two extragenic homologs (int22h-2 or int22h-3). This 
recombination occurs during the meiosis of spermatogenesis, resulting in a large 
inversion in which exons 1-22 are translocated away from exons 23-26, thereby 
disrupting F8.  According to which extragenic homolog is involved, the inversion is 
either proximal or distal. The latter is involved in the majority of cases (15, 36-38). 
 
 
 
 
 
 
 
 
 
Figure 1.3:  F8 inversion and disruption mediated by the F8A gene in intron 22. The 
genomic organization of the F8 consists of the three copies of the F8A genes (two 
upstream of extragenic F8 and one intragenic). The direction of transcription of F8 
is indicated by arrow. This recombination results in an inversion and disruption of 
the F8. Intron 22 inversion is associated with severe haemophilia A.  
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Figure 1.4:  Intron 22 proximal and distal inversion of F8.  
 
1.5.4.2.  Intron 1 Inversion 
 
 There is another recombination called the Intron 1 inversion (Inv1) which 
occurs in about 2-5 % of individuals with severe haemophilia A. This recombination 
involves a 1.0 kb sequence in intron 1 (int1h-1,) and a homologous sequence 
approximately 140 kb 5’ to F8 (int1h-2). As a result of this recombination, there is 
the separation of the promoter and exon 1 of F8 from the reminder of the gene (39). 
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1.5.4.3.   Single-base Substitutions in F8 
 
 Single nucleotide substitutions (point mutations) in F8 can result either in 
missense or nonsense changes. The online database for haemophilia A mutations 
(URL http://hadb.org.uk/) currently lists over 1800 individual reports of F8 variants 
from all over the world (time of writing 20/03/13). Missense mutations can be 
associated with mild or moderate disorder, less so with severe haemophilia A. In 
contrast, nonsense mutations are associated with severe haemophilia A. In addition 
to missense and nonsense mutations, single base substitutions can occur at 
conserved mRNA splice sites (splice site mutation) which interfere with RNA 
processing. Splice site mutations are found in association with mild, moderate and 
severe disorder (40-42).  
 Some mutations are recurrent however in more than 70 % of cases, they are 
unique to individuals. Interestingly, the clinical phenotype may differ for a given 
recurrent missense mutation in different individuals (43, 44).   
 
1.5.4.4.  Insertions and deletions 
 
 The international haemophilia A mutation database catalogues both F8 
insertions and deletions. F8 deletions are divided into large (>50 bp) and small (<50 
bp). A deletion has a high probability of destroying genetic function and there is a 
very high probability that the functional protein is not formed. Large deletions 
typically give rise to a clinically severe disorder with no measurable FVIII activity. 
Large and small deletions may cause frame-shift mutations which are generally 
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associated with severe haemophilia A, but in a few instances a moderate or mild 
disorder results (45-47).  
 Insertions are among the rarer F8 defects. The majority cause frame-shifts 
and are associated with severe haemophilia A (48, 49).  
 When a gene defect abolishes F8 expression, individuals are at risk of 
developing inhibitors in response to FVIII replacement therapy. It is therefore not 
surprising that inhibitor development is higher among individuals with a deletion or 
an insertion.  
 
1.5.5.  Clinical Presentation 
 
1.5.5.1.  Severity and Bleeding  
 
 The severity and frequency of bleeding in haemophilia A is inversely 
correlated with residual FVIII level.  Individuals with haemophilia A present with 
bleeding into joints, muscles or other soft tissue, either spontaneously or after 
trauma or surgery. Bruising and spontaneous bleeding, especially gastrointestinal 
and central nervous system are also typical of the features of haemophilia.  
 The main clinical presentation of severe haemophilia A is haemarthrosis 
(joint bleed), >90 % of all the bleeding occur in the joints and 80 % of 
haemarthrosis occur in the ankles, knees and elbows, however any joint can be the 
site of bleeding (50). Acute haemarthrosis usually start with discomfort and mild 
limitation of joint motion followed by pain, swelling and cutaneous warmth.  
Repeated episodes of haemarthrosis cause irreversible damage to joints which leads 
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to haemophilic arthropathy (a polyarticular disease characterized by joint pain, 
stiffness and severely limited range of motion).  
 Muscle bleeds can occur at any anatomical site, but in most cases, large load 
bearing groups of muscles (thigh, calf, posterior abdominal wall and buttocks) are 
involved. Bleeding into the forearm, calf or perineal muscles can lead to ischemic 
necrosis and contracture (51).  
 Haematuria is less common than joint and muscular bleeding in individuals 
with haemophilia A, but severely affected individuals may have one or two episodes 
per decade. These symptoms may be painless and resolve spontaneously, but in the 
case of heavy bleeding, may produce clot colic. 
 Central nervous system bleeding is uncommon, but can occur after a slight 
head injury and is an important cause of death in individuals with haemophilia A, 
especially those without access to factor VIII or IX. Gastrointestinal tract bleeding 
may present with haematemesis and melena  or rarely as an obstruction due to 
intramural haemorrhage (52). 
 Oropharyngeal bleeding is often seen in young children but is less common 
in adults; clinically it may be dangerous because it may extend through the soft 
tissue of the floor of the mouth and may lead to respiratory obstruction. Tongue 
bleeding after laceration may be persistent due to the fibrinolytic substances in the 
saliva.  
 In the untreated individual with haemophilia A, surgery and open trauma 
invariably lead to dangerous haemorrhage. If clots are formed, they are febrile, 
bulky and break off with renewed haemorrhage occurring irregularly over days and 
weeks. 
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 An individual with haemophilia A may present with bruising, but it remains 
superficial and self-limiting, and does not usually require treatment.  On the other 
hand, large extending ecchymosis may occasionally require treatment (53, 54). 
 
1.5.5.2.  Pathophysiology of Haemophilic Arthropathy 
 
 Mechanical, chemical and genetic factors are involved in the development of 
haemophilic arthropathy, which results in the fibrosis of synovial lining and 
disintegration of hyaline cartilage. Haemophilic arthropathy shows the 
characteristics of both inflammatory and degenerative disease in which the 
extravasation of blood into the joint cavities leads to chronic synovitis and cartilage 
destruction. Acute inflammation with the infiltration of polymorphonuclear cells 
and lymphocytes is followed by the extravasation of blood into the joint capsule. In 
about one week, this acute episode of haemarthrosis is resolved and blood is 
removed from the joint space by synovial lining cells and invading macrophages. 
The blood removal capacity is exceeded by repeated episodes of intra-articular 
bleeding and blood stays longer in the joint space. This leads to the deposition of 
iron containing red blood cells in the synovial membrane and progressive 
accumulation of iron as hemosiderin. This deposited iron is involved in both 
synovial and vascular cells proliferation in the sub-synovial layer.   
 Analysis of two biomarkers of bone turn over (cartilage oligomeric matrix 
protein and type II collagen telopeptides) confirmed that the articular cartilage is an 
early target for the development of this arthropathy (55-58) and changes in the 
composition of articular cartilage matrix are a prominent feature of this condition. 
Articular cartilage is composed of water, electrolytes and solid matrix – collagens 
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and proteoglycans – and its visco-elastic properties are mainly because of water 
flow through the solid matrix (59). The composition of proteoglycans across the 
articular surface varies according to location, patient age and compressive load. The 
continued presence of blood in a joint increases cartilage compliance, which may 
cause the loss of proteoglycans and the production of degenerative enzymes from 
iron-laden synovial and sub-synovial macrophages (60). In vitro, iron plays several 
roles: it stimulates synovial cell proliferation, may increase the c-myc proto-
oncogene expression and promotes DNA synthesis. Iron has an additional effect on 
cytokine activity, it also induces the expression of Mdm2 (as an ubiquitin ligase) 
that binds to p53 (tumour suppressor binding protein) and prevents its function. 
Other potential genetic modifiers include those that impact the innate immune 
system (61, 62) – osteopontin (63), interleukin 6 (IL-6) (64),  interleukin 8 (IL-8) , 
interleukin 17 (IL-17) (65, 66) and the chemokine CXCR1/2 (67, 68) – these control 
neutrophil infiltration into the joint space as well as regulate monocyte/macrophage 
function. In haemarthrosis, angiogenesis and vascular cell proliferation take place 
which are influenced by the aberrant expression of vascular endothelial growth 
factor (VEGF-R) and platelet-derived growth factor (PDGF). In addition to 
angiogenesis, VEGF is also involved in chondrocyte metabolism (69-75). The exact 
role of VEGF and PDGF is not known, however it has been suggested that, in the 
development and progression of haemophilic arthropathy, there is an imbalance 
between cytokine related cartilage degradation and maintenance of proliferative and 
synthetic cell responses. In individuals with haemophilia A, a genetic variation 
between novel receptor activators of nuclear factor kappa-B (RANK) and RANK 
ligand (RANKL) and osteoprotegrin (OPG) occur which also play an important role 
in osteoclast activity. It has been assumed that the increased expression RANK and 
RANKL by both normal and inflammatory neutrophils, together with decrease in 
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OPG, favour osteoclast differentiation and bone resorption. Haemophilic 
arthropathy may directly influence the presence of cellular components of the blood: 
moderate amounts of protein bound heme are very important for various biological 
functions, however if it is present in large quantity, as occur in haemarthrosis, it has 
toxic effects mediated by oxidative stress and inflammation. Within the joint 
microenvironment, chronic oxidative stress leads to the generation of reactive 
oxygen intermediates (ROIs) that further contribute to the destruction of cartilage 
and bone (76-84).  In addition to this, ROIs may alter the expression of the 
osteoblast transcription factor, RUNX2 which leads to decrease of osteoblast 
activity (85, 86). As blood induced joint disease progresses, bone remodelling 
occurs as well as in the presence of inflammation, osteoclastic activity is also 
increased, and bone mineralization is impaired. As the result of this there is the net 
loss of bone and failure of bone repair.   
 Normally the synovial membrane is thin and mostly avascular but, as a result 
of proliferation of synovium, the neovascularization of the sub-synovial layer 
occurs. As the result of neovascularization, an inflamed, villous, friable and highly 
vascular synovial tissue replaces the avascular synovium which is more susceptible 
to further haemorrhage even with a minimal stress.  Due to the presence of blood in 
the joint capsule the mechanical distension and pressure in the joint space further 
increase which additionally induces the apoptosis of chondrocytes and an inhibition 
of proteoglycan synthesis. As a result, involved cartilage is thereby unable to restore 
the synthesis of its matrix which leads to long-lasting joint damage. With time, a 
crippling arthritis is developed, and the final result is a fibrotic and destroyed joint 
(87, 88). 
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Figure 1.5: Blood induced joint damage. The blood induced joint damage is the 
result of the formation of hydroxyl radicals in the vicinity of the articular 
chondrocytes which leads to the apoptosis of these chondrocytes. Hydroxyl radicals 
are formed when hydrogen peroxide is synthesized by chondrocytes upon 
stimulation by IL-1 which originates from activated monocytes/macrophages. 
Chondrocytes apoptosis leads to disturbance and impairment of the cartilage matrix. 
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 Described as above, in the destruction of articular cartilage several 
mechanisms – enzymatic digestion as well as direct cellular destruction, direct toxic 
influence by the presence of blood and certain mechanical factors such as local 
pressure, abrasion , osteopenia and abnormal loading secondary to contractures –  
are involved. In haemophilic arthropathy, several theories explained the formation 
of subchondral bone cyst: osteolysis with coalescence of space, post haematoma, 
infiltration of articular or pararticular surfaces with fibrovascular tissue, ischemic 
necrosis of bone with resorption and collapse of subcondral bone (89). Pressure may 
play an important role in tissue necrosis and it is suggested that hydrostatic pressure 
on epiphyseal vessels by haemoarthrosis may produce subchondral ischemia which 
leads to cyst formation (90). The centrifugal progression of haemophilic arthropathy 
from the load-bearing areas of the condyles, intercondylar notch and patella mention 
a mechanical stress or injury related factor in its pathogenesis (90, 91). As the result 
of subchondral haemorrhage, the worst event is the microfracture of subchondral 
bone plate, this fracture may occur with minimal stress in the osteopenic bone of 
individuals with chronic haemophilic synovitis. Healing of these subchondral 
microfactures provides a stiffer base for the overlying articular cartilage, ultimately 
the subchondral bone disappears, the support for the overlying articular cartilage is 
lost and all is replaced by sclerotic lamellae recessed (92). 
 
1.5.5.3.  The Joint Health Assessment  
 
 It is not easy to detect a joint bleed with radiography but to visualize the 
gross arthritic alteration, plain radiography film is usually used (50).  In children 
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with haemophilia who had no clinical sign of haemophilic arthropathy, magnetic 
resonance imagining (MRI) is very helpful to detect early changes. In haemophilic 
arthropathy, MRI has several advantages over plain radiography: it can be used to 
detect the early changes in the soft tissue – synovium and cartilage – and it is 
anticipated that joint damage starts even after very few bleeding episodes (93). For 
haemophilic arthropathy, two MRI scoring systems are employed: for severe joint 
changes a progressive system is used, for osteochondral and soft tissue-related 
changes an additive system is used. However, MRI has some limitations including 
its ability to distinguish synovial hypertrophy and hemosiderin deposition (94). To 
overcome these deficiencies and to access the joint damage, ultrasound can also be 
used. Ultrasound may detect synovititis as well as bone and cartilage alternation and 
in haemophilic arthropathy it is a reliable tool to evaluate the joint modification 
(95). 
 Measurement of the joint health is critically important when assessing an 
individual with haemophilia A. Joint scores such as the haemophilia joint health 
score (HJHS) and Gilbert score (also known World Federation of Haemophilia 
Physical Examination Score) are a standardised way of assessing the progression of 
joint disease and can be observed over time. 
 
 The HJHS and Gilbert score measure in the domain of body structure and 
function, the joints most commonly affected by bleeding in individuals with 
haemophilia.  HJHS is an 11-items scoring tool (swelling, duration of swelling, 
axial alignment, muscle atrophy, crepitus, flexion loss, extension loss, joint pain, 
instability, gait and strength) for assessing joint impairment of six index joints 
(elbows, knees and ankles). Data from each assessed item are scored on an ordinal 
categorical scale and each of six joints is assessed individually. Knees and ankles 
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are scored using all 11- items, with a total joint score range from 0 to 26. On the 
other hand, elbows are scored using 9 of the 11 items (giant and axial alignment are 
excluded). A global gait score is assessed from 0 (indicating all skills are within 
normal range) to 4 (indicating that no skills are within normal range). All joint and 
global gait scores are then combined to provide a total score ranging from 0 to 148. 
Gilbert score is based on 8 main components: swelling, duration of swelling, 
muscle atrophy, crepitus on motion, flexion loss, extension loss, joint pain and 
strength (96, 97). All of the components of Gilbert score are combined together to 
give a total score ranging from (0-100), excluding the pain and bleeding subscales 
(0-18). 
HJHS is primarily designed for children aged between 4-18 years with mild 
joint impairment (for example, individuals on prophylaxis). On the other hand the 
Gilbert score is mainly designed for adults and older children with established 
arthropathy. It is probably best used for severely affected population such as 
individuals with uncontrolled inhibitors or little assess to factor replacement, 
however it can be used as an outcome measurement of physiotherapy intervention 
(98-101). 
 
1.5.6. Treatment of Haemophilia A 
 
 The WFH strongly recommends the FVIII concentrate (plasma derived or 
recombinant) in preference to the cryoprecipitate (CP) or fresh frozen plasma (FFP) 
for the treatment of haemophilia A (102, 103). In developed countries, widespread 
availability of factor concentrate fundamentally improved haemophilia care, 
resulting in early control of haemorrhages and musculoskeletal damage. However, 
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in developing countries like Pakistan, supportive therapies (FFP and CP) are usually 
used to control the bleed. CP and FFP are not a good option of treatment because 
they are not subjected to viral inactivation procedures – heat or solvent/detergent 
treatment – which lead to an increased risk of viral pathogen (102). The other 
disadvantage is that a large volume of FFP (1 mL of FFP contains 1 unit of factor 
activity) is used to get a required in vivo FVIII level and generally, it is difficult to 
achieve FVIII > 30 IU/dL with FFP alone (104). If factor concentrate is not 
available, CP is preferable to FFP.  
 For the prevention of bleeding episodes, the administration of FVIII 
concentrate, either on prophylaxis or on-demand treatment, is indicated. Prophylaxis 
may be primary or secondary: primary prophylaxis is defined as the regular, 
continuous long term treatment of FVIII concentrate which is usually started before 
the age of 2 years and /or after no more than one joint bleed, whereas secondary 
prophylaxis is defined as all long-term regular continuous treatment not fulfilling 
above mentioned criteria (105-107).  Several international randomized and 
observational studies indicated that prophylaxis initiated in early years of life 
protects from joint damage and decrease the incidence of haemarthrosis and other 
haemorrhages (53, 108).  
 The most challenging complication of FVIII replacement therapy for 
individuals with haemophilia A is the occurrence of inhibitory alloantibodies; 
approximately 25-30 % of severe individuals within the first 50 days of treatment 
face this complication.  In haemophilia, the inhibitor formation is a multifactorial 
process in which a number of genetic – ethnicity, F8 gene mutation and 
polymorphisms of immune response genes –  and acquired – number of FVIII 
exposure days, age at first exposure and type of FVIII concentrate administered  –  
risk factors are involved (109, 110).  
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1.6. Coagulation Tests  
 
 Coagulation tests are the first line investigation of a suspected inherited 
bleeding disorder. These tests reflect the history of coagulation investigation and 
give useful laboratory measures, however these are significantly removed from 
normal physiology. The most commonly used tests to assess the defect in 
coagulation are the prothrombin time (PT) and activated partial thromboplastin time 
(aPTT), these tests require the activity of all of the procoagulant factors except 
FXIII.  Coagulation factors assays are used to identify specific deficiencies but do 
not always correlate with the severity of bleeding. PT and aPTT measure the time 
necessary for clot formation. Neither test assesses the coagulation system as a 
whole, although both are sensitive to deficiencies within the common pathway. 
They are performed using platelet poor plasma (PPP), and clot formation occurs 
only when 5 % of total thrombin has formed. 
 
1.6.1.  Prothrombin Time 
 
 PT measures the extrinsic and common pathways of the classical coagulation 
cascade. In this test, coagulation is triggered by adding thromboplastin (TF plus 
PL).  PT is sensitive to clotting factors V, VII, X and fibrinogen and less so to 
prothrombin.  PT is prolonged if the concentration of any of these factors is about 
10 % or more below the normal range. Vitamin K deficiency, liver disease or 
disseminated intravascular coagulation (DIC) may prolong the PT, however in 
haemophilia, which is an intrinsic pathway defect, a normal result is typically 
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obtained. The sensitivity of this test is influenced by the reagents and techniques 
used, therefore it is important to establish a reference range locally.  The normal 
range is laboratory specific and is typically between 11-15 seconds in healthy 
individuals. 
  
1.6.2. Activated Partial Thromboplastin Time 
 
 aPTT is a test for the intrinsic pathway; It is the time required for plasma to 
clot following surface contact activation and optimal PL and calcium concentration 
are provided. In the presence of a normal PT, aPTT is very sensitive to deficiency of 
prekallikrein (PKK), HMWK, FXII, FXI, FIX and FVIII. It is therefore abnormal in 
haemophilia A and B.  Additionally, aPTT can be prolonged in any deficiency 
involving the common pathway (FV, FX, prothrombin and to lesser extent 
fibrinogen). aPTT is prolonged in the presence of some therapeutic inhibitors of 
coagulation such as heparin and naturally occurring inhibitors such as a lupus 
anticoagulant. In the aPTT, PPP is triggered to clot using a negatively charged 
surface (kaolin or silica) to initiate contact activation; PL and calcium are added to 
the PPP for the further progression. The normal range for the aPTT is laboratory 
dependent and is usually between 29-35 seconds. 
 
1.6.3. Mixing Studies 
  
 A plasma sample that has a prolonged PT or APTT is further investigated to 
define the abnormality. This is done using mixing or correction tests. It is very 
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important to demonstrate whether a defect in patient plasma is corrected with 
normal plasma in order to exclude the presence of an inhibitor.  
 
1.6.4. Thrombin Time 
  
 The thrombin time (TT) is a measure of the conversion of fibrinogen to 
fibrin by thrombin. It is prolonged (normal range 13-15 seconds) when fibrinogen 
level is very low (< 1.0 g/L) or in the presence of heparin and heparin-like 
substances, FDP or dysfibrinogenemia.  TT is performed by adding a dilute 
preparation of thrombin to citrated PPP and measuring the clotting time. PL and 
recalcification are not required. 
1.6.5. One-Stage Clotting Assay for FVIII Activity 
  
 This assay is based upon the ability of a test sample to correct the aPTT in 
standard plasma that is totally deficient in FVIII but containing all of the other 
factors required for normal clotting. FVIII activity (FVIII:C) is measured according 
to the degree of correction of the standard plasma. 
  
1.6.6. Quantitative Measurement of FVIII Inhibitor 
 
 FVIII inhibitors resulting from replacement therapy in haemophilia A are 
typically demonstrated by a mixing test in which the normal and test plasma (with 
prolonged aPTT) are mixed in equal proportions. Failure to correct the aPTT 
indicates the presence of an inhibitor (correction indicates a coagulation factor 
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deficiency as discussed above). If FVIII is added to plasma containing an inhibitor 
and the mixture incubated for some time, the FVIII will be progressively 
neutralized. If the amount of FVIII and the incubation time are standardized, the 
strength of the inhibitor is then defined according to the amount of neutralization. 
 
1.6.7. Bethesda Assay 
 
 A Bethesda unit is defined as the amount of inhibitor that will neutralize 50 
% of one unit of added FVIII in 2 h at 37 
o
C. Test plasma dilutions are mixed with 
normal plasma and the dilutions that gives a residual FVIII:C nearest to 50 % (but 
within the normal range 30-60 %) is chosen for calculation of the inhibitor. 
Alternatively, the result can be calculated from each dilution and the average taken. 
 
1.6.8. von Willebrand Factor Antigen  
 
  The concentration of VWF antigen (VWF:Ag) in plasma can be measured 
using immunological assays. Enzyme-linked immunosorbent assay (ELISA) and 
automated latex immunoassay (LIA) are two commonly used methods. 
 In ELISA, a primary antibody targeting VWF is coated onto the wells of a 
suitable plate. Test plasma is added in a series of dilutions and the constituent VWF 
is bound. The bound VWF is detected using a conjugated anti-VWF secondary 
antibody. The latter provides a colour reaction from which measurement of VWF is 
obtained by comparison to reference plasma. 
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LIA uses latex micro-particles coated with an antibody to VWF. The latex 
particles agglutinate in proportion to the concentration of VWF:Ag in the plasma 
sample. 
 The interpretation of a VWF:Ag value is made in conjunction with other 
assays (FVIII and VWF activity), the blood group and bleeding history. The 
reference range for VWF:Ag is 50-150 IU/dL. 
 
1.6.9. Thrombin Generation Assay 
 
 Thrombin is an essential part of the coagulation enzymatic cascade. The 
thrombin generation test (TGT) measures the amount of active thrombin produced 
in plasma or in whole blood after recalcification and triggering. Thrombin 
generation (TG) curve (thromogram) is a gold standard tool in coagulation research 
(111-114) it indicates the overall function of blood coagulation system.  
 In PPP, TG is very sensitive for pro- and anticoagulation, it expresses all the 
clotting factor deficiencies except FXIII (115, 116). TG is also very sensitive to the 
action of oral anticoagulant, direct thrombin inhibitor and all types of heparins 
(117). In PRP, thrombogram is also very sensitive by platelets, the effect of von 
Willebrand factor, hypofibrinogenemia and different platelets functions disorders 
(118). In PRP, TG exhibits the major part of physiological clotting system. 
 Thrombin generation (TG) can be initiated (triggered) by the addition of 
exogenous activators such as thromboplastin, or a combination of purified TF and 
PL, the latter typically of specific composition (119). The clinical utility of this test 
is extensively reported in haemophilia A (120) in which it is used to tailor individual 
prophylaxis regimens and, in individuals who have high-titer inhibitors, to predict 
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optimal dosing of bypassing agents (121).  Despite the fact of TG test and its utility 
in clinical diagnosis and drug monitoring, it is found not be applicable universally 
because of the technical back ground.  
 
1.6.9.1.  Sub-Sampling Method   
 
 In this method, TG is triggered by a small amount of thromboplastin. 
Samples of the clotting blood or plasma are taken at timed intervals and diluted with 
buffer that contains a chromogenic substrate. TG is measured by a change in optical 
density at the specific wavelength of the product (122). A major advantage of this 
method is that TG can be measured in platelet-poor or -rich plasma (PPP, PRP), or 
in whole blood. Important disadvantages are that the method is very time consuming 
(at least an hour is required to measure TG in just 1 to 4 samples) and is not 
automated.  
 
1.6.9.2.  Chromogenic Technique 
 
 This technique permits continuous measurement of the generation of 
thrombin. Plasma is triggered by TF in the presence of PL and the amount of 
thrombin generated is measured by continuous optical density recording of the 
conversion of a chromogenic substrate. The substrate is cleaved by both free 
thrombin and also thrombin bound to α2 macroglobulin, the proportion of the former 
is then computationally derived. A disadvantage of this technique is the requirement 
for an optically clear sample; platelet-free or defibrinated plasma must therefore be 
used (123).  
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1.6.9.3.  Calibrated Automated Thrombography 
  
 With calibrated automated thrombography (CAT), a fluorogenic substrate is 
used to measure TG in plasma that has been triggered with TF and PL. As TG 
proceeds the substrate is consumed and fluorescence increases. Thrombin 
concentration is calculated from the conversion of velocity of slow reacting 
fluorogenic substrate. With the fluorogenic substrate, constant thrombin activity 
does not correlate a constant increase in the signal output.  The relationship between 
the intensity of fluorescence and amount of thrombin generated is not linear and is 
influenced by the colour of the plasma (inner filter effect) and ageing of the light 
source. The method therefore uses a calibrator with a known thrombin activity; this 
is added to the test plasma and fluoresce measured without triggering. In parallel, 
thrombin generation is measured in the test sample that has been triggered with TF 
and PL. In PPP, a standard amount of PL is added as a procoagulant, whereas in 
PRP, for TG, platelets provide the PL procoagulant.  
  
 Main advantages of this technique include the fact that it is not influenced by 
turbidity and measurements can be done in the presence of platelets or without 
defibrination of plasma. There is a dependency of this fluorogenic method on 
fibrinogen, higher concentrations of which lead to an increase in thrombin 
generation (124). Methods that are not using a calibrator can under- or over-estimate 
the amount of thrombin generated. In vivo, thrombin is neutralized by anti-thrombin 
and complex formation with α2 macroglobulin. However, the thrombin-α2 
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macroglobulin complex is still able to cleave the fluorogenic substrate and the signal 
generated by this needs to be subtracted from the total fluoresce. 
  
 Software is used to calculate the amount of thrombin generated over time for 
a sample. The main parameters in this method are:  lag time (period required for the 
generation of 10 nmol of thrombin, it is roughly equivalent to the clotting time), 
endogenous thrombin potential (ETP, the area under the curve), peak (the maximum 
concentration of thrombin, also called peak height or thrombin peak), time to peak 
(ttpeak, the time it takes to reach the peak) and velocity index (peak divided by the 
ttpeak minus the lag time).  
 
 The thrombogram depends upon certain factors, trigger used for the assay is 
one of them. As excess of TF cause the prothrombinase formation under the 
activation of extrinsic pathway (coagulation factor VII, V and X) and inhibition of 
TF pathway. Decrease the TF concentration, TG depends upon FVIII and FIX 
concentration under the activation of intrinsic pathway. The concentration of PL is 
also very important, even in the absence of TF; excess amount of PL causes the 
activation of intrinsic pathway and bust of thrombin formation.  
 The thrombin generation assay is only sensitive to FVIII deficiency when 
low concentrations of TF are used to trigger the reactions (125). This is because 
higher concentrations of TF overwhelm TFPI and bypass the propagation phase of 
coagulation (126). The amount of TF included in assays is usually achieved by 
diluting Innovin. Final concentrations of TF of 1 pmol/L are often used to 
investigate FVIII deficient samples although more information may be derived from 
using a variety of TF concentrations.  
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Figure 1.6: The key measures of thrombin generation - lag time (the moment when 
10 nmol/L thrombin has been generated, it is equivalent to the clotting time), peak 
height of thrombin generation (maximum velocity of thrombin generation), time to 
peak (tt) and endogenous thrombin potential (ETP) represents the total amount of 
thrombin generated over time and is calculated by the area under the curve) are 
indicated. Velocity index (VI) (rate of thrombin generation per minute) VI = peak 
thrombin/peak time-lag time. 
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1.7. Hypothesis 
  
 The severity of haemophilic arthropathy, in individuals with the same 
baseline FVIII level who are receiving minimal FVIII replacement, is affected by 
their global haemostatic potential despite the mutation underlying haemophilia A. 
This cannot be easily studied in patients treated in the UK because their clinical 
phenotype is modified by prophylactic treatment, but could be studied in 
haemophilia individuals from Pakistan where prophylaxis is uncommon and the 
effect of baseline characteristics could be investigated. 
1.8. Aims 
 
The aim of this study was to: 
a. Undertake genetic, phenotypic and clinical investigation of  individuals with 
hereditary haemophilia A who have minimimal access to treatment (FVIII 
concentrate).  
b. Explore the spectrum of mutations in this geographical group for comparison 
with other nationalities 
c. Investigate predisposing  factors that affect joint damage. 
The phenotypic studies included global haemostasis (TG) for individuals with (i) 
identical causative mutations, (ii) similar FVIII:C but different causative mutations, 
(iii) similar clinical severity but different FVIII:C.   
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 A unique feature of this study was that, unlike many other countries, 
Pakistan has only very limited access to FVIII concentrate, therefore the joint status 
of each patient was not modified by treatment. 
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Chapter 2 
Material and Method 
2.1.  Cohort Recruitment 
 Two cohorts, each of 100 randomly selected individuals, were recruited in 
Pakistan. One cohort comprised unrelated individuals previously diagnosed with 
haemophilia A, and included mild, moderate and severely affected cases. The other 
cohort comprised healthy controls and was recruited to test whether novel genetic 
variants found in the haemophilia cohort were neutral polymorphisms. Ethical 
review was undertaken by the National Bioethical Committee of Pakistan and by 
Cardiff University (respective reference numbers 4-87/10/NBC-52/RDC/2589; 
SMREC number 11). Informed consent was taken according to local regulations in 
Pakistan. 
 The joint health status of each individual was assessed using both HJHS 
(version 2.1) (95) and Gilbert score (98). Researcher recorded clinical details and 
did the assessment of joint score for all individuals. Researcher had training for the 
assessment of joint score from a qualified haemophilia specialist physiotherapist in 
Cardiff prior to cohort recruitment. 
2.2.  Chemicals and Reagents 
 
 All general laboratory reagents were supplied by VWF International Ltd 
(Leighton Buzzard, UK). Sodium citrate anticoagulant tubes were obtained from 
Greinerbio-one LTD (Gloucestershire, UK).  Sodium citrate/corn trypsin inhibitor 
(CTI) blood collection tubes were purchased from Haematologic Technologies Inc 
(Vermont, USA). The following HemosIL
TM
 reagents were supplied by IL 
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Company (Bedford, USA): PT HemosIL
TM
 RecombiPlasTin 2G, aPTT  
HemosIL
TM
, calcium chloride (CaCl2) and HemosIL
TM
 SynthASil aPTT reagent , 
special test control level 2, normal control, Calibrated Plasma, Factor VIII Deficient 
Plasma and Factor Diluent.  Precision Biologic Cryocheck abnormal 1 (Cryo Green) 
and 2 (Cryo Red) were purchased from Precision Biologic (Dartmouth, Canada). 
FVIII Deficient Plasma was obtained from Helena Biosciences Europe (Gateshead, 
UK). Phosphate buffered saline (PBS) was purchased from Microgen Bioproducts 
(Surrey, England). Tween-20 was supplied by Novara Group Ltd (Leicestershire, 
England). K-Blue Substrate and Red Stop Solution were supplied by Neogen 
Europe Ltd (Ayr, Scotland, UK). Pathway Diagnostic Normal Human Control 
Plasma was supplied by Technoclone Ltd (Dorking, UK). Polyclonal rabbit anti-
Human von Willebrand factor (A0082) and Polyclonal rabbit anti-Human von 
Willebrand factor conjugated with horse radish peroxidise (anti-human von 
Willebrand factor/HRP, P0226) were supplied by Dako (Glostrup, Denmark). VWF 
reference standard (6th International Standard plasma for Factor VIII and VWF) 
was obtained from the National Institute for Biological Standards and Control 
(Potters Bar, UK). The PL reagents 1,2-dioleoyl-sn-glycero-3-phospho-L-serine 
(phosphatidylserine), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
(phosphatidylethanolamine) and 1,2-dioleoyl-sn-glycero-3-phosphocholine 
(phosphatidyl choline) were obtained from Avanti Polar Lipids Inc. (Alabama, 
USA). TF was supplied by Siemens Healthcare (Marburg, Germany). Fluorogenic 
substrate Z-Gly-Gly-Arg-AML HCL was purchased from Bachem AG 
(Hauptstrasse, Switzerland).  Bovine Serum Albumin (BSA), N-2-
Hydroxyethylpiperazine-N′-2-ethanesulfonic Acid (HEPES) acid and HEPES salt 
were obtained from Sigma Chemical Company (Dorset, UK). CaCl2 for CAT 
analyses was supplied by Prolabo (Geldenaaksehaan, Belgium). Thrombin calibrator 
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was supplied by Thrombinoscope BV (Maastricht, Netherland). Recombinant 
human FVIII (Advate) was obtained from Baxter HealthCare Corporation (Norfolk, 
UK). BclI and NEBuffer 3, T4 DNA Ligase, T4 DNA ligase buffer, pBR322/MspI 
size markers and 1 kb ladder size standard were obtained from New England 
Biolabs Inc. (Hertfordshire, UK). AmpliTaq DNA Polymerase, PCR Buffer II and 
magnesium chloride (MgCl2) were purchased from Roche Diagnostic Limited (West 
Sussex, UK). Bromophenol blue was purchased from BDH chemicals Ltd (Dorset, 
UK). Primers ID, IU, ED, Int1h-2F, Int1h-2R, 9F, 9cR and all primers for F8 
sequence analysis were obtained from Life Technologies Ltd (Manchester, UK). 
Centri-Sep 8-well strips and the ABI PRISM BigDye Terminator (BDT) Cycle 
sequencing Ready Reaction Kit were purchased from Applied Biosystems, Life 
Technologies Ltd (Paisley, UK).  
 
2.3.  Preparation of Platelet Poor Plasma  
 
 Patients: blood (2x5 mL) was collected into (i) sodium citrate anticoagulant 
(3.2 %, w/v) and (ii) sodium citrate/CTI (20 mmol/L) tris, 150 mmol/L NaCl, 11 
mmol/L citrate, 50 µg/mL CTI, final concentrations in the collected blood). 
Controls: blood (2x5 mL) was collected into sodium citrate as above. PPP was 
prepared by double centrifugation of all anticoagulated samples at 2000 xg for 15 
min. PPP and cell fractions were stored frozen at -80 
o
C and transported to the UK 
on dry ice for phenotypic and genetic analysis.  
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2.4.  Phenotypic Parameters 
 The following phenotypic parameters were measured for citrated plasma 
from all 100 patients: PT, aPTT, fibrinogen, FVIII:C, FIX coagulant activity 
(FIX:C), FVIII inhibitor and VWF:Ag. 
 PT, aPTT, fibrinogen and FVIII:C were measured using an ACL-TOP 500 
automated bench-top random access analyser (Instrumentation Laboratory 
Company, Bedford, USA). FVIII:C was measured with an automated 1-stage aPTT-
based (non chromogenic) assay. Internal quality control was done for each test prior 
to analysis of experimental samples. For each phenotypic parameter, the reagents 
for analysis were prepared as follows: 
2.4.1. PT  
  HemosIL
TM
 RecombiPlasTin 2G (supplied as “diluent reagent” and “PT 
reagent”) was used. Diluent and PT reagent were allowed to equilibrate separately at 
RT for 15 min. Diluent (20 mL) was then added to PT reagent, the mixture was 
swirled gently and allowed to reconstitute for 20 min. The solution was stable for 10 
days at 2-8 
o
C.  
2.4.2. aPTT  
 HemosIL
TM
 CaCl2 (0.02 mol/L) and HemosIL
TM
 SynthASil aPTT reagent 
were used. Both reagents were allowed to equilibrate at RT for 15 min. The 
stabilities were respectively 10 and 30 days for aPTT reagent and CaCl2.  
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2.4.3. FVIII:C   
 
 HemosIL
TM
 special test control level 2, HemosIL
TM
 normal control, 
HemosIL
TM
 FVIII Deficient Plasma and Helena Biosciences FVIII Deficient Plasma 
were each reconstituted in 1 mL of sterile water. Control reagents were kept at 15-
25 
o
C for 30 min. Samples were stored frozen at -70 
o
C prior to analysis. Before use, 
samples were thawed at 37 
o
C for 5 min and then checked to ensure they were fully 
defrosted. The stabilities of the reconstituted reagents were as follows: HemosIL
TM
 
special test control level 2, 8 h at 15 
o
C or 24 h at -20
 o
C; PrecisionBiologic 
Cryocheck abnormal 1 (Cryo Green) and 2 (Cryo Red), 4 h at 15 
o
C; Helena 
Biosciences FVIII Deficient Plasma, 8 h at 2-6 
o
C or 4 h at 15
 o
C. 
 
2.4.4. FVIII Bethesda  
 
 Helena congenital FVIII Deficient Plasma and Pathway Diagnostic Normal 
Human Control Plasma were reconstituted in 1 mL of sterile water at RT for 30 min. 
Test plasma was prediluted (1:1, v/v) in HemosIL
TM
 Factor Diluent reagent. The 
diluted and neat plasma were respectively each mixed (1:1, v/v) with Pathway 
Diagnostic Normal Human Control Plasma to give a final volume of 200 µL. The 
mixture was incubated at 37 
o
C for 2 h. An inhibitor control (used to generate a 
reference curve) was prepared by adding 300 µL of Helena congenital FVIII 
Deficient Plasma into 300 µL Pathway Diagnostic Normal Human Control Plasma. 
The inhibitor control was also incubated at 37 
o
C for 2 h. After 2 h, a calibration 
curve was done prior to analysis of the samples. The stability of the Normal Human 
Control Plasma was 4 h at RT, 8 h at 2-8 
o
C and 1 month at -20
 o
C. 
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2.4.5. von Willebrand Factor Antigen Enzyme-Linked Immuno-Sorbent Assay  
 
PBS (1x) was prepared by diluting stock solution (20 x) with water. PBS-
Tween-20 (PBS-Tween) contained PBS (x1) and Tween-20 (0.1 %, v/v). PBS-
Tween-BSA consisted of PBS (x1), Tween-20 (0.1 %, v/v/) and BSA (0.1 %, w/v). 
PBS, PBS-Tween and PBS-Tween-BSA were stored at 4 
o
C for several weeks. 
 Coating ELISA wells: polyclonal rabbit anti-Human von Willebrand Factor 
antibody (A0082) was diluted 1:1000 (v/v) in PBS and then 100 µL was added to 
each well of the ELISA plate. The plate was sealed and incubated overnight at 4 
o
C.  
The anti-VWF diluents were discarded thoroughly from the wells and 200 µL of 
PBS-Tween were added to each well. The plate was incubated at ambient 
temperature for 15 min to block the well walls. Following this, the wells were 
emptied and rinsed 3 times with PBS-Tween (200 µL). The serial dilutions for the 
standard curve were added in duplicate, and in triplicate for test plasma. The 
secondary antibody (polyclonal rabbit anti-Human von Willebrand Factor/HRP 
(P0226, 1:750 v/v in PBS-Tween-BSA, 50 µL) was then added. The plate was 
incubated at ambient temperature for 2 h. The plate contents were discarded and 
rinsed 3 times with 200 µL PBS-Tween. K-Blue substrate (100 µL) was added to 
each well, incubated at 37 
o
C for 5 min and then 50 µL of Red Stop Solution was 
added, mixed and incubated for 5 min at RT. The ELISA plate was read using a 
BioTek Synergy HT Plate reader (BioTek UK, Bedfordshire, UK). 
 The standard curve comprised serial dilutions (100, 50, 25, 12.5, 6.25, 3.125, 
1.5625) for which the highest value corresponded to 5 µL reference plasma + 95 µL 
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PBS-Tween-BSA. The subsequent dilutions were done using PBS-Tween-BSA. 
Test plasma was diluted 200-fold using PBS-Tween-BSA.   
2.4.6. Calibrated Automated Thrombography 
 
 Thrombin generation was measured according to the method of Hemker et al 
(127). 
Preparation of PL vesicles: phosphatidylserine (120 μL of 25 mg/mL in 
chloroform), phosphatidylethanolamine (120 μL of 25 mg/mL in chloroform) and 
phosphatidylcholine (458 μL of 20 mg/mL in chloroform) were mixed and the 
mixture dried under an argon stream. Buffer A (HEPES (20 mmol/L), NaCl (140 
mmol/L), pH7.35, 4 mL) was added, the PLs were allowed to dissolve and then 
vesicles prepared using a Mini Extruder according to manufacturer’s instructions 
(Avanti Polar Lipids Inc, Alabama, USA). The final concentration of PL was 5 
mmol/L and comprised a 1:1:3 (mole:mole:mole) mixture of 
phosphatidylserine:phosphatidylethanolamine:phosphatidylcholine. 
 Preparation of trigger: the contents of 1 vial of Innovin were reconstituted in 
10 mL of water and the dissolved TF was then diluted 1:6 (v/v), followed by further 
dilution of a sub-aliquot 1:2 (v/v), both dilutions used buffer B (BSA (5 g/L) 
dissolved in buffer A). The final concentration of TF was 6 nmol/L (inferred from 
the serial dilutions). Trigger was prepared by mixing TF (6 nmol/L) and PL vesicles 
(5 mmol/L) in buffer B, to achieve a final concentration of 1 – 5 pmol/L TF 
(according to the experiment) and 4 μmol/L PL. 
 Preparation of fluorogenic substrate: Z-Gly-Gly-Arg-AML HCL was 
dissolved in dimethylsulphoxide to a concentration of 100 mmol/L and stored at -70 
o
C in glass vials. Fluorogenic buffer was prepared with BSA (60 mg/mL) in HEPES 
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buffer (8.21 mmol/L, pH 7.35). Substrate (60 μL of 100 mmol/L), fluorogenic 
buffer (2.1 mL, 20 mmol/L HEPES, pH7.35, 60 g/L BSA) and CaCl2 (240 μL of 1 
mol/L) were mixed (“FluCa mixture”) immediately before use in an experiment. 
 Preparation of thrombin calibrator: the contents of 1 vial of lyophilised 
thrombin calibrator were reconstituted in 1 mL water to give a concentration of 640 
nmol/L. The dissolved calibrator was stored frozen at -70 
o
C until use.  
 For CAT assays, 20 µL of  TF trigger (1 pmol/L, 3 pmol/L or 5 pmol/L TF 
and 4 µmol/L PL) and 80 µL PPP were manually pipetted in triplicate into a 96 well 
round bottom microtiter plate. For each test plasma, a single calibrator well was also 
prepared containing thrombin calibrator (20 µL) and PPP (80 µL). To all wells, 
FluCa mixture (40 μL) was added to initiate both thrombin generation and calibrator 
activity. The fluorescence signal was measured for 120 min at 30 s intervals in a 
Fluoroskan Ascent micro plate fluorimeter, using Thrombinoscope Ascent software 
(version 3.0.0.29) (Thermo Electron Corporation, Vantaa, Finland). 
 
2.5.  Genetic Analysis  
 
2.5.1. DNA Extraction  
 
2.5.1.1.  Rapid Extraction of DNA from Blood  
  
 Cell lysis buffer contained analar sucrose (11 %, w/v), tris-HCl pH 7.6 (1 
mol/L), MgCl2 (5 mol/L), Triton X100 (1 %, v/v) in distilled water. PBS (1x) was 
prepared by diluting stock solution (20x) with water. NaOH (35 mmol/L) and tris-
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HCl (700 mmol/L) pH7.4 were made by diluting stock solution (1 mol/L) with 
water respectively. Sucrose solution 1 (33 %, w/v) and 2 (11 %, w/v) were prepared 
by adding analar sucrose to double distilled water. Thawed packed cells (50 µL) 
were added to 200 µL cell lysis buffer. The mixture was mixed thoroughly and 
gently with repeated uptake and evacuation of the pipette. Sucrose solution 1 (50 
µL) was added to the base of tube followed by centrifugation at 10,000 xgfor 2 min. 
The supernatant was removed without disturbing the nuclei pellet which was then 
resuspended in 100 µL PBS (x1). Sucrose solution 2 (50 µL) was added to the base 
of the tube. The mixture was centrifuged at 10,000 xg for 2 min. The supernatant 
was discarded without disturbing the pellet of nuclei. NaOH (350 mmol/L, 50 µL) 
was added to the tube and the nuclei pellet resuspended thoroughly. The mixture 
was incubated at 95 
o
C for 8 min followed by brief centrifugation. Tris-HCl (700 
mmol/L, 7 µL) was added and the mixture was vortexed briefly. The mixture was 
centrifuged at 10,000 xg for 2 min to pellet denatured protein and other debris. 
Supernatant (50 µL), which contained DNA, was transferred to a 0.5 mL Eppendorf 
tube and stored  at -70 
o
C. 
 
2.5.1.2.  Rapid Extraction of High Molecular Weight DNA from Blood  
 
  Tris-EDTA-Citrate buffer (TEC) (10x) was prepared by adding tris-HCl (1 
mol/L, pH7.4), EDTA (0.5 mol/L, pH8.0), Na3Citrate (1 mol/L) to double distilled 
water. TEC-SDS buffer was prepared by adding TEC buffer (final concentration 1x) 
and SDS (final concentration 0.1 %, w/v) to double distilled water.  
 Thawed packed cells (500 µL) were added to 500 µL PBS (1x). The mixture 
was vortexed briefly and then centrifuged at 2800 xg for 5 min. The supernatant was 
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removed without disturbing the nuclei pellet. The nuclei pellet was washed by 
resuspension in PBS (1x, 500 µL) and then centrifugation was repeated as above.  
The supernatant was discarded without disturbing the nuclei pellet. The pellet was 
then frozen on dry ice for 1 min, followed by thawing at 55 
o
C for 1 min. Freeze-
thawing was repeated two further times.  
 Saturated NaCl (100 µL) and chloroform (500 µL) were added and the 
mixture was inverted gently several times to create an emulsion, and then left for 5 
min. The tube was then centrifuged at 10,000 xg for 5 min. The supernatant (300 
µL) was decanted into 600 µL of 100 % (v/v) ethanol. The tube was inverted gently 
until the DNA precipitated. The mixture was centrifuged at 10,000 xg for 15 min to 
harvest the DNA pellet. The supernatant was removed thoroughly and then 25 µL of 
water was added and the DNA was left to dissolve at 37 
o
C for 1 h. The DNA 
solution was then vortexed gently to ensure uniformity, centrifuged very briefly and 
stored at -70
 o
C.  
2.5.2.1.  F8 Intron 22 Inversion Analysis Using Inverse Polymerase 
Chain Reaction  
 
 High molecular weight DNA was prepared as described earlier. The inverse  
polymerase chain reaction (PCR) was done in three stages: Stage 1: Restriction 
enzyme digestion. DNA (500 ng) was added directly into mineral oil (25 µL) and 
the volume made up to 15 µL by the addition of water. Restriction enzyme digestion 
mix (10 µL) comprising BclI (10 U), NEBuffer3 x10 (2.5 µL) and water was added 
directly into the DNA (final volume 25 µL). The mixture was incubated at 50 
o
C for 
2h and then the digested DNA was transferred to a sterile tube. Stage 2: Ligation. 
The ligation master mix (225 µL) comprising T4 DNA ligase (1 U), T4 DNA ligase 
buffer x10 (25 µL) and water was added (final volume 250 µL). The mixture was 
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incubated at 15 
o
C overnight. The ligated DNA was transferred to a sterile tube and 
precipitated by adding 600 µL of ethanol (100 %, v/v) followed by 50 µL of  NaCl 
(1.8 mol/L).The mixture was inverted gently several times and left at -20 
o
C
 
 for 5 
min. The DNA was harvested at 10,000 xg for 10 min. The supernatant was 
removed and the pellet was allowed to air dry for 5 min. The pellet was 
reconstituted in 15 µL water and allowed to dissolve for a minimum of 5 min at 
room temperature. Stage 3: PCR amplification. Primers ID + IU + ED were used in 
multiplex to test each ligated product. Each primer was present at a final 
concentration of 1 µmol/L in the PCR. Ligated product (1 µL) was added to PCR 
mega mix (9 µL) comprising Taq DNA polymerase (5U), deoxynucleotide 
triphosphate (dNTPs) (100 μmol/L), MgCl2 (1.5 mmol/L), Taq DNA polymerase 
buffer (1x) and water (5.17 µL). The PCR regimen comprised (94 
o
C
 
for 5 min; 55 
o
C for 1 min; 72 
o
C for 1 min) x35 cycles.  PCR product (5 µL) was analysed using 
agrose gel electrophoresis (2 % (w/v), 120 V, 80 mA). Products were visualised 
using ethidium bromide staining and UV light. The result was recorded using a 
Polaroid MP4 Land Camera (http://www.polaroid.co.uk/) and Fuji Film FP-3000 
black and white film (Fujifilm UK Ltd, Bedford, UK). Amplification products of 
487 bp and 559 bp were obtained for normal DNA and Inv22 respectively. 
 
Table 2.1 Primers ID, IU and ED used for F8 Intron 22 Inversion. 
 
Primer name   Primer Sequence (5`-3`) 
ID   5`-ACATACGGTTTAGTCACAAGT-3` 
IU   5`-CCTTTCAACTCCATCTCCAT-3` 
ED   5`-TCCAGTCACTTAGGCTCAG-3` 
 
52 
 
2.5.2.2.  Analysis of F8 Intron 1 Inversion  
 
 High molecular weight DNA was prepared as described earlier. The 
following four primer pairs were used to test each DNA: Int1h-2F + Int1h-2R, 9F + 
9cR, Int1h-2R + 9F, Int1h-2F + 9cR. Each primer was present at a final 
concentration of 1 µmol/L in the PCR. 
 
Table 2.2 Primers Int1h-2F, Int1h-2R, 9F and 9cR used for analysis of F8 
Intron 1 Inversion. 
 
Primer name    Primer Sequence (5`→3`) 
Int1h-2F 
Int1h-2R 
  GGCAGGGATCTTGTTGGTAAA 
  TGGGTGATATAAGCTGCTGAGCTA 
9F      GTTGTTGGGAATGGTTACGG 
9cR      CTAGCTTGACTCCCTGTGG 
 
 PCR amplifications were done in a final volume of 25 µL and contained the 
following reagents: DNA (125 ng/µL), Taq DNA polymerase (5U), dNTPs (each at 
100 μmol/L), MgCl2 (1.5 mmol/L) and Taq DNA polymerase buffer (1x).  The PCR 
regimen was (94 
o
C for 30 s; 65 
o
C for 60 s; 72 
o
C for 90 s) x30 cycles.  PCR 
product (5 µL) and appropriate DNA size standard (1 kb ladder) were analysed 
using agrose gel electrophoresis (0.6 % w/v, 120 V, 40 mA). Products were 
visualised using ethidium bromide staining and UV light. The result was recorded 
using a Polaroid MP4 Land Camera and Fuji Film FP-3000 black and white film. 
The product profile indicated the genotype (Table 2.3). 
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Table 2.3 Result interpretation for F8 Intron 1 Inversion 
 
Primer pair Product Genotype 
Int1h-2F + Int1h-2R ~1 kb 
Normal 
9F + 9cR ~1.5 kb 
Int1h-2R + 9F None 
Int1h-2F + 9cR None 
Int1h-2F + Int1h-2R None 
Intron 1 inversion present 
9F + 9cR None 
Int1h-2R + 9F ~1.5 kb 
Int1h-2F + 9cR ~1 kb 
 
 
 
2.5.2.3.  F8 Sequence Analysis  
 
 The sequencing strategy was based on that of Keeney, S. (http://hadb.org.uk 
/ WebPages /Database/Methods/pcr.html): 37 primer pairs were used to amplify the 
essential regions of F8 and the products were then sequenced using common 
forward and reverse sequencing primers (N13F and N13R respectively) (Table 2.4). 
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Table 2.4 Primers used for amplification of F8. 
 
Primer 
PCR Primer sequences Product 
size 
(bp)  
 
(5’ - 3’) 
F8P2F gtagcgcgacggccagtGAGCTCACCATGGCTACATTC 
595 
F8P2R cagggcgcagcgatgacAATTTAAAACTATAAAGCGAGTCCTG 
   
F8P1F gtagcgcgacggccagtGGACCTAGGCCATGGTAAAGA 
634 
F8P1R cagggcgcagcgatgacTGCAGAGCATTTTAAGGAACTTT 
   
F8EX1F   gtagcgcgacggccagtTAGCAGCCTCCCTTTTGCTA 
514 
F8EX1R   cagggcgcagcgatgacCTAACCCGATGTCTGCACCT 
   
F8EX2F   gtagcgcgacggccagtCATTACTTCCAGCTGCTTTTTG 
324 
F8EX2R   cagggcgcagcgatgacTTTGGCAGCTGCACTTTTTA 
   
F8EX3F   gtagcgcgacggccagtGCATGCTTCTCCACTGTGAC 
333 
F8EX3R   cagggcgcagcgatgacGCCACCATTACAAAGCACAC 
   
F8EX4F   gtagcgcgacggccagtCATGTTTCTTTGAGTGTACAGTGG 
406 
F8EX4R   cagggcgcagcgatgacTTCAGGTGAAGGAACACAAATG 
   
F8EX5F   gtagcgcgacggccagtTCTCCTCCTAGTGACAATTTCC 
293 
F8EX5R   cagggcgcagcgatgacCCCATCTCCTTCATTCCTGA 
   
F8EX6F   gtagcgcgacggccagtGCGGTCATTCATGAGACACA 
292 
F8EX6R   cagggcgcagcgatgacCCGAGCTGTTTGTGAACTGA 
   
F8EX7F   gtagcgcgacggccagtTGTCCTAGCAAGTGTTTTCCATT 
434 
F8EX7R   cagggcgcagcgatgacAATGTCCCCTTCAGCAACAC 
   
F8EX8F   gtagcgcgacggccagtCACCATGCTTCCCATATAGC 518 
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F8EX8R   cagggcgcagcgatgacATGGCTTCAGGATTTGTTGG 
   
F8EX9F   gtagcgcgacggccagtTTTGAGCCTACCTAGAATTTTTCTTC 
334 
F8EX9R   cagggcgcagcgatgacGGTATTTTAGAAACTCAAAACTCTCC 
   
   
F8EX10F   gtagcgcgacggccagtTTCTTGTTGATCCTAGTCGTTTT 
284 
F8EX10R   cagggcgcagcgatgacGCTGGAGAAAGGACCAACATA 
   
F8EX11F   gtagcgcgacggccagtCCCTTGCAACAACAACATGA 
396 
F8EX11R   cagggcgcagcgatgacTTTCTTCAGGTTATAAGGGGACA 
   
F8EX12F   gtagcgcgacggccagtTGCTAGCTCCTACCTGACAACA 
332 
F8EX12R   cagggcgcagcgatgacCATTCATTATCTGGACATCACTTTG 
   
F8EX13F   gtagcgcgacggccagtCATGACAATCACAATCCAAAATA 
398 
F8EX13R   cagggcgcagcgatgacCATGTGAGCTAGTGGGCAAA 
   
F8EX14AF   gtagcgcgacggccagtCTGGGAATGGGAGAGAACCT 
601 
F8EX14AR   cagggcgcagcgatgacATGTCCCCACTGTGATGGAG 
   
F8EX14BF   gtagcgcgacggccagtGATCCATCACCTGGAGCAAT 
633 
F8EX14BR   cagggcgcagcgatgacGGGCCATCAATGTGAGTCTT 
   
F8EX14CF   gtagcgcgacggccagtAGCTCATGGACCTGCTTTGT 
729 
F8EX14CR   cagggcgcagcgatgacCATTCTCTTGGATTAATGTTTCCTT 
   
F8EX14DF   gtagcgcgacggccagtTCCAAGCAGCAGAAACCTATT 
629 
F8EX14DR   cagggcgcagcgatgacAGTAATGGCCCCTTTCTCCT 
   
F8EX14EF   gtagcgcgacggccagtGGATGACACCTCAACCCAGT 
604 
F8EX14ER   cagggcgcagcgatgacCCTTCCACGAGATCCAGATG 
   
F8EX14FF   gtagcgcgacggccagtTCCCTACGGAAACTAGCAATG 720 
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F8EX14FR   cagggcgcagcgatgacTCACAAGAGCAGAGCAAAGG 
   
F8EX15F   gtagcgcgacggccagtTGAGGCATTTCTACCCACTTG 
333 
F8EX15R   cagggcgcagcgatgacCCAAAAGTGGGAATACATTATAGTCA 
   
F8EX16F   gtagcgcgacggccagtCAGCATCCATCTTCTGTACCA 
502 
F8EX16R   cagggcgcagcgatgacAAAGCTTCTTATTGCACGTAGG 
   
F8EX17F   gtagcgcgacggccagtcAGGTTGGACTGGCATAAAAA 
431 
F8EX17R   cagggcgcagcgatgacCCCTGGATCAAGTCTCATTTG 
   
F8EX18F   gtagcgcgacggccagtTGGTGGAGTGGAGAGAAAGAA 
396 
F8EX18R   cagggcgcagcgatgacAGCATGGAGCTTGTCTGCTT 
   
F8EX19F   gtagcgcgacggccagtTTGGTATGTATCTCATGCTCATTTT 
282 
F8EX19R   cagggcgcagcgatgacGGAAGAAAGCTGTAAAGAAGTAGGC 
   
F8EX20F   gtagcgcgacggccagtTTTGAGAAGCTGAATTTTGTGC 
262 
F8EX20R   cagggcgcagcgatgacGAAGCATGGAGATGGATTCATTA 
   
F8EX21F   gtagcgcgacggccagtCCACAGCTTAGATTAACCTTTCTCA 
295 
F8EX21R   cagggcgcagcgatgacTGAGCTTGCAAGAGGAATAAGTAA 
   
F8EX22F   gtagcgcgacggccagtTCAGGAGGTAGCACATACAT 
321 
F8EX22R   cagggcgcagcgatgacGTCCAATATCTGAAATCTGC 
   
F8EX23F   gtagcgcgacggccagtTTGACAGAAATTGCTTTTTACTCTG 
328 
F8EX23R   cagggcgcagcgatgacTCCCCCAGTCTCAGGATAACT 
   
F8EX24F   gtagcgcgacggccagtACTGAGGCTGAAGCATGTCC 
284 
F8EX24R   cagggcgcagcgatgacCCCAACCACTGCTCTGAGTC 
   
F8EX25F   gtagcgcgacggccagtTGGGAATTTCTGGGAGTAAATG 
334 
F8EX25R   cagggcgcagcgatgacAAGCTCTAGGAGAGGTGGTATTTTT 
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F8EX26AF  gtagcgcgacggccagtCTGTGCTTTGCAGTGACCAT 
591 
F8EX26AR  cagggcgcagcgatgacTTCTACAACAGAGGAAGTGGTGA 
   
F8EX26BF  gtagcgcgacggccagtGGAGAAACCTGCATGAAAGC 
630 
F8EX26BR  cagggcgcagcgatgacTTGGCCATCACAAATTTCAA 
   
F8EX26CF  gtagcgcgacggccagtTGCAAATGTGCATTTTTCTGA 
614 
F8EX26CR  cagggcgcagcgatgacCCTCCAGCCCCCTTTACTAT 
   
F8EX26DF  gtagcgcgacggccagtCCACCCCCATAAGATTGTGA 
614 
F8EX26DR  cagggcgcagcgatgacCTGAAGAAACCAGCAGGAAAA 
  
264 F8EX26EF  gtagcgcgacggccagtCCCCAAAGGTGATATGGTTTT 
F8EX26ER  cagggcgcagcgatgacTCAGTGTTCACATTTTTATTTCCA 
   
N13F GTAGCGCGACGGCCAGT N/A 
N13R CAGGGCGCAGCGATGAC N/A 
 
“F” and “R” in the primer names abbreviate “forward” and “reverse” respectively 
and define the primer pair used for each amplification. Italicised letters indicate 
N13F and N13R tails that were used for sequencing with primers N13F and N13R 
respectively. “N/A” abbreviates “not applicable.”  “bp” abbreviates base pair. 
 
 Sequence analysis of each test sample involved 37 PCR amplifications that 
included the genomic DNA and a further 12 reactions that used water instead of 
DNA (negative controls for contamination). The 12 negative control amplifications 
used the 37 primer pairs in multiplex as shown in Table 2.5. 
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Table 2.5 Primers pair used for negative control multiplex PCR 
 
Negative Control Multiplex 
F8EX14C+ F8EX8+ F8EX15+ F8EX20 
F8EX14F+ F8EX1+ F8EX12 
F8EX16+ F8EX14A+ F8EX23 
F8EX14B+ F8EX7+ F8EX2 
F8EX26B+ F8EX17+ F8EX22 
F8EX14D+ F8EX4+ F8EX21 
F8EX26C+ F8EX13+ F8EX5 
F8EX26D+ F8EX11+ F8EX6 
F8EX14E+ F8EX18+ F8EX10 
F8P1+ F8EX9+ F8EX24 
F8P2+ F8EX25+ F8EX19 
F8EX26A+ F8EX3+ F8EX26E 
 
 Each control multiplex PCR in Table 2.5 contained both the upstream and 
downstream primers for the relevant exons. For example: F8Ex14C consisted of 
F8Ex14CF+F8Ex14CR.  
 For all amplifications, each primer was present at a final concentration of 1 
µmol/L in the PCR. PCR amplifications were done in a final volume of 25 µL and 
contained the following reagents: DNA (125 ng/µL), Taq DNA polymerase (5U), 
dNTPs (each at 100 μmol/L), MgCl2 (1.5 mmol/L) and Taq DNA polymerase buffer 
(1x).  The PCR regimen comprised (94 
o
C for 30 s; 60 
o
C for 1 min; 72 
o
C for 1 
min) x35 cycles.  
 The PCR product (25 µL) was purified using ethanol precipitation. NaCl 
(0.5 mol/L, 5 µL) and ethanol 100 % (v/v, 60 µL) were added to each well. The 
wells were sealed, the contents mixed by gentle inversion and left for 5 min at RT. 
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The 96 well plate was then centrifuged at 1780 xg for 30 min. The supernatant (85 
µL) was removed and plate was kept at RT for 5 min to dry. Then  50 µL of water 
was added and left for 5 min at RT. Purified PCR product (2 µL) and appropriate 
DNA size standard (pBR322/MspI) were analysed using agarose gel electrophoresis 
(2 % w/v, 450 V, 80 mA). Products were visualised using ethidium bromide staining 
and UV light. The result was recorded using a Polaroid MP4 Land Camera and Fuji 
Film FP-3000 black and white film.  
 For cycle sequencing, a main mix (8 µL) comprising BDT v3.1 Mix (2 µL, 
2.5x stock), sequencing buffer (2 µL, 5x stock), sequencing primer N13 F or N13R  
(1 µL, 3.2 pmol/µL), and water (3 µL) was added directly to purified PCR product 
(2 µL). The cycle sequencing regimen comprised (96 
o
C for 3 min) then (96 
o
C
 
for 
30 s; 50 
o
C
 
for 30 s; 60 
o
C
 
for 4 min) x 25 cycles. Following cycle sequencing, 
reaction products were purified using Centri-Sep columns. Briefly, 7 µL of water 
was added to the cycle sequencing reaction products and then the entire 17 µL was 
gel filtered through a Centri-Sep column. The purified products were submitted to 
be sequenced to the Sequencing Core Facility, Central Biotechnology Services 
(CBS) of Cardiff University School of Medicine. The facility uses a 3130XL 
Applied Biosystems genetic analyser (Applied Biosystems, Warwickshire, UK). 
Sequencing data were analysed using Mutation Surveyor Software Version 4.0.6 
(SoftGenetics, Philadelphia, USA). 
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Chapter 3 
 
Recruitment of Cohorts 
 
 
3.1.  Recruitment of Cohorts  
 
 Two cohorts, each containing 100 individuals, were recruited in Pakistan. 
One cohort consisted of individuals who had previously been diagnosed with 
haemophilia A, whilst the other comprised random healthy controls. Health normal 
controls were recruited from different centres. Individuals were recruited from all 
five provinces of Pakistan (Punjab, Sindh, Baluchistan, Khyber Pakhtunkhwa, Gilgit 
Baltistan) (Figure 3.1). All relevant blood samples and clinical information (age, age 
at first bleed, family history and treatment history) were obtained at the time of 
recruitment. 
 
3.2.  Phenotypic Parameters 
 
  The PT, aPTT, fibrinogen, FVIII:C, FVIII inhibitor, VWF:Ag, FIX:C 
and ABO blood group determination were repeated in Cardiff (Table 3.1). A 
diagnosis of haemophilia A was confirmed for 92 individuals, whilst 7 were found 
to have haemophilia B and 1 was found not to have haemophilia. The 92 
haemophilia A individuals were found to comprise the following severities: mild 
n=5 (5 %), moderate n=24 (26 %) and severe n=63 (69 %) (Table 3.1).  An inhibitor 
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was detected in 4 (4 %) individuals; these were included in Table 3.1, however they 
were excluded from the analyses for all figures. 
 
 
Figure 3.1: Map of Pakistan with location of recruitment centres. Pakistan is a 
sovereign country in South Asia, comprising five provinces – Punjab, Sindh, 
Baluchistan, Khyber Pakhtunkhwa, Gilgit Baltistan – as well as the Islamabad 
capital territory and the federally administered tribal areas in the northwest.  
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Table 3.1 Phenotypic data for haemophilia A individuals from Pakistan 
 
Patient 
ID 
PT 
(sec) 
aPTT 
(sec) 
FVIII:C 
(IU/Dl) 
VWF:Ag 
(U/dL) 
ABO 
Blood 
group 
  
Patient 
ID 
PT 
(sec) 
aPTT 
(sec) 
FVIII:C 
(IU/Dl) 
VWF:Ag 
(U/dL) 
ABO 
Blood 
group 
1 11.6 71.1 2.2 107 O  51 12.3 84 1.2 68 AB 
2 9.8 68.1 3.4 128 B  52 12.7 92.2 1.5 75 A 
3 11.8 131.5 <1 337 B  53 11.1 118.5 <1 173 O 
4 11.1 132.5 <1 181 O  54 11.4 91.7 <1 50 O 
5 13.7 82.5 2.3 179 B  55 11.7 58.5 5 57 O 
6 12.3 81.3 4.5 118 B  56 12.5 117.6 <1 155 B 
7 11.1 97.2 1.3 28 B  57 12.8 114.4 <1 87 O 
8 11.2 114.6 <1 55 AB  58 10.2 62.3 2.8 76 AB 
9 13.1 115.8 <1 58 B  59 13.5 108.3 <1 148 B 
10 12.2 129.9 <1 33 O  60 11 118.1 <1 61 O 
11 10.5 59.9 3.1 41 B  61 9.6 101.9 <1 44 O 
12 11.3 75.6 2.6 66 A  62 11.4 93 <1 186 AB 
13 11.1 121.4 <1 29 A  63* 13.1 110.4 99 100 O 
14 11.2 54.6 <1 39 B  64* 11.7 107.7 82.7 101 B 
15 10.7 98.1 2.2 59 AB  65 12.8 47.3 <1 74 A 
16 11.9 85.6 1.1 37 O  66 12.4 50 9.2 124 A 
17 11.3 102.1 <1 76 B  67* 12.3 54.1 102 125 B 
18 12.5 120.6 <1 46 O  68* 12.3 48 105 174 AB 
19 11.8 127.8 2.7 132 O  69** 12.7 31.7 70 51 O 
20* 13.6 156.4 57 121 B  70 12.4 101.1 <1 60 O 
21 11.3 129.8 <1 34 O  71 10.7 119 <1 84 A 
22 11 116.5 <1 29 O  72 9.3 126.5 <1 39 AB 
23 10.9 78 5.1 36 B  73 16.2 107.1 <1 125 B 
24 12.3 132.5 10.2 121 B  74 10 96.3 <1 81 B 
25 11.4 122.5 <1 35 O  75 10.6 123.6 <1 88 O 
26 10.1 146.3 <1 53 O  76 10.9 129.5 <1 149 A 
27 10.8 112.4 <1 121 O  77 11.3 132.4 <1 82 A 
28 9.9 130.9 <1 90 B  78 10.9 114.6 <1 97 B 
29 11.6 144.5 <1 50 B  79 12.5 98.5 <1 92 O 
30 11.6 92.6 <1 132 A  80 10.3 75.7 2.1 39 B 
31 9.1 54.2 7.5 38 AB  81 12.8 134.4 <1 86 A 
32 13.8 124.1 2.6 50 O  82 13.7 139.2 <1 69 A 
33 12.6 84.7 <1 88 A  83 10.1 106.4 <1 122 O 
34 12.1 104.5 <1 85 B  84 11 109 <1 183 B 
35 13.7 48.6 17.7 38 O  85 10.7 107.7 <1 36 O 
36 12.6 120.2 <1 111 B  86 13.1 71 2.1 77 A 
37 11.4 85.3 1.7 60 O  87 11.3 133.3 <1 40 B 
38 11.3 114.1 <1 63 B  88 12.2 91.4 2.2 127 A 
39 10.2 142.4 3.5 55 O  89 10.8 98 <1 35 A 
40 10 77.8 1.2 122 AB  90 10.2 118.9 <1 51 A 
41 10.7 74.3 1.6 60 O  91 10.5 126.3 <1 67 A 
42 11.2 136.7 <1 73 AB  92 10.7 68.6 2 171 B 
43 10.7 135.8 <1 61 B  93 11.4 61.8 4.3 102 A 
63 
 
44 12 117.6 <1 38 B  94 10.6 135.4 <1 117 A 
45 11.1 143 <1 93 B  95 10.4 92.7 <1 61 O 
46 11.2 135.6 <1 93 A  96 10.8 132.7 <1 148 AB 
47 11.3 148.8 <1 163 AB  97 11.1 115.2 <1 83 B 
48 11 119.1 <1 97 B  98 10.5 115.4 <1 183 O 
49 14.1 103.9 <1 29 O  99* 11.2 71.1 114 119 B 
50 12.5 85 <1 52 B  100* 10.9 51.8 111 127 B 
*Individuals with haemophilia B. ** Individual haemostatistically normal. 
 
 A minor proportion (19 %) of the cohort had minimal access to FVIII 
concentrate, the exact amount used is not known because accurate records were not 
available. Direct questioning of each individual suggested the FVIII concentrate 
usage was about once per year. Individuals with no access to FVIII concentrate (81 
%) were treated intermittently with FFP. Furthermore, none of the individuals had 
access to physiotherapy support. 
 
3.3.  Clinical Findings 
 
Individuals with mild haemophilia A presented with a first bleed at a similar 
age compared to severe (Table 3.2). For all severities, a high proportion of 
individuals first bled at circumcision, other types of first presentation were rarer: 
post traumatic bleed (7 %), bleeding from mouth (4 %), nose (3 %) and tongue (2 
%) and joint pain (2 %). Eighty per cent of the individuals presented with a positive 
family history of bleeding. More than half of the individuals had ≥2 target joints, 
knee was the most affected followed by elbow and ankle (Figure 3.2). Although 
target joint was more prevalent among severe individuals, a high proportion of 
moderately and mildly affected cases also had at least one target joint. For all 
severities combined, 13 % of individuals had no affected joint but most of these 
cases were in their early years of life. Of the moderate individuals, 76 % had at least 
one affected joint compared to 90 % of severe cases. The proportion of knees as the 
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target joint was similar in severe and nonsevere individuals. Severe individuals had 
a higher proportion of elbows and a lower proportion of ankles as target joints 
compared to nonseveres. The findings for haemophilic arthropathy were similar to 
those for target joints.  
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Table 3.2 Characteristics of haemophilia A cohort from Pakistan 
 
 
Parameter Mild Moderate Severe  All 
  (n=5) (n=24) (n=63) (n=92) 
Age at recruitment (years)* 9 (8-40) 18.5 (1.5-50) 13 (1.5-47) 14 (1.5-50) 
Individuals with no access to FVIII concentrate  
n (%) 
3 (60 %) 17 (70 %) 50 (79 %) 70 (76%)   
Individuals with minimal access to FVIII 
concentrate** 
 2 (40 %) 7 (30 %) 13 (21 %) 17 (19 %) 
Age of first bleed (weeks)*  28 (20-288) 38 (1-192) 24 (1-192) 24 (1-288) 
First bleed: circumcision 80 % 80 % 85 % 82 % 
                 Other 20 % 20 % 15 % 18 % 
Positive family history 80 % 88 % 72 % 80 % 
Number of joints with haemophilic arthropathy:     
Knee  4 (40 %) 19 (40 %) 66 (52 %) 89 (48 %) 
Elbow 3 (30 %) 12 (25 %) 50 (40 %) 65 (35 %) 
Ankle  2 (20 %) 10 (21 %) 20 (16 %) 32 (17 %) 
Total number of affected joints* 0 (0-3) 1 (0-3) 2 (0-6) 2 (0-6) 
Individuals with no affected joint 2 (40 %) 4 (17 %) 7 (11 %) 13 (14 %) 
Target joint:   none  60 % 24 % 11 % 17 % 
            1 0 % 37 % 31 % 31 % 
           ≥2 40 % 39 % 59 % 52 % 
Target joint***      
Knee  3 (30 %) 23 (48 %) 67 (53 %) 93 (51 %) 
Elbow  2 (20 %) 6 (13 %) 34 (27 %) 42 (23 %) 
Ankle  3 (30 %) 10 (21 %) 16 (13 %) 29 (16 %) 
 
*Values presented are median (range). ** The exact access to FVIII concentrate is 
not known because accurate records had not been kept, on average treatment with 
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FVIII concentrate was about once per year. ***Values presented are: the absolute 
number of the target joint and the proportion as a percentage of the total number of 
that joint in the relevant group.  For example in severe individuals: 67 knee target 
joints in 63 individuals, percentage = (67/126) x 100 = 53 %. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Joint arthropathy in haemophilia A individuals in Pakistan. (A) 18 -year-
old man (severe), (B) 21-year-old man (severe), (C) 9-year-old boy (severe with 
inhibitors), (D) 41-year-old man (mild). 
A 
B 
C 
D 
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3.4.  Discussion 
 
 In the present study, a cohort of 100 individuals – for whom a diagnosis of 
haemophilia A had been made in Pakistan – was recruited from the five provinces of 
the country. Confirmatory phenotypic testing in Cardiff revealed that 7 individuals 
in fact had haemophilia B and one person was unaffected.  
 Most of the individuals in this study had multiple joint involvements, 
including those with laboratory defined mild disease. Knees were the most 
frequently affected joints, followed by elbows and ankles. A number of factors 
might explain the more frequent involvement of these joints: first, the knee, elbow 
and ankle predominately move only in two directions compared with other joints 
that can move more freely; second, these three joints are not surrounded by muscles 
that may provide protection while moving.  More than half of individuals had 
involvement of ≥ 2 joints; the number of joints involved increased with age and 
severity. In this cohort, about 78 % of individuals bled at circumcision, very few 
individuals gave a history of bleeds from nose, mouth, tongue or post-trauma. 
Overall, the bleeding history was less in mild individuals, greater in moderate 
individuals and greatest in severe. Individuals with severe haemophilia A and mild 
haemophilia had first bleeds at about the same age because these were induced by 
circumcision. These results are consistent with other international studies: a group 
from China reported that most severe haemophilia A individuals presented with a 
first  bleed in their initial year of life (128), a group from Germany reported a 
similar finding that most individuals with haemophilia A have their first bleeding 
68 
 
episode within the first year of life (129). However, the studies cannot be compared 
because of the important effect that circumcision has had in the cohort from 
Pakistan.    
 The misdiagnosis of haemophilia revealed here-in may be due to a lack of 
relevant laboratory expertise and facilities in some parts of Pakistan. The 
misdiagnoses may have gone unnoticed because very few individuals had access to 
coagulation factor concentrate. Treatment, when it was accessible, was principally 
with FFP which contains both factor VIII and IX. Haemophilia expertise in Pakistan 
is localized principally to certain developed areas. Pakistan, a country with an 
approximate population of 176 million (World Health Organisation (WHO) 2011 
data, URL http://www.who.int/gho/countries/pak.pdf) is one of several countries 
comprising the “Eastern Mediterranean region” as designated by the World 
Federation of Haemophilia (WFH) (URL 
http://www.who.int/gho/countries/pak.pdf). Pakistan is relatively less urbanized 
than other areas of this region, with 36 % of the population living in urban districts 
compared to the regional average of 50 % (WHO 2011 data, URL 
http://www.who.int/gho/countries/pak.pdf). Availability of medical services is 
limited in non-urban areas. There is a relatively lower rate of available health 
workforce: 8.1 physicians per 10,000 capita compared to 10.9/10,000 in the Eastern 
Mediterranean region, and similarly 5.6/ per 10,000 nurses/midwives compared to 
15.6 per 10,000). The factor VIII concentrate usage in Pakistan is 0.01 U/head of 
population which is one of the lowest on the world 
(http://www1.efh.org/publications/files/pdf). Many people with haemophilia have 
limited access to clinicians and physiotherapists with expertise in haemophilia care.  
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The findings highlight the need for more wide spread expertise in the 
laboratory diagnosis and clinical management of haemophilia in Pakistan. Although 
these findings are consistent with  those of other studies, the severity of clinical 
symptoms is greater overall in this cohort, possibly reflecting lack of access to on-
demand or prophylatic treatment.  
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Chapter 4 
 
Characterisation of F8 defects in haemophilia A in Pakistan 
 
4.1.  Results  
 
4.1.1. Characterization of Pathological Sequence Variants 
 
 The causative F8 defect was investigated in the 92 individuals with 
haemophilia A. Initially, all of the severe haemophilia A individuals (n=63) were 
investigated for the Inv22 and Inv1 and the former was found to be present in 18 of 
the 63 (29 %) severe individuals, whilst the latter was present in 1/63 (1.6 %) (Table 
4.2).  F8 sequence analysis, covering the essential regions of the gene (promotor, 
exons, splice junctions and 3’ polyadenylation signal region), was then applied to 
the remaining severe individuals and to the mild and moderate cases (a total of 73 
altogether). This identified the pathological sequence variant (or a candidate variant) 
in 62 cases, leaving 11 individuals in whom a causative gene defect was not found 
(Table 4.1). 
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Table 4.1 Genetic and phenotypic data for haemophilia A individuals from 
Pakistan. 
 
Individual 
 
FVIII:C 
(IU/dL) 
Pathological Sequence Variant HAMSTeRS 
 
1 2.2 c.536C>G; p.(Ser179Cys) N 
2 3.4 c.5324T>G; p.(Leu1775Trp) N 
3 <1 c.5507G>A; p.(Trp1836Arg) N 
4 <1 Inv22 - 
5 2.3 c.6187+1G>A N 
6 4.5 c.6406G>A; p.(Gly2136Arg) Y 
7 1.3 c.4099A>T; p.(Thr1367Ser) N 
8 <1 c.6972C>T; p.(Tyr2324*) Y 
9 <1 c.3385C>T; p.(Gln1129*) N 
10 <1 Inv22 - 
11 3.1 No result n/a 
12 2.6 c.4379delA; p.(Asn1460Ilefs*5) N 
13
Inhib
 <1 del of Ex 15,16,17 & 18 Y 
14 <1 Inv22 - 
15 2.2 c.4379delA; p.(Asn1460Ilefs*5) N 
16 1.1 c.4379delA; p.(Asn1460Ilefs*5) N 
17 <1 c.1332delA; p.(Val445Serfs*37) N 
18 <1 c.1775delT; p.(Val592Alafs*68) N 
19 2.7 c.862delA; p.(Ile288Tyrfs*10) N 
21 <1 Inv22 - 
22 <1 Inv22 - 
23 5.1 c.3930T>A; p.(Tyr1310*) N 
24 10.2 c.601+17G>A N 
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25 <1 c.1694G>A; p.(Gly565Glu) N 
26 <1 c.1694G>A; p.(Gly565Glu) N 
27 <1 c.4825dupA; p.(Thr1609Asnfs*4) N 
28 <1 Inv22 - 
29 <1 No result n/a 
30 <1 c.-966G>T N 
31 7.5 c.7021G>A; p.(Glu2341Lys) Y 
32 2.6 c.1786T>C; p.(Ser596Pro) Y 
33 <1 c.1332A>C; p.(Lys444Asn) Y 
34 <1 c.3280G>T; p.(Glu1094*) N 
35 17.7 c.6047G>A; p.(Arg1216Gln) N 
36
 Inhib
 <1 c.5724G>A; p.(Trp1908*) N 
37 1.7 c.4379delA; p.(Asn1460Ilefs*5) N 
38 <1 No result n/a 
39 3.5 c.4430delA; p.(Glu1477fs*90) N 
40 1.2 c.4379delA; p.(Asn1460Ilefs*5) N 
41 1.6 No result n/a 
42 <1 c.2962-2963delAG; p.(Ser988Trpfs*2) N 
43 <1 c.2962-2963delAG; p.(Ser988Trpfs*2) N 
44 <1 c.195C>G; p.(Tyr65*) Y 
45 <1 c.195C>G; p.(Tyr65*) Y 
46
 Inhib
 <1 c.1332delA; p.(Val445Serfs*37) N 
47 <1 c.2686A>T; p.(Lys869*) N 
48 <1 Inv22 - 
49 <1 c.1332delA; p.(Val445Serfs*37) N 
50 <1 c.1332delA; p.(Val445Serfs*37) N 
51 1.2 No result n/a 
52 1.5 No result n/a 
53 <1 c.1332delA; p.(Val445Serfs*37) N 
54 <1 c.5797G>T; p.(Glu1933*) N 
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55 5 c.1898T>C; p.(Met633Thr) N 
56 <1 No result n/a 
57 <1 Inv22 - 
58 2.8 No result n/a 
59 <1 c.1694G>A; p.(Gly565Glu) N 
60 <1 c.1365dupT; p.(Lys456fs*) N 
61 <1 Inv22 - 
62 <1 c.5566T>G; p.(Tyr1856Asp) N 
65 <1 Inv22 - 
66 9.2 No result n/a 
70 <1 c.205-206delCT; p.(Leu69Valfs*13) N 
71 <1 Inv22 - 
72 <1 c.1576G>T; p.(Glu526*) N 
73
 Inhib
 <1 c.5866-5867dupAG; 
p.(Asp1956Glufs*75) 
N 
74 <1 c.1332delA; p.(Val445Serfs*37) N 
75 <1 c.1786T>C; p.(Ser596Pro) Y 
76 <1 c.1786T>C; p.(Ser596Pro) Y 
77 <1 c.1786T>C; p.(Ser596Pro) Y 
78 <1 c.1332delA; p.(Val445Serfs*37) N 
79 <1 Inv1 - 
80 2.1 No result n/a 
81 <1 c.6869G>A; p.(Trp2290*) Y 
82 <1 c.6869G>A; p.(Trp2290*) Y 
83 <1 c.1063C>T; p.(Arg355*) Y 
84 <1 c.901C>T; p.(Arg301Cys) Y 
85 <1 Inv22 - 
86 2.1 c.5999-11G>A N 
87 <1 Inv22 - 
88 2.2 c.3637delA; p.(Ile1213Phefs*5) N 
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89 <1 Inv22 - 
90 <1 Inv22 - 
91 <1 Inv22 - 
92 2 c.6972C>T; p.(Tyr2324*) Y 
93 4.3 No result n/a 
94 <1 Inv22 - 
95 <1 Inv22 - 
96 <1 c.6972C>T; p.(Tyr2324*) Y 
97 <1 c.6972C>T; p.(Tyr2324*) Y 
98 
 
<1 
 
No result n/a 
 
 
Y and N respectively indicate mutation present or not listed (novel variant) in 
Haemophilia A Mutation, Structure, Test and Resource Site (HAMSTeRS). There 
were 30 novel variants, recurrence of 8 of these results in 43 instances of N in the 
table. “-” indicates known pathogenic change not listed in HAMSTeRS; Inv22 and 
Inv1 respectively abbreviate intron 22 and intron 1 inversion; “n/a” abbreviates “not 
applicable”. InhibIndicates individuals with FVIII inhibitors.   
 A diverse spectrum of mutations was found in the cohort and these 
comprised point mutations (n=39, including missense, nonsense, splice site and 
promoter region changes), inversions (n=19, Inv22 and Inv1) and frameshifts (n=22, 
deletions nucleotide duplications) (detailed in Table 4.1, summarized in Table 4.2). 
The most frequent mutation type overall was point mutation (42 % of individuals), 
followed by the Inv22 (20 % of all cases). 
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Table 4.2 Summary of F8 defects in a haemophilia A cohort from Pakistan. 
 
Point mutation 
(n=39) 
Inversion 
(n=19) 
Frame Shift 
(n=22) 
Deletion 
of exons 
(n=1) 
No 
change  
(n=11) 
Total 
Individuals 
(n=92) 
      
Missense Nonsense Splice 
site 
Promoter 
region 
Inv22 Inv1 nucleotide 
deletion 
nucleotide 
duplication 
   
18 17 3 1 18 1 19 3 1 11 92 
 
 
Inv22 and Inv1 respectively abbreviate intron 22 and intron 1 inversions. “No change” indicates individuals for whom no mutation was 
detected.  
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Aside from the Inv22, 8 mutations were recurrent (Tables 4.1 and 4.3). 
Analysis of 7 intragenic single nucleotide polymorphisms (SNPs) showed that each 
recurrent mutation was associated with a specific haplotype (Table 4.3). 
 
Table 4.3 Haplotypes found in recurrent mutations among individuals with 
haemophilia A from Pakistan. 
Mutation 
Individual 
ID 
Number 
Haplotype 
rs7058826 rs28370212 rs1800291 rs1800292 rs489352 rs1509787 rs1050705 
Intron 7 Exon 14 Exon 14 Exon 14 Intron 18 Intron 25 Exon 26 
c.1010-
27G>A 
c.3621C>T c.3780C>G c.3864A>C c.5998+91T>A 
c.6901-
2607C>T 
c.*1672A>G 
c.1332delA 17 G C C C A C G 
  46 G C C C A C G 
  49 G C C C A C G 
  50 G C C C A C G 
  53 G C C C A C G 
 74 G C C C A C G 
 78 G C C C A C G 
         
c.1786T>C 32 A C G A A C G 
 75 A C G A A C G 
 76 A C G A A C G 
 77 A C G A A C G 
         
c.1694G>A 25 G C C A T C A 
 26 G C C A T C A 
 59 G C C A T C A 
         
c.195C>G 44 G C C A T C A 
 45 G C C A T C A 
         
c.2962-
2693delAG 
42 G C C A T C A 
 43 G C C A T C A 
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c.4379delA 12 G C C A T C A 
 15 G C C A T C A 
 16 G C C A T C A 
 37 G C C A T C A 
 40 G C C A T C A 
         
c.6869G>A 81 G C C A T C A 
 82 G C C A T C A 
         
c.6972C>T 8 G C C A T C A 
 92 G C C A T C A 
 96 G C C A T C A 
  97 G C C A T C A 
 
“rs” designations refer to reference SNP identity numbers in the international SNP 
data base (URL http:www.ncbi.nlm.nih.gov/snp/). 
 
 
Table 4.4 Prediction of functional effect of the protein 
 
Mutation   Polyphen-2 Score   SIFT Score 
 
c.5362C>G; p.(Ser179Cys)  1     0 
c.5324T>G; p.(Leu1775Trp)  1     0 
 
c.5507G>A; p.(Trp1836Arg)  1     0 
 
c.1694G>A; p.(Gly565Glu)  1     0 
 
c.1898T>C; p.(Met633Thr)  0.993     0 
 
c.5566T>G; p.(Tyr1856Asp)  1     0 
 
c.4099A>T; p.(Thr1367Ser)  0.20     0.25 
 
PolyPhen-2 scores: 1 = most damaging, 0 = least damaging. SIFT Human Protein 
scores: 0 = most damaging, 1 = least damaging. 
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Table 4.5 List a mixture of nationality and country names for noval mutation, 
the nationalities are: 
 
 
Nationality   Noval Mutation (%)  References 
 
 Indian    37 %   (130) 
 Spanish   11 %   (131) 
 French    75 %   (132) 
 Spanish   32 %   (133) 
 American   38 %   (134) 
 
 
Table 4.6 List a mixture of nationality and country names for Inv22, the 
nationalities are: 
 
Nationality   Inv22  Mutation  References 
 
 Indian    51 %    (130) 
 Spanish   52 %    (133) 
 Italian    42 %    (135) 
 Mexican   45 %    (136) 
 Hungarian   50 %    (137) 
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4.2.  Discussion 
 
 The causative gene defect was investigated in the 92 individuals with 
haemophilia A, a mutation or candidate mutation in F8 was found in 81 of them. 
The sequence variants found were heterogeneous:  point mutations (including 
missense, nonsense, splice site and promoter region changes), inversions (Inv22 and 
Inv1) and frameshifts (deletions and duplications). Point mutation (42 % of 
individuals) was the most frequent change found in this cohort, followed by Inv22 
(20 % of cohort, 29 % of severe cases).  
  The lack of laboratory expertise and facilities for pheontypic diagnosis in 
Pakistan (Chapter 2, section 2.4.) is paralleled by an even greater insufficiency for 
genetic diagnosis. Although carrier status and prenatal diagnosis using molecular 
analysis are availible for thalassaemia, such services have not yet been adopted for 
haemophilia. Access to molecular diagnosis would allow women to establish their 
carrier status and make informed reproductive decisions. Families with a severe 
phenotype are particularly dependent on haemophilia care, and for these families 
carrier detection and genetic counselling are important, among the other factors. 
The genetic information generated in this study can be used within the relevant 
families for diagnosis of individuals with haemophilia A and for the carrier 
detection and prenatal diagnosis.  
Research into F8 defects has been undertaken by other investigators for 
haemophilia A individuals from Pakistan, however the cohort size was not large 
(n=56) and comprised an unknown complement of both Pakistani and Indian cases 
(138). The latter study predated the discovery of the Inv22 and focused specifically 
on potentially hypermutable CpG sites. The screening strategy led to the 
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identification of CG-transitions in three Pakistani individuals, but no other F8 
defects in this ethnic group were reported.  
 The study presented here-in identified 30 mutations that have not been 
previously reported (Table 4.1) and the frequency of noval mutation is similar with 
other nationality (Table 4.3). The novel mutations comprised 8 missense, 7 
nonsense, 3 splice site, 1 promoter region, 3 single nucleotide duplications and 8 
with nucleotide deletions (Table 4.1). 
  The novel variants can be divided into those with a high probability 
of pathology (nonsense, duplication, deletion and the splice site change 
c.6187+1G>A which destroys the conserved GT of the splice junction) (total = 19) 
and those for which a detrimental effect was uncertain (missense, promoter region 
and the other two splice site changes) (total = 11). The latter represent unclassified 
sequence variants. The possibility that these may be neutral SNPs present in the 
population was explored by screening for each in a cohort of 50 haemostatically 
normal males from Pakistan which was recruited from different region of the 
country. Ten of the unclassified variants were not found in the normal population, 
supporting a pathogenic role. The remaining unclassified variant (c.601+17G>A) 
was detected in one control sample. This sequence change was associated with mild 
haemophilia A (P24, Table 4.1) and its presence in the normal population may be 
explained by individuals with a low FVIII level who do not come to clinical 
attention. 
 The unclassified missense variants were assessed for potential pathological 
impact using two programs for the prediction of functional effects:  Polyphen 2 uses 
features comprising the sequence, phylogenetic and structural information to assess 
the impact of the missense change on the structure and function of a protein (139)] 
(URL http://genetics.bwh.harvard.edu/pph2/); SIFT impact prediction is based on 
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the degree of conservation of amino acid residues in sequence alignments derived 
from closely related sequences (140)] (URL http://sift.jcvi.org/). Each missense 
variant scored highly for predicted pathological effect in both programs (Table 4.4). 
The above findings support a causative role for the novel missense variants 
in haemophilia A. In the case of c.1694G>A p.(Gly565Glu) and c.1786T>C 
p.(Ser596Pro), further support for a causative role arises from the observation that 
they are recurrent (Table 4.1). Indeed, 8 sequence variants characterised in this 
cohort were recurrent. The possibility that recurrence may be due to a founder effect 
was investigated by comparison of F8 SNP haplotypes associated with each. A 
given recurrent mutation was found in association with an identical F8 haplotype in 
all individuals in whom it occurred (Table 4.3), supporting the possibility of a 
founder effect.  
 A causative gene defect was not found in 11 individuals, a plausible 
explanation for this is that the defect occurs outside the F8 regions screened. 
However, why this should occur so frequently is difficult to explain and may 
ultimately only be understood when the mutation(s) is(are) finally characterized.  
 This study of a large haemophilia A cohort from Pakistan showed a diverse 
spectrum of mutations, similar to studies done in other nationalities. Consistent with 
those studies, point mutations were the predominant gene defect in the cohort and, 
in severe individuals, the Inv22 showed a high frequency (Table 4.6). This cohort 
additionally provided 30 novel mutations thereby expanding the known molecular 
basis for hereditary haemophilia A. 
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Chapter 5 
 
Haemophilia Joint Health Score and Gilbert Score 
 
Recurrent joint bleeding in an individual with haemophilia A leads to joint 
damage which is associated with pain, loss of range of motion and function and 
physical and psychological destruction (141). Knees, elbows and ankles are the 
most commonly affected joint in haemophilia, about 80% of haemarthrosis occur in 
these joints (142).  
 
Different joints score are used to monitor the joint health and evolution of 
treatment in haemophilic, HJHS and Gilbert scores are among them (142). Gilbert 
score mainly composed of four parameters pain, bleeding, physical examination and 
X-ray examination; it is the most widely used tool for the joint assessment for 
individuals with severe haemophilia A who have severe arthropathy. HJHS is an 
11-items score, mainly composed for young children with minimal arthropathy or 
the group who have on prophylaxis.  
 
There are certain limitations of the HJHS, this instrument is primarily 
designed for the individuals with milder arthropathy, therefore it may not be very 
useful in developing countries where prophylaxis is not available and majority of 
the haemophilia population are on-demand treatment.  
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In this study, both HJHS and Gilbert score were employed to assess the joint 
changes in individuals who had minimal access to replacement therapy and found a 
very close association between them. Preferably, both health scores are not 
performed in acute condition: in the presence of joint bleed, acute pain or in 
inflamed joint.   
5.1.  Results  
 
5.1.1. Haemophilia A severity and joint health scores  
 
 HJHS and Gilbert score were determined for all recruited individuals. A 
strong correlation (r =0.97) was found between the scores in individuals with both 
severe and mild arthropathy (Figure 5.1). 
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Figure 5.1: Correlation between HJHS and Gilbert score. The two measures of joint 
health score showed a strong positive correlation. 
 Both HJHS and Gilbert score were studied according to disease severity and 
found to be higher for severe compared with nonsevere individuals, this was 
statistically significant (Figure 5.2A and 5.2B). Despite this, many individuals with 
nonsevere disease had significant joint pathology. In the severe group, the median 
(range) for HJHS was 25 (0-87) and for Gilbert score was 19 (0-63) compared to 
nonsevere 17 (0-53) and 12 (0-40) respectively (Figure 5.2A and 5.2B). The 
nonsevere group comprised 5 individuals with mild haemophilia and 24 moderate 
cases, of which some also had significant arthropathy: median (range) of HJHS and 
Gilbert score were respectively 0 (0-52) and 0 (0-40) (mild group), 9 (0-53) and 14 
(0-36) (moderate group). 
 
5.1.2. Age and Joint Health Scores 
  
 Both HJHS and Gilbert score were studied according to developmental age 
group (<12 years, 12-16 years and >16 years) and across three groups, a statistically 
significant difference (P≤0.001) was observed. Inter-group comparisons showed 
that both scores were significantly different between individuals <12 years and the 
other age groups, whilst there was no significant difference in joint health scores 
between individuals 12-16 years compared with those >16 years (Figure. 5.3A and 
5.3B). 
In the age group <12 years, both scores were significantly different between 
severe and nonsevere groups; this difference was not seen in the older individuals 
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(Figure 5.4A and 5.4B). The median ages of the two groups were 13 years for 
severe and 16 years for nonsevere. 
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Figure 5.2: HJHS and Gilbert score according to haemophilia A severity. HJHS 
(Panel A) and Gilbert score (Panel B) both showed a statistically significant 
difference between severe and nonsevere individuals, however there was 
considerable overlap between both groups. Box-whisker plots show interquartile 
range and median value. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Figure 5.3: HJHS and Gilbert score according to age. HJHS (Panel A) and Gilbert 
score (Panel B) showed a statistically significant difference between <12 years and 
each of the other two age groups. There was no significant difference in the joint 
scores between 12-16 years and >16 years. “o” indicates an outlier. 
88 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
Figure 5.4: Trend of HJHS and Gilbert score according to haemophilia A severity 
and age. Both HJHS (Panel A) and Gilbert score (Panel B) were significantly 
different between severe and nonsevere groups in age <12 years, but not thereafter. 
The perpendicular lines indicate the standard error of the mean.  
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 In the subset of individuals with severe haemophilia A, both scores gave a 
very similar picture to the above with regard to age, with the exception that both the 
HJHS and Gilbert Score were not significantly different between <12 years and 12-
16 years (Figure 5.5A and 5.5B). Due to insufficient individuals in the nonsevere 
group, similar comparisons according to age were not possible.   
 When comparing the severe and nonsevere groups there was a marked 
difference in the < 12 year olds. At this age the severe individuals had evidence of 
significant arthropathy (median HJHS 12 and Gilbert score 11). In contrast, in the 
nonsevere individuals < 12 years the HJHS and Gilbert scores were low with a 
median of 1.5 and 1.5, respectively. This difference between severe and nonsevere 
individuals was not found in older as the joint scores in the severe group tended to 
plateau whilst in the nonsevere the joint scores progressed.  
 
5.1.2. Causative Mutation and Joint Health Scores  
 
 In order to explore whether different mutation types underlying severe 
haemophilia A may have a differential effect on joint health, HJHS and Gilbert 
score were inspected for missense, nonsense, frameshift and Inv22 mutations (52 of 
the 59 severe, non-inhibitor individuals). There was no significant difference for 
either score across these mutation types or in pair-wise comparisons between them 
(Figure 5.6A and 5.6B). 
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Figure 5.5: HJHS and Gilbert score according to age for severe haemophilia A 
individuals. Both HJHS (Panel A) and Gilbert score (Panel B) were significantly 
different between <12 years and >16 years but not between <12 years and 12-16 
years (P~0.2 for each score). 
91 
 
 
 
 
 
 
 
 
 
 
 
 
 
.  
 
 
 
 
 
 
 
 
 
 
Figure 5.6: HJHS and Gilbert score according to F8 mutation type in severe 
haemophilia A. HJHS (Panel A) and the Gilbert score (Panel B) showed no 
statistical difference between any of the mutation types. 
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5.2.  Discussion 
 Haemophilia A is associated with recurrent joint bleeding which leads to 
synovitis and debilitating arthropathy. Coagulation FVIII level is an important 
determinant of bleed number and development of arthropathy. This study 
investigated musculoskeletal status in individuals with haemophilia A who had 
minimal assess to both FVIII concentrate and multidisciplinary haemophilia care. 
HJHS and Gilbert score were found to be higher in severe compared with nonsevere 
individuals, consistent with international studies in which cohorts did have access to 
FVIII replacement: a Canadian study investigated 226 boys with mild, moderate or 
severe haemophilia (both A and B included) and found a higher HJHS in severe 
individuals. They also observed that HJHS was 97 % more efficient than the Gilbert 
score at differentiating severe haemophilia from mild and moderate, it was also 
noticed that HJHS was 74 % more efficient than  Gilbert score at differentiating 
individuals treated with prophylaxis compared to on demand (143). Even though the 
individuals in those studies were on prophylaxis or on-demand therapy, the severity 
of haemophilia still played an important role in joint health, as found in our cohort 
which had minimal access to FVIII concentrate.  
 An important issue with regard to the joint score measurements is 
reproducibility. In keeping with studies such as those cited above, joint scores in the 
present investigation were measured on a single occasion only, however all were 
assessed by the same person throughout the study, thereby minimizing differences 
that could arise through subjectivity on the part of the investigator. Reproducibility 
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is, however, an issue in that, even with a sole investigator, joint measurements taken 
on different days for the same affected individual could differ according to the 
circumstances of the latter. 
 The progression of haemophilic arthropathy was investigated according to 
developmental age. Both joint health scores were significantly lower in younger 
individuals compared with older. Joint bleeds typically start between 1 and 3 years 
of age in children with haemophilia (144), especially those with severe disease, and 
this was found in the present study. This was reflected in the joint scores because 
most of the children aged less than 12 years had evidence of significant arthropathy. 
In contrast, individual with nonsevere disease had much lower joint scores at this 
age, probably because they were less prone to spontaneous and recurrent 
haemarthroses. These differences in joint scores between severe and nonsevere 
individual had narrowed and disappeared by the age of 12 years and old. This 
implies that factor VIII levels in the mild to moderate range cannot protect joints 
longer term if individuals have very limited access to factor VIII replacement 
therapy. The high proportion of individual with nonsevere disease who had target 
joints, as described in chapter 3 supports this concept.  This has been seen by other 
groups (145, 146). In the absence of FVIII concentrate, there is little to prevent 
arthropathy appearing as early as the first decade in severely affected individuals. 
Our data suggest that haemophilic joint damage starts at an early age in severely 
affected individuals and progresses until the age of 12-16 years, by which time 
aggregative damage approaches maximum and little further progression in 
arthropathy is possible. In contrast, the low levels of factor VIII in mild and 
moderate disease can partially protect against arthropathy in young children but not 
old individual.  
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 Several studies have reported a positive relationship between age and HJHS: 
a Lithuanian study (n=20) showed higher HJHS in older children (mean score = 
24.5) compared with younger (mean score = 11.6) (147); a cohort of 39 individuals 
with haemophilia from Brazil showed a statistically significant positive correlation 
of Gilbert score with age (148). A group from London examined the influence of 
various factors – age, prophylaxis, history of high-titre inhibitors (HTI) and 
bleeding events on HJHS and found a positive association of HJHS with age. 
Furthermore, they observed that in the non-HTI group, HJHS was higher in those 
individuals where prophylaxis was started in late age group compared to other 
group where prophylaxis started in early years of life (149). Despite the fact that in 
each of these studies, the cohorts were either on prophylaxis or on-demand 
treatment, the joint health scores increased with age, however the magnitude of 
increase was not as great as observed in our cohort. The protection against joint 
pathology afforded by prophylaxis is not only a result of increasing the 
baseline/trough FVIII level, but also on intermittent peaks and appropriate 
physiotherapy. The progression of arthropathy with age is likely to be, at least in 
part, a result of inadequate access to FVIII replacement, and also due to a lack of 
access to specialised physiotherapy care. It is not possible to define what impact 
specialist physiotherapy would have had, but at a minimum it could be expected to 
help individuals cope better with their musculoskeletal disability and potentially 
improve joint function.  
In this cohort, more than half of individuals had ≥ 2 joint involvement and 
the number of joints involved increased with age (Chapter 3, Table 3.2). 
Importantly, target joints were common in individuals with both moderate and mild 
haemophilia. 
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As shown the next chapter (Chapter 6, Figure 6.12), a negative correlation 
between TG and joint health scores was observed in nonsevere individuals (there 
was no correlation in the severe group). This suggests that the baseline FVIII level 
is more important than global haemostasis in predisposing an individual to 
arthropathy. Additionally, it is also plausible that, once joint damage is initiated, it 
becomes an on-going process in which TG has little (if any) role whilst, in contrast, 
factors relating to inflammation may come to the fore. Our data indicate that 
destructive changes occur before 12 years of age, from which it could be inferred 
that coagulant treatment early in life may be important to limit or prevent 
arthropathy as shown previously (150).  
The comparison of HJHS and Gilbert score between different mutation types 
– missense, nonsense, frameshift and the intron 22 inversion – in severe 
haemophilia A showed no significant difference for either joint health score. Thus, 
although the mutation is the basis of the disorder, in severe individuals the nature of 
the gene defect does not correlate with the degree of arthropathy. This is consistent 
with the findings of  Chapter 6 (151) in which it was demonstrated that TG does not 
appear to be influenced by the nature (missense or null) of the F8 mutation.  
This study provides the first data on musculoskeletal assessment using 
HJHS and Gilbert score in individuals with haemophilia A who have minimal 
access to FVIII replacement therapy. Pakistan, a country with an approximate 
population of 176 million (World Health Organisation (WHO) 2011 data, URL 
http://www.who.int/gho/countries/pak.pdf) has around 1,500 individuals diagnosed 
with haemophilia (A or B) (http://www.org/publications/files/pdf), a significant 
under-representation based upon the size of the populace with the expected number 
being about 17 500. The management of haemophilia in Pakistan has been limited 
until now, the per capita usage of FVIII concentrate is very low compared to other 
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countries in the same region (“Eastern Mediterranean”, World Federation of 
haemophilia (WFH) designation). The WFH has established that 1 IU per capita of 
FVIII concentrate should be the minimum target to achieve the optimal survival 
within the haemophilia population. However, to preserve the joint function or 
achieve a good quality of life, a higher level of FVIII concentrate would be 
required. According to a WFH 2010 report, Pakistan has the lowest per capita 
usage of FVIII concentrate (0.01 IU/person) compared to the rest of the countries in 
this region (http://www1.efh.org/publications/files/pdf). The problems with 
management of haemophilia in Pakistan are insufficient awareness, inadequate 
diagnostic facilities, insufficient multidisciplinary teams (especially physiotherapy) 
and limited factor concentrates for treatment. Despite the fact that 80 % of the 
individuals had positive family history, due to the insufficient awareness of this 
disorder, parents circumcised their children in the early weeks of life resulting in 
bleeding in many cases. In Pakistan, priorities in establishing services for 
haemophilia should include the training of health care workers, setting up 
haemophilia care centres, establishing laboratories able to diagnose inherited 
bleeding disorders, introducing a registry, educating affected individuals and their 
families about the condition, providing low-cost factor concentrate and appropriate 
education regarding the management of joint bleeds.  
 In conclusion, this study of haemophilia A individuals from Pakistan who 
had minimal access to FVIII concentrate is the first to assess the correlation 
between HJHS and Gilbert score in such a cohort and demonstrated that the two 
scores correlate strongly. In addition, this study showed a relationship between the 
joint health scores and (i) severity of haemophilia A, and (ii) age. The study 
revealed that having a baseline FVIII above 1 IU/dL did not protect against severe 
musculoskeletal disability in older individuals. In the absence of proper treatment 
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(prophylaxis or on demand), individuals are at risk of target joints and severe 
arthropathy from their early years of life. Additionally, this study indicated that for 
individuals with severe haemophilia A, although the gene defect underlies the 
disorder, the nature of the defect has little influence on the severity of arthropathy. 
Thus, whether FVIII is produced but dysfunctional or not produced at all 
(respectively missense and null mutations), appears to have little bearing on the 
mechanisms that lead to arthropathy. 
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Chapter 6 
 
Thrombin Generation 
  
 To measure the ability of plasma to generate thrombin, TG assay is used 
which investigate the propagation phase (where the bulk amount of thrombin is 
generated) and termination phase (where the thrombin generation is shut down by 
anticoagulant pathway), in contrast to PT and aPTT which investigate the initiation 
phase (where the trace amount of thrombin is generated) of cell based model of 
coagulation.  Therefore, the resulting thrombogram reflects all pro- and 
anticoagulant reactions that regulate all the process involved in the formation and 
inhibition of thrombin (152). 
 In 1953, the first TG assay was introduced; thrombin was measured by 
subsampling method. Due to time consumption and technical difficulty, over time, 
subsampling method was replaced by chromogenic technique and as a result of 
successive improvement both techniques were replaced by CAT. Among several 
advantages of CAT assay, one of important fact is that this assay can be easily 
modified for specific purpose.   
 In CAT assay, low affinity fluorogenic substrate (Z-Gly-Gly-Arg-AMC) is 
used to continue monitor of thrombin activity in plasma. In this assay, plasma is 
triggered with an appropriate amount of TF and synthetic phospholipids vesicles 
PL. To correct the” inner-filter” effect, a known amount of substrate converting 
activity known as thrombin calibrator (α2-macroglobulin) is used. The α2-
macroglobulin is a form of thrombin that cannot be inhibited by plasma protease 
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inhibitor. The assay is performed in a microtitre plate and fluoresce reading is 
automatically converted by using a reserved software. To minimize the artefacts 
introduced at the time of sample collection following parameters were taken: blood 
was collected using 21-gauge needle with minimum suction into Haematologic 
Technologies Inc blood collecting tubes containing sodium citrate/CTI (20 mmol/L) 
tris, 150 mmol/L NaCl, 11 mmol/L citrate, 50 µg/mL CTI. CTI collecting tubes 
were used for mesurment at 1 pmol/L, 3 pmol/L and 5 pmol/L. During the whole 
process, for a internal quality control pooled PPP from healthy individuals were run 
in triplicate.  
  Several studies have been described the correlation between TG parameters 
and the risk of bleeding or clotting disorders. In bleeding disorder like haemophilia, 
TG assay is well reported in PPP, this test is also helpful in monitoring the 
haemophilia treatment with inhibitor bypassing agents (153).   
 
 
6.1.  Result  
 
6.1.1. Thrombin Generation Measurement Using Calibrated Automated 
Thrombography 
 
 CAT analysis was done for all haemophilia A individuals in order to 
investigate thrombin generation between and within severity.  According to the 
analysis, the final concentration of TF trigger used was either 1 pmol/L alone, or 1 
pmol/L, 3 pmol/L and 5 pmol/L. Different concentrations were used where 
appropriate, to ensure maximum sensitivity of the assay, especially in the case of 
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severe FVIII deficiency. Unless otherwise stated, the data refer to 1 pmol/L. For 
reference, the normal range for peak and VI in Cardiff for 1 pmol/L TF were 26-
65.1 nmol/L and 3.1-15 nM/min respectively. A typical CAT analysis is shown in 
Figure 6.1, highlighting the different parameters of the thrombogram.  In many 
cases in individuals with severe haemophilia the thrombin generation curve did not 
complete and, hence, the ETP could not be reported and therefore peak and VI are 
used. 
 
6.1.2. Relationship between Parameters of Thrombin Generation 
 
 The relationship between different parameters of TG with 1 pmol/L of TF 
trigger was investigated in haemophilia A plasmas. Peak showed a moderate 
positive correlation with both time to peak (tt) and velocity index (VI) and this was 
statistically significant (Figure 6.2A and 2B).  A statistically significant moderate 
positive correlation between lag time and tt peak was also found (Figure 6.2C).  
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Figure 6.1: CAT analysis for Individual 24 (mild haemophilia A). Three different 
concentrations of TF (1 pmol/L, 3 pmol/L and 5 pmol/L) were used to trigger 
coagulation. The key measures of thrombin generation are indicated: lag time, peak 
height of TG, time to peak (tt) and ETP. 
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Figure 6.2: Correlation of thrombin generation parameters in haemophilia A 
plasmas. Positive correlations were found between peak and tt peak (Panel A), peak 
and VI (panel B), lag time and tt peak (Panel C). All correlations were moderate but 
statistically significant. 
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 The possibility of correlation between peak and ETP was investigated. A 
large proportion of plasmas did not give an ETP at 1 and 3 pmol/L (the curve did 
not complete and no tail was obtained) (Figure 6. 3A,6.4A ETP = 0) and in the case 
of 5 pmol/L, a small number of plasma did not give ETP (Figure 6. 5A). Individuals 
with a high peak at 1 and 3 pmol/L were less likely to have a completed ETP than 
those with a lower peak. Although an incomplete ETP can not be given a value it is 
not appropriate to label them as 0. After the exclusion of individuals with “zero” 
ETP, a strong positive correlation was observed at 1 pmol/L (r = 0.92) between 
peak and  ETP. Weaker but statistically significant correlations were also seen at 3 
and 5 pmol/L (r = 0.74 and 0.64, respectively) (Figure 6.3B, 6.4B and 6.5B). Peak 
showed a wide range of values  when the ETP was either 0 or measurable (>0) 
(Figure 6.3C, 6.4C and 6. 5C). Peak was significantly higher in individuals with 
unrecordable ETP compared with those who had a measurable ETP at 1 and 3 
pmol/L but not 5 pmol/L (Figure 6. 3C,6. 4C and 6.5C). 
 
6.1.3. FVIII:C and Thrombin Generation 
  
 Log FVIII:C did not correlate with Peak r=0.027 but there was a moderate 
positive correlation (r=0.33) with VI (P<0.05) (Figures 6.6A and 6.6B). This 
suggests that whilst VI is influenced by FVIII level in this cohort using the 
described reagents and triggers, the peak is not. The influence of FVIII on the VI is 
not large and the wide variation between VI at similar FVIII levels suggests that 
other coagulation factors and inhibitors are influencing the result. The peak 
thrombin does not correlate with FVIII level and the variability must, therefore, be 
related to the influence of other coagulation factors and inhibitors.   
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Figure 6.3:  Peak thrombin generation in relation to ETP at 1pmol/L.  Peak varied 
considerably irrespective of whether ETP was unrecordable (termed 0) or 
measurable (Panels A and C). Where ETP was measurable, it showed a strong 
positive correlation with peak (Panel B). “o” indicates an outlier. 
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Figure 6.4:  Peak thrombin generation in relation to ETP at 3pmol/L.  Peak had a 
wide-range irrespective of whether ETP was recordable (termed 0) or measurable 
(Panels A and C). Where ETP was measurable, it showed a moderate positive 
correlation with peak (Panel B). “o” indicates an outlier. 
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Figure 6.5:  Peak thrombin generation in relation to ETP at 5pmol/L.  Peak showed 
wide-range irrespective of whether ETP was unrecordable (termed 0) or measurable 
(Panels A and C). Where ETP was measurable, it showed a moderate positive 
correlation with peak (Panel B). “o” indicates an outlier. 
 
107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6: Correlation between LogFVIII:C and parameters of thrombin 
generation. LogFVIII:C (all severities included) showed no correlation with Peak  
(panel A), and a moderate positive correlation with VI (panel B). 
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6.1.4. Thrombin Generation and Severity of Haemophilia A 
 
 The parameters peak and VI varied widely in both severe and nonsevere 
haemophilia A individuals (Figure 6.7A and 6.7B) suggesting that haemostatic 
factors other than factor VIII were having a marked effect. Of note, peak and VI 
showed considerable overlap between severe and nonsevere individuals, and peak 
was negligible or zero for some nonseveres. There was a statistically significant 
difference between the VI of severe and nonsevere individuals but not peak 
thrombin. This is expected because FVIII correlated with VI but not peak.  
 Peak and VI were compared between severe and nonsevere groups, at 1, 3 
and 5 pmol/L of TF trigger. Increasing the trigger TF concentration resulted in an 
increase in peak and VI for both groups of individuals as expected and this 
increment was statistically significant between each TF concentration (Figure 6.8). 
As TF concentration increased, the spread of values for peak and VI widened. At 
each concentration of TF, the absolute values for peak were similar in severe and 
nonsevere groups, likewise for VI (Figure 6.8). 
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Figure 6.7: Comparison of thrombin generation parameters between severe and 
nonsevere haemophilia A individuals. Peak (panel A) and VI (panel B) each 
showed considerable overlap between severe and nonsevere groups. Of the two 
parameters, only VI was statistically different between the groups. “o” indicates an 
outlier. 
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Figure 6.8:  Peak and VI at different concentrations of TF trigger in severe and 
nonsevere haemophilia A plasmas.  Peak (Panel A) and VI (Panel B) increased 
significantly with increasing concentrations of TF but the overlap between severe 
and nonsevere remained. “o” indicates an outlier. 
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6.1.5. Influence of added exogenous FVIII on thrombin generation 
 
 Plasmas from severe haemophilia A individuals (n=22) were used to 
investigate the effect of added exogenous FVIII on thrombin generation. Plasmas 
were spiked with recombinant human coagulation FVIII (Advate) at the following 
final concentrations: 1 %, 3 %, 5 %, 25 %, 50 % and 100 % (% relative to a normal 
activity of 100 %) and TG were monitored.  Peak and VI rose as the concentration 
of FVIII increased.  Within an individual a positive correlation (Table 6.1) was 
observed between logFVIII and peak and same was noticed with VI (Figure 6.9). 
The correlation between logFVIII and peak or VI ranged from very strong to 
moderate (Table 6.1). The mean r (SD) for peak was 0.70 (0.19) and for VI 0.77 
(0.21). Figure 6.9 shows the relationship between FVIII and peak and VI in 8 
representative individuals, there was wide variation in the slope of the lines 
suggesting that FVIII affected TG differently between them.  
 When the data for all individuals was pooled, a statistically significant 
difference was observed for both peak and VI across the FVIII range tested 
(P<0.001, ANOVA). However, despite significance across the FVIII range, there 
was no statistical difference between consecutive FVIII values either for peak or for 
VI (Figure 6.10A and 6.10B).  At all concentrations of exogenous FVIII, VI was 
statistically different compared with control plasma.  In notable contrast, peak 
showed no statistical difference for any FVIII level tested compared with control 
plasma. 
112 
 
 
Table 6.1 r value for peak and VI in severe haemophilia A plasma of added 
FVIII 
 
Individual ID 
r logFVIII and 
peak  
r logFVIII and 
VI  
P04  0.98 0.91 
P08  0.96 0.96 
P10  0.58 0.83 
P18 0.53 0.85 
P21 0.55 0.93 
P29  0.65 0.9 
P33 0.39 0.83 
P34  0.87 0.86 
P44 0.78 0.62 
P57  0.67 0.65 
P59 0.39 0.02 
P74  0.97 0.66 
P79  0.67 0.89 
P83 0.68 0.67 
P85  0.95 0.99 
P87  0.78 0.59 
P91 0.75 0.7 
P94 0.44 0.93 
P95  0.94 0.96 
P96  0.88 0.93 
P97  0.59 0.88 
P98 0.53 0.8 
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Figure 6.9: Effect of added FVIII on thrombin generation in severe haemophilia A 
plasma. The peak (Panel A) and VI (Panel B) plotted against Log FVIII:C. Each 
coloured line represented an individual patient. A positive correlation with wide 
inter- individual variability for both parameters was observed (table 6.1).  
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Figure 6.10: Effect of added FVIII on thrombin generation in severe haemophilia A 
plasma. Peak (Panel A) and VI (Panel B) were measured for different severe 
haemophilia A plasma samples (n=22) spiked with increasing amounts of 
recombinant FVIII.   Both peak and VI increased as FVIII increased. For both peak 
and VI there was no statistically significant difference between consecutive FVIII 
values, however there was a significant increase across the FVIII range (P<0.001, 
ANOVA).   
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6.1.6. Comparison of Thrombin Generation and Causative Mutation 
 
In order to investigate the possibility of association between TG parameters 
and different severe mutations, peak and VI were inspected according to mutation 
type in individuals with severe haemophilia A. Neither parameters showed any 
difference between severe missense mutations nor null defects (which comprised 
Inv22, frameshifts and nonsense changes collectively) (Figure 6.11A and 6.11B).  
When peak and VI were inspected according to different severe mutation 
types (missense, nonsense, frameshifts, Inv22), there was no significant difference 
for either TG parameter between the various defects (Figure 6.12A and 6.12B). 
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Figure 6.11:  Peak and VI for missense and null mutations in severe haemophilia A. 
Peak (panel A) and VI (panel B) each showed no significant difference according to 
the presence of dysfunctional FVIII (missense) or absence of the coagulation factor 
(null). “o” indicates an outlier. 
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Figure 6.12:  Comparison of thrombin generation parameters between F8 mutation 
types in severe haemophilia A. Neither peak (panel A) nor VI (panel B) differed 
significantly between the various gene defects. “o” indicates an outlier. 
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6.1.7. Thrombin Generation and Joint Health Score 
 
 In order to investigate a possible relationship between in vitro TG and joint 
health, the parameter peak and VI were inspected according to HJHS and Gilbert 
score. For individuals with severe haemophilia A there was no correlation between 
joint score and peak (Figure 6.13A and 6.13B) whereas in nonsevere haemophilia 
A, peak showed a negative correlation with both scores (HJHS P=0.006; Gilbert 
score, P=0.01) (Figure 6.13C and 6.13D). VI showed no correlation with Gilbert 
score or HJHS in either severe or nonsevere groups in severe and HJHS in 
nonsevere group (Figure 14A-D).  A negative correlation was observed between 
FVIII:C and joint health score in all individuals with haemophilia A (Figure 6.15) 
and the nonsevere group alone (figure 5.16).  This was despite the peak not being 
correlated to factor VIII levels and possible suggests that differences in peak TG 
related to factors other than factor VIII might play a role in joint pathology.  
 
 
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.13:  Correlation of HJHS and Gilbert score in severe (Panel 13A and Panel 
13B) and nonsevere (Panel 13C and Panel 13D) individuals with haemophilia A. In 
nonsevere individuals, a significant correlation was observed between peak and 
each joint health score; this was not seen in severe individuals. 
 
120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.14:  Correlation of HJHS and Gilbert score in severe (Panel 13A and Panel 
13B) and nonsevere (Panel 13C and Panel 13D) individuals with haemophilia A. 
No significant correlations were seen.  
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Figure 6.15: Correlation of HJHS and Gilbert score in (Panel A and Panel B) 
individuals with haemophilia A. A significant negative correlation was observed 
between FVIII:C and each joint health score.  
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Figure 6.16: Correlation of HJHS and Gilbert score in (Panel A and Panel B) 
individuals with nonsevere haemophilia A. A negative correlation was observed 
between FVIII:C and each joint health score. 
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6.2.  Discussion 
 
 Coagulation tests are the first line investigation of a suspected inherited 
bleeding disorder. The most commonly used tests are the PT and aPTT, both of 
which measure the time to clot formation after non-physiological activation of 
plasma. There has been much recent interest in assays that measure the integrated 
activity of all coagulation factors, such as TG tests. These measure the amount of 
thrombin produced in plasma or in whole blood after recalcification and triggering 
by the addition of activators such TF and PL. Various methods have been employed 
to measure the total TG capacity of the blood: sub-sampling method (122), 
chromogenic technique (123) and CAT (124).  
 Haemophilia is a disease characterised by a defect in the propagation phase 
of haemostasis. The initiation and amplification phase of TG depends on the 
concentration of different components, such as TF, TFPI, FII, FV, FVIII, FXI and 
phospholipid supplied by activated platelets. In general, the sensitivity of TG assays 
to the propagation phase through the tenase complex increases as TF concentration 
decreases. Excess of TF (>5 pmol/L) will cause prothrombinase formation to follow 
the initiation (extrinsic) pathway (120, 126) bypassing the tenase and propagation 
phase by overwhelming the action of TFPI.  Decreased concentration of TF allows 
the assay to become sensitive to the propagation phase which includes FVIIIa and 
FIXa activation of FX because TFPI can regulated the TF/FVIIa complex (154). 
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 Using 1 pmol/L TF trigger, peak was positively correlated with tt and VI. 
When the comparison was done between lag time and tt peak, a similar finding was 
observed. The ETP, peak height of TG and VI increased with increasing 
concentrations of TF trigger for nonsevere and severe haemophilia plasma. This 
was expected because, irrespective of the severity of FVIII deficiency, an increase 
in the concentration of TF will cause supra-physiological levels of activated FVII 
which overcome TFPI and drive activation of the prothrombinase complex without 
the need for the tenase to function correctly. The latter is effectively bypassed. 
 As anticipated, in FVIII deficient plasma, parameters of TG were strongly 
influenced by TF concentration. There was no recordable ETP with 1 and 3 pmol/L 
in most of the severe individuals (due to negligible FVIII: C) compared to 
nonsevere. Peak and VI were significantly increased when the concentration of TF 
increased from 1 pmol/L to 5 pmol/L in both severe and nonsevere. In most of the 
individuals, ETP was obtained with 5 pmol/L of TF suggesting that this 
concentration (and higher) is sufficient to trigger coagulation without contribution 
from the tenase complex (154).  
A moderate – but significant – correlation was observed between log 
FVIII:C and VI, but not between the coagulation factor activity and peak. The latter 
observation is in contrast to the findings of Dargaud (154), who obtained a 
significant relationship between plasma FVIII/FIX and peak (and also between both 
coagulation factor activities and ETP or tt peak). A possible explanation is that the 
former study included a larger proportion of nonsevere individuals (50 %) 
compared with the study here-in (31 %), peak being more accurately determined for 
nonsevere than for severe plasma. Another likely explanation is that in this study 
different reagents were used and so even though we and Dargaud report using 1 
pmol/L this is an arbitrary value based on dilution of different batches of innovin. 
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Also the phospholipid vesicles are likely to be different. Veer et al. showed the 
activity of different batches of calibrator and found a significant batch to batch 
difference in the measurement (155). 
In this study, a comparsion of TG parameters was made between severe and 
nonsevere haemophilia A individuals. VI was significantly higher in nonsevere 
individuals compared with severe, however there was no difference between peak 
thrombin levels. This suggests that at low FVIII concentration, using the reagents 
described here, peak thrombin was not affected by FVIII whereas VI was. This is a 
suprising result which contrasts with other studies and is mostly due to the specific 
reagents used. Peak and VI were the more useful parameters for the determination 
of TG in this cohort because ETP was unrecordable in many cases. VI appeared to 
be more sensitive to low levels of FVIII than the peak in this assay, possibly 
because the former is related to the rate of TG. This effect may be specific to the 
reagents and assay used in this study and may not be replicated if a different trigger 
mix was used. The finding that peak varied widely at similar FVIII levels may 
allow it to be used to investigate the effect of other coagulation factors and 
inhibitors whereas results with VI, to some degree, may be confounded by FVIII.  
At higher FVIII levels, ETP was measureable and could be used for the 
determination of TG. Lewis et al. (156) obtained similar findings when TG was 
measured in PRP and PPP in severe haemophilia A individuals and noticed that 
only the rate of TG was measurable in severe FVIII deficient plasma. Others found 
a significant relationship between FVIII:C and peak, ETP and VI (157) in contrast 
to the finding presented here for peak and ETP, again differences in reagents are the 
most like explanation.  Others have also shown a correlation between PPP, TG and 
bleeding phenotype (158). The individuals included in that study had varying 
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baseline FVIII:C and it was concluded that clinical severity could be correlated with 
FVIII activity as well as TG parameters.  
 In addition to the general diffferences observed, a variation was noticed in 
both VI and peak thrombin  for individuals with FVIII <1 IU/dL. This may reflect 
differences in levels of other pro- and anti-coagulant proteins and could, in part, 
explain the variation in clinically observed bleeding in severe haemophilia A 
individuals.  
In the severe group, there was no significant difference for either VI or peak 
when missense and null mutations were compared. This suggests that the tenase 
complex malfunctions similarly in individuals with severe haemophilia A whether 
FVIII is absent altogether (null defects) or present but dysfunctional (missense 
changes). There was, however, a wide variation in TG comparing the null and 
missence groups suggsting that other factors play a similarly varied role in global 
haemostasis irrespective of the underlying FVIII mutation. Sangostino et al. 
obtained similar findings when comparing TG parameters between severe 
individuals with a typical bleeding tendency and those with an extremely mild 
clinical phenotype: using PPP, the TG parameters ETP, lag time, peak, time to peak 
and start tail were similar in mild and severe bleeders. In contrast, using PRP,  
higher ETP values were obtained for mild bleeders (other TG parameters were not 
increased). These researchers found that non-null mutations were a main 
determinant of bleeding tendency in severe haemophilia, and they proposed that this 
may be through marginally increased TG (reflected in the ETP) arising from very 
low activity of the dysfunctional coagulation factor (159). 
Several different studies investigated correlation between in vitro TG and 
phenotypic measures of coagulation. One group showed a positive correlation 
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between ETP and Log FVIII:C in 39 individuals with haemophilia A (160).  Veer et 
al. reported a similar finding and showed a correlation between TG parameters 
(ETP and peak) and FVIII:C (120). Some investigators reported the parameters of 
TG in PRP and suggested that results might vary from individual to individual due 
to the difference in platelet characteristics (161). The possibility that genetic factors 
such as  factor V Leiden and the prothrombin gene variant could impact upon TG 
and hence phenotypic severity has been proposed (162)  but not formally 
substantiated.  Differences between the studies reported in the literature and this 
study may be related to differnces in access to FVIII concentrate.  
A negative correlation between TG and joint health scores was observed in 
nonsevere individuals (there was no correlation in the severe group). This suggests 
that the baseline FVIII level is more important than global haemostasis in 
predisposing an individual to arthropathy in situations where access to FVIII 
concentrates is very limited. Additionally, it is also plausible that, once joint 
damage is initiated, it becomes an on-going process in which TG has little (if any) 
role whilst, in contrast, factors relating to inflammation may come to the fore. The 
potential effect of thrombin generation on joint score may have been masked by the 
effect of age and it would have been important to perform a multivariate analysis to 
establish whether these are independent risk factors. There were too few individuals 
in the study to allow this analysis to be done.  
 
Taken together with the results presented in Chapter 5 , our data indicate 
that destructive changes occur <12 years, from which it could be inferred that 
coagulant treatment early in life may be important to limit or prevent arthropathy as 
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shown previously. The effect of global haemostasis is unclear and large cohorts of 
individuals need to be studied.  
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Chapter 7 
 
General Discussion 
 
 Pakistan, a developing country with an approximate population of 176 
million (World Health Organisation (WHO) 2011 data, URL 
http://www.who.int/gho/countries/pak.pdf) has around 1,500 individuals diagnosed 
with haemophilia (A or B) (http://www.org/publications/files/pdf). Most of the 
individuals with haemophilia A have minimal access to FVIII concentrate and are 
treated intermittently with FFP. Most of them also have no access to physiotherapy 
support. In addition to a paucity of clinical support, there is also a major lack of 
facilities to diagnose and research bleeding disorders in Pakistan. On the basis of 
these facts, the study presented within this thesis was designed, exploring clinical, 
genetic and phenotypic aspects of haemophilia A in Pakistan. A main aim of this 
study was to investigate an association between haemophilic arthropathy in 
individuals with minimal access to haemostatic replacement therapy, and to 
investigate thrombin generation in PPP in relation to the underlying F8 defect.   
 One hundred apparently unrelated individuals, who had previously been 
diagnosed with hereditary haemophilia A, and 100 random healthy controls, were 
recruited from Pakistan. Confirmatory phenotypic testing in Cardiff revealed that 7 
individuals had been misdiagnosed and in fact had haemophilia B, whilst one did 
not have haemophilia at all and was actually haemostatically normal and both joint 
health scores were 0. Such misdiagnoses represent an important finding within this 
study, demonstrating the need for improved diagnostic facilities in Pakistan. 
Possible explanations for misdiagnosis include minimal government spending (9.7 
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% of total budget:   http://finance.punjab.gov.pk/system/files/2013-2014ABS.pdf) 
in health care sector, with priority given to economic affairs and housing (64.7% of 
total budget). Furthermore, most of the modern health services in Pakistan are 
provided in the private sector which is usually not accessible for a common man. 
Pakistan has multiple problems regarding management of haemophilia and 
insufficient awareness of the disorder within the population is among them. Direct 
questioning of each individual with haemophilia suggested that 80 % of them had a 
positive family history. However due to insufficient knowledge of this disorder, 
parents circumcised their children in the early weeks of life resulting in serious 
bleeding in many cases. 
 The 92 haemophilia A individuals within the affected cohort were 
categorized according to disease severity: mild n=5 (5 %), moderate n=24 (26 %) 
and severe n=63 (69 %). Four individuals with severe haemophilia A were found to 
have an inhibitor. A minor proportion (19 %) of them had minimal access to FVIII 
concentrate, the exact amount used is not known because accurate records were not 
available. Individuals with no access to FVIII concentrate (81 %) were treated 
intermittently with FFP. Furthermore, none of the individuals had access to proper 
physiotherapy support. 
 Ninety two individuals with haemophilia A were investigated for the 
causative gene defect. Out of those, a candidate mutation in F8 was found in 80. 
The sequence variants obtained were heterogeneous: point mutations (missense, 
nonsense, splice site and promoter region changes), inversions (Inv22 and Inv1) and 
frameshifts (deletions and duplications). The most frequent variation was point 
mutation (42 % of individuals), followed by Inv22 (20 % of cohort, 29 % of severe 
cases). The results are consistent with the findings of other international studies, for 
example point mutations predominated in cohorts from Korea (40.9 %) (163)], 
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China (46 %) (164)] and India (43%) (130)] and, in these studies Inv22 was 
frequent among severe cases (Korea 39.5 %, Chinese 38.5 % , Taiwanese 38.7 %) 
(164-166)]. The frequency of Inv22 in this cohort is lower than for other studies, 
possibly a sampling artefact. 
 When the musculoskeletal status in individuals with haemophilia A who had 
minimal assess to multidisciplinary haemophilia care was investigated, it was found 
that multiple joint involvement was present in most cases and this involvement 
increased with age. Arthropathy was common in mild and moderate haemophiliacs 
as well as severely affected individuals demonstrating that low levels of FVIII do 
not protect against joint damage in many cases. Due to lack of awareness of this 
disease, many individuals with mild or moderate haemophilia A present quite late 
when their joints are already affected. Even after the diagnosis, due to the lack of 
appropriate management, their joint disease progresses similar to severe disease. 
Knees are the most commonly affected joint as compared to elbow and ankles. 
These findings are consistent with other studies which reported the knee to be the 
most affected joint (167). In this study, HJHS and Gilbert score were used to assess 
the joint health. This study showed that the two joint scores correlated well across 
the whole spectrum of severity. Both scores were found to be higher in severe 
individuals when compared with nonsevere. Similar findings were reported by 
Dutch study, they observed HJHS for 47 cases and concluded that individuals with 
mild or moderate haemophilia can be expected to have less joint damage (168). 
Furthermore, when HJHS and Gilbert score were studied according to 
developmental age, both scores were found to be lower in younger age group 
compared to older. In individuals not receiving FVIII concentrate, gross clinical 
findings of haemophilic arthropathy appeared in severe children during the first 
decade of life and in nonsevere individuals mainly during the second and 
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subsequent decades. This further emphasises that, irrespective of the severity of the 
disease, early and accurate diagnosis and access to factor concentrate is critical for 
good long term outcomes.  
 Both health scores were compared between different mutation types – 
missense, nonsense, frameshift and the intron 22 inversion – in individuals with 
severe haemophilia A, no significant difference was found between the gene 
defects. Although, on first principles, this result may have been anticipated, the data 
formally exclude the possibility that the presence or absence of FVIII protein per se 
in the tenase complex may subtly influence in vitro parameters of TG. 
Our data suggest that haemophilic joint damage may begin at an early age 
and advances until the age of 12-16 years, by which time aggregative damage 
approaches maximum and little further development in arthropathy is possible. 
Although the F8 defect is the basis of the disorder, the nature of the mutation does 
not appear to correlate with the arthropathy, at least in the case of severe FVIII 
deficiency. 
TG was measured in all individuals with haemophilia A: TG parameters 
were  studied according to disese severity and VI, but not peak, found to be higher 
in nonsevere individuals when compared with severe. In individuals with FVIII < 1 
and > 1 IU/dL, variation was observed in TG parameters and this variation could be 
due to differences in the levels of pro- and anti-coagulant proteins between 
individuals.   A group from Denmark showed similar findings and noticed a wide 
variation in TG parameters in individuals with severe haemophilia A (169). Similar 
differences were also obtained in other studies (170) and the authors concluded that 
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the combination of each individual coagulation factor (besides FVIII) determines 
each individual’s baseline thrombin potential and may affect bleeding risk. It can be 
concluded that it is not one factor alone that contributes to overall TG dynamics, but 
it is the combination of different coagulation factors. With the same level of FVIII, 
individuals with procoagulant factors at the high end of the normal range and 
anticoagulant factors at the low end, the ability to generate thrombin will be faster 
than those who have lower than normal procoagulant levels and higher than normal 
anticoagulant levels. Therefore, an individual could potentially be at a haemostatic 
benefit over another even though the FVIII levels are equivalent. In addition to this, 
in individuals with severe haemophilia A, TG was investigated  according to  F8 
defect and no association was observed with any mutatuion type.  This suggested 
that on average global haemostasis is similar in individuals with severe haemophilia 
A whether FVIII is absent altogether (null defects) or present but dysfunctional 
(missense changes), although there is wide inter-individual variation. 
This study provides a rare opportunity for musculoskeletal assessment in a 
haemophilia population with minimal access to haemostatic replacement therapy. 
The data demonstrate a strong correlation between HJHS and Gilbert Score. Both 
scores are considered to be applicable to different age groups with different clinical 
severity: HJHS is considered more helpful for younger individuals aged between 4-
18 years with mild joint impairment while the Gilbert score is considered more 
applicable for adults and older people with established arthropathy.  
 Further studies into the factors affecting haemophilic arthropathy in this 
population are required. Most importantly, it has not been possible to investigate the 
effect of global haemostasis fully because of the important and large effect of age. 
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Increasing the numbers of individuals and performing a multivariate analysis would 
be useful. In addition, it would be interesting to investigate the immune system in 
this group to establish whether some individuals are more prone to the 
inflammatory responses that result in severe arthropathy.    
 This study also provides 30 novel candidate mutations that have not been 
previously reported. The novel candidate mutations comprise 8 missense, 7 
nonsense, 3 splice site, 1 promoter region, 3 single nucleotide duplications and 8 
with deletions. 
 The novel variants those with a significant likelihood of pathology 
(nonsense, duplication, deletion and the splice site change c.6187+1G>A which 
destroys the conserved GT splice site donor motif) (total = 19) and those for which 
a detrimental effect was uncertain (missense, promoter region and the other two 
splice site changes) (total = 11). In silico analysis of the latter 11 variants gave 
results that strongly supported involvement in pathology. 
In Pakistan, the genetic analysis of haemophilia is not available. Currently, 
there is a major insufficiency for genetic investigation of this disorder. Although 
carrier status and prenatal diagnosis using molecular analysis are available for 
thalassaemia and other congenital disorders, such services have not yet been 
implemented for haemophilia. Haemophilia care is important for the families with a 
severe phenotype, and for them genetic counselling as well as carrier detection is 
necessary.  
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In conclusion, the data generated in this study provide insight that addresses 
the hypothesis stated at the outset: “The severity of haemophilic arthropathy, in 
individuals with the same baseline FVIII level who are receiving minimal FVIII 
replacement, is affected by their global haemostatic potential despite the mutation 
underlying haemophilia A” (Chapter 1, section 1.7). The data suggest that 
haemophilia arthropathy correlate with disease severity and individual age; among 
the severe group there is no association between joint health score and either the 
underlying mutation or in vitro TG. Ultimately the study has too few individuals to 
address whether global haemostasis affects arthropathy because of the very marked 
effect of age. Further cohorts of minimally treated individuals of similar ages would 
be required to answer this question fully. This study contributes novel genetic and 
phenotypic data that broaden knowledge and understanding in the complex field of 
haemophilia A. 
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Annex 
Table A1 
Gilbert score  
 
Individual 
ID 
 Elbow Knee Ankle Total joint 
score 
Individual 
ID 
  Elbow Knee Ankle Total joint 
score   Left Right Left Right Left Right   Left Right Left Right Left Right 
1 
Swelling 0 0 0 0 0 0 
  
48 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 1 1 1 1 1 1 Muscle atrophy 0 0 1 1 1 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 1 2 1 2 0 0 Joint pain 1 1 1 1 0 0 
Strength 0 1 1 1 0 0 Strength 0 0 1 1 1 0 
Total joint score 2 4 3 4 1 1 15+2=17 Total joint score 1 1 3 3 2 0 10+2=12 
                  
2 
Swelling 0 0 0 0 0 0 
  
49 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 1 0 0 0 Muscle atrophy 1 0 1 0 0 0 
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 1 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 1 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 1 0 0 0 Joint pain 1 0 1 0 0 0 
Strength 0 0 1 0 0 0 Strength 1 0 1 0 0 0 
Total joint score 0 0 6 0 0 0 6+2=8 Total joint score 3 0 3 0 0 0 6 
                  
3 
Swelling 0 0 0 2 0 0 
  
50 
Swelling 1 0 1 0 1 0 
  
Duration (swelling) 0 0 0 1 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 0 0 0 0 0 0 
Crepitus on motion 0 0 0 1 0 0 Crepitus on motion 0 0 1 0 0 0 
Flexion loss 1 0 0 2 0 0 Flexion loss 0 0 2 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 0 2 0 0 Joint pain 0 0 0 0 0 0 
Strength 0 0 1 1 0 0 Strength 2 0 2 0 1 0 
Total joint score 1 0 1 10 0 0 12+3=15 Total joint score 3 0 6 0 2 0 11+2=13 
                  
4 
Swelling 1 0 0 0 0 0 
  51 
Swelling 1 0 1 0 0 0 
  
Duration (swelling) 1 0 0 0 0 0 Duration (swelling) 1 0 1 0 0 0 
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Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 0 0 2 0 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 1 0 0 0 0 0 
Flexion loss 3 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 2 1 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 1 1 0 1 0 0 Joint pain 1 0 0 0 0 0 
Strength 1 1 0 1 0 0 Strength 1 0 0 0 0 0 
Total joint score 9 3 0 3 0 0 15+1=16 Total joint score 5 0 4 0 0 0 9+1=10 
                  
5 
Swelling 0 1 0 0 0 0 
  
52 
Swelling 0 0 1 2 0 0 
  
Duration (swelling) 0 1 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 1 1 0 0 
Crepitus on motion 0 1 0 0 0 0 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 0 3 3 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 1 1 1 0 0 Joint pain 0 0 1 1 0 0 
Strength 0 0 1 1 0 0 Strength 0 0 3 3 1 1 
Total joint score 0 4 5 5 0 0 14+3=17 Total joint score 0 0 7 8 1 1 17+2=19 
                  
6 
Swelling 0 0 0 0 0 0 
  
53 
Swelling 0 0 1 1 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 0 0 1 1 1 1 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 3 0 0 0 0 Flexion loss 3 0 3 3 0 0 
Extension loss 1 0 2 2 0 0 Extension loss 1 0 3 3 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 1 1 2 1 1 1 
Strength 1 1 2 2 1 1 Strength 2 2 3 3 1 1 
Total joint score 2 4 4 5 1 1 17+1=18 Total joint score 7 3 14 13 3 3 43+3=46 
                  
7 
Swelling 0 0 0 0 0 2 
  
54 
Swelling 0 1 0 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 1 1 0 0 0 0 Muscle atrophy 0 1 0 1 0 0 
Crepitus on motion 0 0 0 0 0 1 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 3 0 0 1 Flexion loss 1 1 0 0 0 0 
Extension loss 1 1 0 0 0 0 Extension loss 0 0 1 0 0 0 
Joint pain 0 0 0 0 0 2 Joint pain 0 1 0 1 0 0 
Strength 2 2 1 1 0 4 Strength 0 1 0 1 0 0 
Total joint score 4 4 4 1 0 9 22+4=28 Total joint score 1 5 1 3 0 0 10 
                  
8 
Swelling 0 0 0 0 0 0 
  55 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
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Muscle atrophy 0 1 1 1 1 1 Muscle atrophy 0 1 0 0 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 1 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 3 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 1 0 1 1 Joint pain 0 1 0 0 0 0 
Strength 0 0 1 1 1 1 Strength 0 1 0 0 0 0 
Total joint score 0 2 6 2 3 3 16+1=17 Total joint score 0 3 0 0 0 0 3 
                  
9 
Swelling 2 0 0 0 0 0 
  
56 
Swelling 0 0 1 1 0 0 
  
Duration (swelling) 1 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 2 0 2 0 1 0 Muscle atrophy 1 1 2 2 1 1 
Crepitus on motion 1 0 1 0 0 0 Crepitus on motion 1 0 1 1 0 0 
Flexion loss Ne 0 3 0 0 0 Flexion loss 0 0 2 2 1 0 
Extension loss Ne 0 1 0 0 0 Extension loss 0 0 1 1 0 0 
Joint pain 2 0 2 0 1 0 Joint pain 0 0 1 1 0 0 
Strength 4 0 4 1 4 0 Strength 1 1 4 4 1 1 
Total joint score 12 0 13 1 6 0 32+2=34 Total joint score 3 2 12 12 3 2 34+3=37 
                  
10 
Swelling 1 0 0 0 0 2 
  
57 
Swelling 0 0 2 0 0 0 
  
Duration (swelling) 1 0 0 0 0 1 Duration (swelling) 0 0 1 0 0 0 
Muscle atrophy 0 0 1 0 0 1 Muscle atrophy 0 0 0 0 1 0 
Crepitus on motion 0 0 0 0 0 1 Crepitus on motion 0 0 1 0 0 0 
Flexion loss 2 0 2 0 0 Ne Flexion loss 0 0 3 0 0 0 
Extension loss 0 0 0 0 0 Ne Extension loss 0 0 2 0 0 0 
Joint pain 1 0 0 0 0 2 Joint pain 0 0 1 0 0 0 
Strength 1 0 0 0 0 3 Strength 0 0 3 0 2 0 
Total joint score 6 0 3 0 0 10 19+0= 19 Total joint score 0 0 13 0 3 0 16+2=18 
                  
11 
Swelling 0 0 2 0 0 0 
  
58 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 1 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 1 1 1 1 0 Muscle atrophy 0 0 0 0 0 0 
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 1 1 1 1 0 Joint pain 0 0 1 1 0 0 
Strength 0 0 2 0 1 1 Strength 1 0 1 1 0 0 
Total joint score 0 2 8 2 3 1 16+2=18 Total joint score 1 0 2 2 0 0 5 
                  
12 
Swelling 0 0 1 0 0 0 
  59 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 1 0 0 0 Duration (swelling) 0 0 0 0 0 0 
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Muscle atrophy 0 0 1 1 1 0 Muscle atrophy 0 0 0 0 0 0 
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 1 1 0 0 Joint pain 1 1 0 1 0 0 
Strength 0 0 1 1 0 0 Strength 0 0 0 0 1 1 
Total joint score 0 0 6 3 1 0 10+2=12 Total joint score 1 1 0 1 1 1 5 
                  
13
 Inhib
 
Swelling 0 0 1 1 0 0 
  
60 
Swelling 1 1 2 2 0 1 
  
Duration (swelling) 0 0 1 1 0 0 Duration (swelling) 0 0 0 0 0 1 
Muscle atrophy 0 0 2 1 0 0 Muscle atrophy 0 0 1 1 1 1 
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 0 2 3 0 0 Flexion loss 2 0 3 3 0 1 
Extension loss 0 0 0 0 0 0 Extension loss 0 2 2 0 0 1 
Joint pain 1 1 1 1 0 0 Joint pain 1 1 1 1 1 1 
Strength 0 0 1 1 0 0 Strength 1 2 3 3 1 2 
Total joint score 1 1 9 8 0 0 19+1=20 Total joint score 5 6 13 11 3 8 46+3=49 
                  
14 
Swelling 0 0 2 2 0 0 
  
61 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 1 1 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 1 1 2 2 1 1 Muscle atrophy 0 0 0 0 0 0 
Crepitus on motion 0 0 1 1 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 2 3 0 0 3 3 Flexion loss 0 0 0 0 0 0 
Extension loss 0 2 3 3 1 1 Extension loss 0 0 0 0 0 0 
Joint pain 1 1 2 2 0 0 Joint pain 0 0 1 0 0 0 
Strength 2 2 4 4 1 1 Strength 0 0 1 0 0 0 
Total joint score 6 9 15 15 6 6 57+4=61 Total joint score 0 0 2 0 0 0 2 
                  
15 
Swelling 0 0 0 0 0 0 
  
62 
Swelling 2 2 2 2 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 1 1 2 2 0 1 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 1 1 1 
Flexion loss 0 0 0 0 0 0 Flexion loss 3 0 3 1 1 1 
Extension loss 0 0 0 0 0 0 Extension loss 2 3 1 2 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 2 1 1 1 1 1 
Strength 0 0 0 0 0 0 Strength 3 3 4 4 2 1 
Total joint score 0 0 0 0 0 0 0 Total joint score 13 10 14 13 5 5 60+3=63 
                  
16 
Swelling 0 0 0 0 0 0 
  65 
Swelling 0 0 1 1 2 2 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
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Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 1 1 1 1 2 2 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 1 1 1 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 1 2 3 3 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 1 1 1 3 
Joint pain 0 0 0 0 0 0 Joint pain 1 1 1 1 1 1 
Strength 0 0 0 0 0 0 Strength 1 1 3 3 3 3 
Total joint score 0 0 0 0 0 0 0 Total joint score 3 3 9 10 13 15 53+2=55 
                  
17 
Swelling 0 0 1 0 0 0 
  
66 
Swelling 0 1 1 1 0 0 
  
Duration (swelling) 0 0 1 0 0 0 Duration (swelling) 0 1 0 0 0 0 
Muscle atrophy 1 0 1 1 0 0 Muscle atrophy 0 2 1 1 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 1 1 1 0 0 
Flexion loss 2 1 3 3 0 0 Flexion loss 0 3 0 0 0 0 
Extension loss 3 1 1 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 1 1 1 1 1 1 Joint pain 0 1 1 1 0 0 
Strength 3 0 2 2 1 1 Strength 1 3 3 3 0 0 
Total joint score 10 3 10 7 2 2 34+3=37 Total joint score 1 11 7 7 0 0 26+2=28 
                  
18 
Swelling 0 2 2 0 0 0 
  
70 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 1 1 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 1 1 0 0 0 Muscle atrophy 0 0 0 0 0 0 
Crepitus on motion 0 1 2 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 2 n/m 3 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 n/m 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 2 2 0 0 0 Joint pain 0 0 1 0 0 0 
Strength 0 4 4 0 0 0 Strength 0 0 1 0 0 0 
  Total joint score 2 11 15 0 0 0 28+1=29 Total joint score 0 0 2 0 0 0 2 
                  
19 
Swelling 0 0 0 0 0 0 
  
71 
Swelling 0 2 0 3 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 1 1 2 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 1 0 1 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 1 3 3 3 1 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 3 1 0 
Joint pain 0 0 0 0 0 0 Joint pain 1 1 1 1 0 0 
Strength 0 0 0 0 0 0 Strength 1 2 2 3 1 1 
Total joint score 0 0 0 0 0 0 0 Total joint score 3 10 7 16 3 1 40+2=42 
                  
21 
Swelling 0 0 1 1 0 0 
  72 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
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Muscle atrophy 1 1 1 1 0 0 Muscle atrophy 0 0 0 0 0 0 
Crepitus on motion 0 0 1 1 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 3 0 2 2 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 2 0 1 2 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 1 1 1 1 0 0 Joint pain 0 0 1 1 0 0 
Strength 2 2 4 4 0 0 Strength 0 0 1 1 0 0 
Total joint score 9 4 11 12 0 0 36+3=39 Total joint score 0 0 2 2 0 0 4 
                  
22 
Swelling 0 0 0 0 0 0 
  
73
 Inhib
 
Swelling 1 1 2 2 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 1 1 0 0 
Muscle atrophy 0 0 1 0 0 0 Muscle atrophy 0 0 1 2 1 1 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 2 2 2 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 1 0 0 0 
Joint pain 0 0 1 1 0 0 Joint pain 0 0 1 0 1 1 
Strength 1 1 1 1 0 0 Strength 1 1 2 3 1 2 
  Total joint score 1 1 3 2 0 0 7+2=9 Total joint score 4 4 11 9 3 4 35+3=38 
                  
23 
Swelling 0 0 0 0 0 0 
  
74 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 0 0 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 0 0 0 0 0 0 
Strength 0 0 0 0 0 0 Strength 0 0 0 0 0 0 
Total joint score 0 0 0 0 0 0 0 Total joint score 0 0 0 0 0 0 0 
                  
24 
Swelling 0 0 0 0 0 0 
  
75 
Swelling 1 1 1 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 1 1 1 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 1 0 1 1 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 3 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 3 0 0 0 1 1 
Joint pain 0 0 0 0 0 0 Joint pain 1 1 1 1 0 0 
Strength 0 0 0 0 0 0 Strength 3 2 2 1 1 1 
Total joint score 0 0 0 0 0 0 0 Total joint score 10 5 10 4 2 2 33+3=36 
                  
25 
Swelling 0 1 0 0 0 0 
  76 
Swelling 1 1 2 3 0 0 
  
Duration (swelling) 0 1 0 0 0 0 Duration (swelling) 1 1 1 0 0 0 
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Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 1 1 1 2 1 1 
Crepitus on motion 0 1 0 0 0 0 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 1 0 0 0 0 Flexion loss 0 0 3 0 1 1 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 3 3 1 1 
Joint pain 0 1 0 0 0 0 Joint pain 0 0 2 2 0 0 
Strength 0 2 0 0 0 0 Strength 1 1 3 4 2 2 
Total joint score 0 7 0 0 0 0 7 Total joint score 4 4 16 13 5 5 47+4=51 
                  
26 
Swelling 0 0 0 0 0 0 
  
77 
Swelling 1 0 1 1 1 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 1 1 1 0 
Muscle atrophy 0 0 0 0 1 1 Muscle atrophy 1 1 1 1 1 1 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 1 1 Flexion loss 2 0 0 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 1 0 0 
Joint pain 0 0 0 0 1 1 Joint pain 0 0 1 1 0 0 
Strength 0 0 0 0 1 1 Strength 1 1 2 2 1 2 
Total joint score 0 0 0 0 4 4 8+1=9 Total joint score 5 2 6 7 4 3 27+2=29 
                  
27 
Swelling 0 0 0 0 0 0 
  
78 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 0 0 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 1 1 0 0 Joint pain 0 0 0 0 0 0 
Strength 0 0 1 1 0 0 Strength 0 0 0 0 0 0 
Total joint score 0 0 2 2 0 0 4+1=5 Total joint score 0 0 0 0 0 0 0 
                  
28 
Swelling 0 0 0 0 0 0 
  
79 
Swelling 0 0 1 1 1 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 1 1 1 1 
Muscle atrophy 2 2 1 1 0 0 Muscle atrophy 1 1 2 1 1 1 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 1 1 0 0 Flexion loss 2 1 3 0 0 0 
Extension loss 1 2 0 0 0 0 Extension loss 0 0 0 0 1 1 
Joint pain 1 0 1 1 1 0 Joint pain 0 0 0 0 0 0 
Strength 4 4 2 2 1 1 Strength 1 1 3 2 2 1 
Total joint score 8 8 5 5 2 1 29+3=32 Total joint score 4 3 10 5 6 4 32+2=34 
                  
29 
Swelling 0 0 0 0 0 0 
  80 
Swelling 2 0 0 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 1 0 0 0 1 0 
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Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 0 0 1 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 1 1 0 0 0 0 Flexion loss 0 0 3 3 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 3 0 0 0 0 
Joint pain 1 1 0 0 0 0 Joint pain 2 1 0 0 1 0 
Strength 1 1 0 0 0 0 Strength 4 1 1 1 1 0 
Total joint score 3 3 0 0 0 0 6 Total joint score 9 5 4 4 4 0 26 
                  
30 
Swelling 0 0 0 0 0 2 
  
81 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 0 0 0 1 Duration (swelling) 2 0 0 0 0 0 
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 1 1 0 0 0 0 
Crepitus on motion 0 0 0 0 0 2 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 1 Flexion loss 3 2 0 0 0 1 
Extension loss 0 0 0 0 0 1 Extension loss 3 0 0 0 0 0 
Joint pain 0 0 0 0 0 2 Joint pain 1 0 0 0 1 1 
Strength 0 0 0 0 0 4 Strength 3 0 0 0 1 1 
Total joint score 0 0 0 0 0 13 13+2=15 Total joint score 13 3 0 0 2 3 31+2=33 
                  
31 
Swelling 0 1 1 1 0 0 
  
82 
Swelling 0 1 3 2 0 0 
  
Duration (swelling) 0 1 0 0 0 0 Duration (swelling) 0 1 0 0 0 0 
Muscle atrophy 1 1 1 1 0 0 Muscle atrophy 0 0 2 2 1 1 
Crepitus on motion 1 0 1 0 0 0 Crepitus on motion 1 1 0 0 0 0 
Flexion loss N 0 3 3 1 0 Flexion loss 3 0 2 2 0 0 
Extension loss N 0 1 1 1 1 Extension loss 0 0 0 0 0 0 
Joint pain 1 1 1 1 1 1 Joint pain 1 1 0 0 1 1 
Strength 2 3 1 2 1 1 Strength 3 2 3 3 2 1 
Total joint score 5 7 9 9 4 3 37+3=40 Total joint score 8 6 10 9 4 3 40+2=42 
32 
Swelling 0 0 2 0 0 0 
  
83 
Swelling 0 0 1 2 1 1 
  
Duration (swelling) 0 0 1 0 0 0 Duration (swelling) 0 0 0 0 0 1 
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 1 2 2 2 1 1 
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 1 3 3 1 1 Flexion loss 1 0 3 3 0 0 
Extension loss 0 0 0 3 0 0 Extension loss 0 0 3 0 0 0 
Joint pain 1 1 2 2 0 0 Joint pain 1 1 1 1 1 1 
Strength 1 1 4 4 0 0 Strength 2 3 2 3 2 2 
Total joint score 2 3 13 13 1 1 33+3=36 Total joint score 5 6 12 11 5 6 44+3=47 
                  
33 
Swelling 0 0 2 0 0 0 
  84 
Swelling 0 0 1 1 1 1 
  Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 1 1 1 0 0 0 Muscle atrophy 2 2 11 0 1 1 
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Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 2 3 3 0 0 0 Flexion loss 3 1 3 3 1 1 
Extension loss 0 0 3 0 0 0 Extension loss 2 0 3 0 0 0 
Joint pain 1 1 2 1 0 0 Joint pain 1 1 1 1 0 0 
Strength 3 3 4 3 1 1 Strength 2 3 2 1 1 2 
Total joint score 7 8 16 4 1 1 36+3=39 Total joint score 10 7 21 6 4 5 53+3=56 
                  
34 
Swelling 0 0 0 0 0 0 
  
85 
Swelling 0 0 1 1 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 1 Muscle atrophy 0 0 2 1 1 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 1 3 3 1 1 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 1 1 1 1 1 1 
Strength 0 0 0 0 0 1 Strength 1 0 2 3 1 1 
Total joint score 0 0 0 0 0 2 2 Total joint score 2 2 9 9 4 3 29+3=32 
                  
35 
Swelling 0 0 0 0 0 0 
  
86 
Swelling 0 0 1 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 1 0 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 1 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 0 0 1 0 0 0 
Strength 0 0 0 0 0 0 Strength 0 0 2 0 0   
Total joint score 0 0 0 0 0 0 0 Total joint score 0 0 6 0 0 0 6+1=7 
                  
36
 Inhib
 
Swelling 0 0 1 2 0 0 
  
87 
Swelling 0 0 0 1 0 0 
  
Duration (swelling) 0 0 1 1 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 1 1 0 1 Muscle atrophy 0 0 0 1 0 0 
Crepitus on motion 0 0 0 1 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 1 1 2 2 1 1 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 3 3 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 1 2 1 1 Joint pain 0 0 1 1 0 0 
Strength 0 0 3 4 1 1 Strength 1 1 0 1 0 0 
Total joint score 1 1 12 16 3 4 37+3=40 Total joint score 1 1 1 4 0 0 7+2=9 
                  
37 
Swelling 0 0 0 1 0 0 
  88 
Swelling 0 0 1 0 0 0 
  Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 0 0 1 1 0 0 
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Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 1 3 0 0 Flexion loss 0 0 2 1 1 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 1 1 0 0 0 
Joint pain 0 0 1 1 0 0 Joint pain 0 0 1 1 0 0 
Strength 0 0 1 2 0 0 Strength 0 0 2 1 1 0 
Total joint score 0 0 3 8 0 0 11+1=12 Total joint score 0 1 8 4 2 0 15+2=17 
                  
38 
Swelling 0 0 0 0 0 0 
  
89 
Swelling 0 0 1 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 1 0 0 0 
Muscle atrophy 1 0 0 0 1 0 Muscle atrophy 0 0 1 0 1 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 0 0 0 
Flexion loss 0 0 0 3 0 0 Flexion loss 0 0 1 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 1 0 0 0 1 1 Joint pain 0 0 1 1 0 0 
Strength 2 0 2 1 1 1 Strength 0 0 1 0 1 1 
Total joint score 4 0 2 4 3 2 15+2=17 Total joint score 0 0 7 1 2 1 11+1=12 
                  
39 
Swelling 0 0 0 0 0 0 
  
90 
Swelling 0 0 2 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 1 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 1 0 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 2 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 1 1 2 0 1 1 
Strength 0 0 0 0 0 0 Strength 1 1 1 0 1 1 
Total joint score 0 0 0 0 0 0 0 Total joint score 2 2 10 0 2 2 18 
                  
40 
Swelling 0 0 1 0 0 0 
  
91 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 1 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 1 0 Muscle atrophy 0 0 0 0 0 0 
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 1 1 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 1 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 1 0 1 0 Joint pain 0 0 1 0 0 0 
Strength 0 0 3 0 2 0 Strength 0 0 1 0 0 0 
Total joint score 0 0 8 0 5 1 14+2=16 Total joint score 0 0 2 0 0 0 2+1=3 
                  
41 
Swelling 0 0 1 0 0 0 
  92 
Swelling 1 0 0 2 0 0 
  Duration (swelling) 0 0 1 0 0 0 Duration (swelling) 0 0 0 1 0 0 
Muscle atrophy 2 0 2 0 0 0 Muscle atrophy 2 0 0 1 0 0 
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Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 1 0 0 1 0 0 
Flexion loss 3 0 3 0 0 0 Flexion loss 0 0 0 3 0 0 
Extension loss 3 0 0 0 0 0 Extension loss 2 0 0 0 1 0 
Joint pain 0 0 1 0 1 0 Joint pain 1 0 0 2 0 0 
Strength 4 0 3 0 1 0 Strength 3 0 0 2 1 1 
Total joint score 12 0 12 0 2 0 26+2=28 Total joint score 10 0 0 12 2 1 25+1=26 
                  
42 
Swelling 0 0 1 0 0 0 
  
93 
Swelling 0 0 0 0 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 0 1 0 0 0 Muscle atrophy 0 0 0 0 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 1 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 1 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 0 1 0 1 0 Joint pain 0 0 1 0 0 0 
Strength 0 0 2 0 1 0 Strength 0 0 1 0 0 0 
Total joint score 0 0 5 0 4 0 9+2=11 Total joint score 0 0 2 0 0 0 2+1=3 
                  
43 
Swelling 0 0 0 0 0 0 
  
94 
Swelling 0 0 2 1 1 1 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 1 0 0 1 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 2 2 1 1 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 2 3 3 1 1 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 3 3 1` 0 
Joint pain 1 1 0 0 0 0 Joint pain 0 0 1 1 1 0 
Strength 1 1 0 0 0 0 Strength 0 0 3 3 1 1 
Total joint score 2 2 0 0 0 0 4 Total joint score 0 2 16 13 6 5 42+4=46 
                  
44 
Swelling 0 0 1 1 0 0 
  
95 
Swelling 0 2 1 2 1 1 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 1 0 1 1 0 
Muscle atrophy 0 1 1 1 0 0 Muscle atrophy 1 0 1 1 1 1 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 1 0 0 
Flexion loss 3 3 0 0 0 0 Flexion loss 3 3 1 0 1 1 
Extension loss 0 3 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 1 2 2 0 0 Joint pain 0 0 1 2 1 0 
Strength 0 3 4 4 0 0 Strength 1 0 2 2 1 1 
Total joint score 3 11 8 8 0 0 30+3=33 Total joint score 5 6 6 9 6 4 36+2=38 
                  
45 
Swelling 0 0 0 1 0 0 
  96 
Swelling 0 0 1 2 1 1 
  Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 1 1 1 1 
Muscle atrophy 0 0 1 1 1 1 Muscle atrophy 0 1 1 2 1 1 
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Crepitus on motion 0 0 1 1 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 3 0 0 0 Flexion loss 0 0 1 1 0 0 
Extension loss 0 0 3 0 0 0 Extension loss 0 0 0 0 1 1 
Joint pain 0 0 0 1 0 0 Joint pain 0 1 1 1 0 0 
Strength 0 0 3 4 1 1 Strength 1 1 3 2 1 2 
Total joint score 0 0 11 8 2 2 23+4=27 Total joint score 1 3 8 9 5 6 32+4=36 
                  
46
 Inhib
 
Swelling 0 0 0 0 0 0 
  
97 
Swelling 0 0 1 1 0 0 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 0 0 0 0 
Muscle atrophy 0 1 0 1 0 0 Muscle atrophy 0 0 1 1 0 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 3 2 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Joint pain 0 1 0 1 0 0 Joint pain 0 0 0 0 0 0 
Strength 0 1 0 1 0 0 Strength 0 0 1 2 1 1 
Total joint score 0 3 0 3 0 0 6+1=7 Total joint score 0 0 6 6 1 1 14+2=16 
                  
47 
Swelling 0 0 0 0 0 0 
  
98 
Swelling 0 0 1 0 1 1 
  
Duration (swelling) 0 0 0 0 0 0 Duration (swelling) 0 0 1 0 0 0 
Muscle atrophy 1 1 0 0 0 0 Muscle atrophy 1 1 1 0 1 0 
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 1 1 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 1 0 0 0 1 0 
Joint pain 1 1 0 0 0 0 Joint pain 0 0 1 0 1 1 
Strength 1 1 0 0 0 0 Strength 2 1 3 0 1 1 
Total joint score 3 3 0 0 0 0 6 Total joint score 4 2 9 1 5 3 24+3=27 
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Table A2 
 
Haemophilia joint health score (2.1) 
Individual 
ID 
  
Ankle Knee Elbow Total 
score 
Individual 
ID 
  
Ankle Knee Elbow Total 
score Left Right Left Right Left Right Left Right Left Right Left Right 
1 
Swelling 0 0 0 0 0 0 
  48 
Swelling 0 0 0 0 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 1 1 1 1 1 1 Muscle atrophy 1 0 1 1 0 0 
Axial alignment 1 1 1 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 0 0 0 1 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 1 1 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 1 2 0 1 Joint pain 0 0 1 1 1 1 
Strength 0 0 1 1 0 1 Strength 1 0 1 1 0 0 
Gait 1 1 1 2   Gait 1 2 1 1   
Joint total 3 3 6 8 1 3 24+2=26   Joint total 3 2 4 4 1 1 15+2=17 
                                    
2 
Swelling 0 0 0 0 0 0 
  49 
Swelling 0 0 0 0 0 0 
0 
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 1 0 0 0 Muscle atrophy 0 0 1 0 1 0 
Axial alignment 0 0 0 0   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 1 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 1 0 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 1 0 0 0 Joint pain 0 0 1 0 1 0 
Strength 0 0 1 0 0 0 Strength 0 0 1 0 1 0 
Gait 0 0 1 1   Gait 0 0 0 0   
Joint total 0 0 7 1 0 0 8+2=10   Joint total 0 0 3 0 3 0 6 
                                    
3 
Swelling 0 0 0 2 0 0 
  50 
Swelling 1 0 1 0 1 0 
16+2=18 
Duration swelling 0 0 0 1 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 0 0 0 0 1 0 
Axial alignment 0 0 1 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 1 0 0 Crepitus on motion 0 0 0 0 1 0 
Flexion loss 0 0 1 2 1 1 Flexion loss 0 0 2 0 0 1 
Extension loss 0 0 1 1 0 0 Extension loss 0 0 0 0 0 0 
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Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 0 2 0 0 Joint pain 0 0 0 0 0 0 
Strength 0 0 1 1 0 0 Strength 1 0 2 0 2 0 
Gait 1 1 1 2   Gait 1 0 2 0 0 
Joint total 1 1 5 14 1 1 23+3=26   Joint total 3 0 7 0 5 1 
                                    
4 
Swelling 0 0 0 0 1 0 
  51 
Swelling 0 0 1 0 1 0   
Duration swelling 0 0 0 0 1 0 Duration swelling 0 0 1 0 1 0   
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 0 0 2 0 0 0   
Axial alignment 0 0 0 0   Axial alignment 0 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 1 0   
Flexion loss 0 0 0 0 2 0 Flexion loss 0 0 0 0 0 0   
Extension loss 0 0 1 1 2 1 Extension loss 0 0 0 0 0 0   
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0   
Joint pain 0 0 0 0 1 1 Joint pain 0 0 0 0 1 0   
Strength 0 0 0 1 1 1 Strength 0 0 0 0 1 0   
Gait 0 0 1 1   Gait 0 0 1 0 0   
Joint total 0 0 2 4 8 3 17+1=18 
52 
Joint total 0 0 4 0 5 0 9+1=10 
                                  
5 
Swelling 0 0 0 0 0 1 
  
Swelling 0 0 1 2 0 0 
  
Duration swelling 0 0 0 0 0 1 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 1 1 1 0 0 
Axial alignment 1 0 1 1   Axial alignment 1 1 1 1   
Crepitus on motion 0 0 0 0 0 1 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 0 3 3 1 1 Flexion loss 0 0 1 0 0 0 
Extension loss 0 0 0 1 1 1 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 1 1 0 1 Joint pain 0 0 1 1 0 0 
Strength 0 0 1 1 0 0 Strength 1 1 3 3 0 0 
Gait 3 0 1 1   Gait 1 1 2 2     
Joint total 4 0 7 8 2 6 27+3=30 Joint total 3 4 11 11 0 0 29+2=31 
                                    
6 
Swelling 0 0 0 0 0 0 
  53 
Swelling 0 1 1 1 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 1 1 1 1 0 0 
Axial alignment 0 0 0 0   Axial alignment 1 1 1 1   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 2 0 2 0 0 Flexion loss 0 0 3 3 2 0 
Extension loss 2 0 0   0 0 Extension loss 0 0 2 2 1 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
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Joint pain 0 0 0 0 0 0 Joint pain 1 1 2 1 1 1 
Strength 1 1 2 2 1 1 Strength 1 1 3 3 2 2 
Gait 1 1 1 1   Gait 1 1 3 3   
Joint total 4 4 3 6 1 1 19+1=20 Joint total 5 6 17 16 6 3 53+3=56 
                                    
7 
Swelling 0 2 0 0 0 0 
  
54 
Swelling 0 0 0 0 0 1 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 1 1 1 1 Muscle atrophy 0 0 0 1 1 1 
Axial alignment 1 1 0 0 0 O Axial alignment 0 0 0 0   
Crepitus on motion 0 1 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 1 3 0 0 0 Flexion loss 0 0 0 0 1 1 
Extension loss 0 0 0 0 1 1 Extension loss 0 0 0 0 0 1 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 2 0 0 0 0 Joint pain 0 0 0 0 0 1 
Strength 0 4 1 1 2 2 Strength 0 0 0 1 0 1 
Gait 2 2 3 2   Gait 0 0 0 0   
Joint total 3 13 8 4 4 4 36+4=40 Joint total 0 0 0 2 2 6 10 
                                    
8 
Swelling 0 0 0 0 0 0 
  
55 
Swelling 0 0 0 0 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 1 1 1 1 0 1 Muscle atrophy 0 0 0 0 0 1 
Axial alignment 0 0 1 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 1 1 0 1 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 1 Instability 0 0 0 0 0 0 
Joint pain 1 1 1 1 0 0 Joint pain 0 0 0 0 0 1 
Strength 1 1 1 1 0 0 Strength 0 0 0 0 0 1 
Gait 1 1 1 1   Gait 0 0 0 0   
Joint total 4 4 6 6 0 2 22+1=23 Joint total 0 0 0 0 0 3 3 
                                    
9 
Swelling 0 0 0 0 2 0 
  56 
Swelling 0 0 1 1 0 0 
  
Duration swelling 0 0 0 0 1 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 1 0 2 0 2 0 Muscle atrophy 1 1 2 2 1 1 
Axial alignment 0 0 1 0     Axial alignment 0 0 1 1   
Crepitus on motion 0 0 1 0 1 0 Crepitus on motion 0 1 1 1 1 0 
Flexion loss Ne 0 2 0 0 0 Flexion loss 0 1 2 2 0 0 
Extension loss Ne 0 2 0 0 0 Extension loss 1 0 1 1 0 0 
Instability 0 0 1 1 1 0 Instability 0 0 1 1 0 0 
Joint pain 1 0 2 0 2 0 Joint pain 0 0 0 1 0 0 
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Strength 4 0 4 0 4 0 Strength 1 1 4 4 1 1 
Gait 2 0 2 2   Gait 1 1 2 3   
                                
Joint total 8 0 17 3 13 0 41+2=43 Joint total 4 5 15 17 3 2 46+3=49 
10 
Swelling 0 2 0 0 1 0 
  
57 
Swelling 0 0 2 0 0 0 
  
Duration swelling 0 1 0 0 1 0 Duration swelling 0 0 1 0 0 0 
Muscle atrophy 0 1 1 0 0 0 Muscle atrophy 1 0 0 0 0 0 
Axial alignment 0 1 0 0     Axial alignment 0 0 1 0   
Crepitus on motion 0 1 0 0     Crepitus on motion 0 0 1 0 0 0 
Flexion loss 0 Ne 2 0 2 0 Flexion loss 0 0 3 0 0 0 
Extension loss 0 Ne 0 0 0 0 Extension loss 0 0 1 0 0 0 
Instability 0 0 0 0 1 0 Instability 0 0 0 0 0 0 
Joint pain 0 2 0 0 1 0 Joint pain 0 0 1 0 0 0 
Strength 0 3 0 0 1 0 Strength 2 0 3 0 0 0 
Gait 0 2 0 1     Gait 1 1 2 1   
Joint total 0 13 3 1 7 0 24+0=24 Joint total 4 1 15 1 0 0 21+2=23 
                                    
11 
Swelling 0 0 2 0 0 0 
  
58 
Swelling 0 0 0 0 0 0 
  
Duration swelling 0 0 1 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 1 0 1 1 0 1 Muscle atrophy 0 0 0 0 0   
Axial alignment 0 0 1 0     Axial alignment 0 0 0 0   
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 1 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 1 0 1 0 0 1 Joint pain 0 0 1 1 0 0 
Strength 1 1 2 0 0 0 Strength 0 0 1 1 1 0 
Gait 1 1 2 1 2 Gait 0 0 0 0   
Joint total 4 2 11 2 0 3 22+2=24 Joint total 0 0 2 2 1 0 5 
                                    
12 
Swelling 0 0 1 0 0 0 
  59 
Swelling 0 0 0 0 0 0 
  
Duration swelling 0 0 1 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 1 0 1 1 0 0 Muscle atrophy 0 0 0 0 0 0 
Axial alignment 0 0 0 0   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 1 1 0 0 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 1 1 0 0 Joint pain 0 0 1 1 1 1 
Strength 0 0 1 1 0 0 Strength 1 1 0 1 1 1 
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Gait 0 0 1 1   Gait 0 0 0 0   
Joint total 2 1 7 4 0 0 14+2=16 Joint total 1 1 1 2 2 2 9 
                                    
13
 Inhib
 
Swelling 0 0 1 1 0 0 
  
60 
Swelling 0 1 2 2 1 1 
  
Duration swelling 0 0 1 1 0 0 Duration swelling 0 1 0 0 0 0 
Muscle atrophy 0 0 2 1 0 0 Muscle atrophy 1 1 1 1 0 0 
Axial alignment 0 0 0 0   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 0 2 2 0 0 Flexion loss 0 1 3 3 2 1 
Extension loss 0 0 1 0 0 0 Extension loss 0 1 2 1 2 2 
Instability 0 0 0 1 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 1 1 1 1 Joint pain 1 1 1 1 1 1 
Strength 0 0 1 1 0 0 Strength 1 2 3 3 1 2 
Gait 1 1 1 1   Gait 1 1 2 3   
Joint total 1 1 11 9 1 1 24+1=25 Joint total 4 9 15 15 7 7 57+3=60 
                                    
  Swelling 0 0 2 2 0 0 
  
61 
Swelling 0 0 0 0 0 0 
  
  Duration swelling 0 0 1 1 0 0 Duration swelling 0 0 0 0 0 0 
  Muscle atrophy 1 1 2 2 1 1 Muscle atrophy 0 0 0 0 0   
  Axial alignment 1 1 1 1   Axial alignment 0 0 0 0   
14 Crepitus on motion 0 0 1 1 0 0 Crepitus on motion 0 0 0 0 0 0 
  Flexion loss 1 1 0 1 2 3 Flexion loss 0 0 0 0 0 0 
  Extension loss 3 3 3 3 1 2 Extension loss 0 0 0 0 0 0 
  Instability 0 0 1 1 1 1 Instability 0 0 0 0 0 0 
  Joint pain 0 0 2 2 1 1 Joint pain 0 0 1 0 0 0 
  Strength 1 1 4 4 2 2 Strength 0 0 1 0 0 0 
  Gait 4 4 4 4   Gait 0 0 1 0   
  Joint total 11 11 21 22 8 10 83+4=87 Joint total 0 0 3 0 0 0 3 
                                    
15 
Swelling 0 0 0 0 0 0 
  62 
Swelling 1 0 2 2 2 2 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 1 1 2 2 1 1 
Axial alignment 0 0 0 0   Axial alignment 1 1 1 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 1 1 1 1 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 1 1 2 1 3 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 1 2 2 3 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 1 1 1 1 3 1 
Strength 0 0 0 0 0 0 Strength 2 1 4 4 3 3 
Gait 0 0 0 0   Gait 2 1 3 3   
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Joint total 0 0 0 0 0 0 0 Joint total 10 7 17 16 14 10 74+3=77 
16 
Swelling 0 0 0 0 0 0 
  
65 
Swelling 0 0 1 1 2 2 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 1 1 1 1 2 2 
Axial alignment 0 0 0 0   Axial alignment 0 0 1 1   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 1 1 1 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 1 2 3 3 
Extension loss 0 0 0 0 0 0 Extension loss 1 0 1 1 1 3 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 1 1 1 1 1 1 
Strength 0 0 0 0 0 0 Strength 1 1 3 3 3 3 
Gait 0 0 0 0   Gait 1 0 2 2   
Joint total 0 0 0 0 0 0 0 Joint total 5 3 12 13 13 15 61+2=62 
17 
Swelling 0 0 1 0 0 0 
  
66 
Swelling 0 0 1 1 0 1 
  
Duration swelling 0 0 1 0 0 0 Duration swelling 0 0 0 0 0 1 
Muscle atrophy 0 0 1 1 1 0 Muscle atrophy 0 0 1 1 0 2 
Axial alignment 0 0 1 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 1 0 1 
Flexion loss 0 0 3 3 2 1 Flexion loss 0 0 0 0 0 2 
Extension loss 0 0 1 0 2 1 Extension loss 0 0 0 0 0 1 
Instability 0 0 1 0 1 0 Instability 0 0 0 0 0 0 
Joint pain 1 1 1 1 1 1 Joint pain 0 0 1 1 0 1 
Strength 1 1 2 2 3 0 Strength 0 0 3 3 1 3 
Gait 1 1 2 1   Gait 0 0 2 2   
Joint total 3 3 14 9 10 3 42+3=45 Joint total 0 0 9 9 1 12 31+2=33 
                                    
18 
Swelling 0 0 2 0 0 2 
  
70 
Swelling 0 0 0 0 0 0 
  
Duration swelling 0 0 1 0 0 1 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 1 0 0 0 Muscle atrophy 0 0 0 0 0 0 
Axial alignment 1 1 1 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 2 0 0 1 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 2 0 1 Ne Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 Ne Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 2 0 0 2 Joint pain 0 0 1 0 0 0 
Strength 0 0 4 0 0 4 Strength 0 0 1 0 0 0 
Gait 1 1 1 1   Gait 0 0 0 0   
Joint total 2 2 16 2 1 10 33+1=34 Joint total 0 0 2 0 0 0 2 
                                    
19 Swelling 0 0 0 0 0 0   71 Swelling 0 0 0 3 0 2   
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Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 1 2 0 1 
Axial alignment 0 0 0 0   Axial alignment 1 1 1 1   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 1 0 1 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 3 3 1 2 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 3 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 0 0 1 1 1 1 
Strength 0 0 0 0 0 0 Strength 1 1 2 3 1 2 
Gait 0 0 0 0   Gait 1 1 2 2   
Joint total 0 0 0 0 0 0 0 Joint total 3 3 10 19 3 9 47+2=49 
                                    
21 
Swelling 0 0 1 1 0 0 
  
72 
Swelling 0 0 0 0 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 1 1 1 1 Muscle atrophy 0 0 0 0 0 0 
Axial alignment 0 0 1 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 1 1 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 2 2 3 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 1 2 2 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 1 1 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 1 1 1 1 Joint pain 0 0 1 1 0 0 
Strength 0 0 4 4 2 2 Strength 0 0 1 1 0 0 
Gait 1 1 3 3   Gait 0 0 0 0   
Joint total 1 1 16 17 9 4 48+3= 51 Joint total 0 0 2 2 0 0 4 
                                    
22 
Swelling 0 0 0 0 0 0 
  
73
 Inhib
 
Swelling 0 0 2 2 1 1 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 1 1 0 0 
Muscle atrophy 0 0 1 0 0 0 Muscle atrophy 1 1 1 2 0 0 
Axial alignment 0 0 0 0   Axial alignment 0 0 1 1   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 0 1 0 1 1 Flexion loss 0 0 2 0 2 2 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 1 0 0 0 
Instability 0 0 1 0   Instability 0 0 1 1 0 0 
Joint pain 0 0 1 1 0 0 Joint pain 1 1 0 0 0 0 
Strength 1 1 1 1 0 0 Strength 1 2 2 3 1 1 
Gait 1 1 2 2   Gait 1 1 2 3   
Joint total 2 2 7 4 1 1 17+2=19 Joint total 4 5 14 13 4 4 44+3=47 
                                    
23 
Swelling 0 0 0 0 0 0 
  74 
Swelling 0 0 0 0 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Page 167 of 197 
 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 0 0 0 0 
Axial alignment 0 0 0 0   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 0 0 0 0 0 0 
Strength 0 0 0 0 0 0 Strength 0 0 0 0 0 0 
Gait 0 0 0 0   Gait 0 0 0 0   
Joint total 0 0 0 0 0 0 0 Joint total 0 0 0 0 0 0 0 
                                    
  Swelling 0 0 0 0 0 0 
  
75 
Swelling 0 0 1 0 1 1 
  
  Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 1 0 1 1 
  Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 1 1 1 0 
24 Axial alignment 0 0 0 0   Axial alignment 1 0 1 1   
  Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 1 0 0 
  Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 3 0 0 0 
  Extension loss 0 0 0 0 0 0 Extension loss 0 0 1 1 3 0 
  Instability 0 0 0 0   Instability 0 0 0 0 0 0 
  Joint pain 0 0 0 0 0 0 Joint pain 1 1 1 1 1 1 
  Strength 0 0 0 0 0 0 Strength 1 1 2 1 3 2 
  Gait 0 0 0 0 0 0 Gait 2 1 2 3   
  Joint total 0 0 0 0 0 0 0 Joint total 5 3 14 9 9 5 45+3=48 
25 
Swelling 0 0 0 0 0 1 
  
76 
Swelling 0 0 2 3 1 1 
  
Duration swelling 0 0 0 0 0 1 Duration swelling 0 0 1 0 1 1 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 1 1 1 2 1 1 
Axial alignment 0 0 0 0   Axial alignment 1 1 1 1   
Crepitus on motion 0 0 0 0 0 1 Crepitus on motion 0 0 1 1 0 0 
Flexion loss 0 0 0 0 0 1 Flexion loss 1 1 3 0 0 0 
Extension loss 0 0 0 0 1 0 Extension loss 1 1 3 3 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 1 1 0 0 
Joint pain 0 0 0 0 0 1 Joint pain 0 0 2 2 0 0 
Strength 0 0 0 0 0 2 Strength 2 2 3 4 1 1 
Gait 0 0 0 0   Gait 3 3 2 4   
Joint total 0 0 0 0 1 7 8 Joint total 9 9 20 21 4 4 67+4=71 
26 
Swelling 0 0 0 0 0 0 
  77 
Swelling 1 0 1 1 1 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 1 0 1 1 0 0 
Muscle atrophy 1 1 0 0 0 0 Muscle atrophy 1 1 1 1 1 1 
Axial alignment 0 0 0 0   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
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Flexion loss 1 1 0 0 0 0 Flexion loss 0 0 0 0 2 1 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 1 0 0 
Instability 0 1 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 1 1 0 0 0 0 Joint pain 0 0 1 1 0 0 
Strength 1 1 0 0 0 0 Strength 1 2 2 2 1 1 
Gait 1 1 0 0   Gait 1 1 2 2   
Joint total 5 6 0 0 0 0 11+1=12 Joint total 5 4 8 9 5 3 34+2=36 
27 
Swelling 0 0 0 0 0 0 
  
78 
Swelling 5 4 8 9 5 3 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 0 0 0 0 
Axial alignment 0 0 1 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 1 1 0 0 Joint pain 0 0 0 0 0 0 
Strength 0 0 1 1 0 0 Strength 0 0 0 0 0 0 
Gait 1 1 1 1   Gait 0 0 0 0   
Joint total 1 1 4 4 0 0 10+1=11 Joint total 0 0 0 0 0 0 0 
                                    
28 
Swelling 0 0 0 0 0 0 
  
79 
Swelling 1 0 1 1 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 1 1 1 1 0 0 
Muscle atrophy 0 0 1 1 2 2 Muscle atrophy 1 1 2 1 1 1 
Axial alignment 1 1 1 1   Axial alignment 0 0 1 1   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 1 1 0 0 Flexion loss 0 0 3 0 2 1 
Extension loss 0 0 0 1 1 2 Extension loss 1 1 1 0 1 0 
Instability 0 0 1 1 1 1 Instability 0 0 0 0 0 0 
Joint pain 1 0 1 1 1 1 Joint pain 0 0 0 0 0 0 
Strength 1 1 2 2 4 4 Strength 2 1 3 2 1 1 
Gait 1 1 2 2   Gait 1 1 2 2   
Joint total 4 2 9 10 9 10 44+3=47 Joint total 7 5 14 8 5 3 42+2=44 
                                    
29 
Swelling 0 0 0 0 0 0 
  80 
Swelling 0 0 0 0 2 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 1 0 0 0 1 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 1 0 0 0 0 0 
Axial alignment 0 0 0 0   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 1 0 Flexion loss 0 0 3 3 0 0 
Extension loss 0 0 0 0 1 0 Extension loss 0 0 0 0 0 3 
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Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 0 0 1 1 Joint pain 1 0 0 0 2 1 
Strength 0 0 0 0 1 1 Strength 1 0 1 1 4 1 
Gait 0 0 0 0   Gait 1 1 0 1   
Joint total 0 0 0 0 4 2 6 Joint total 5 1 4 5 9 5 29+1=30 
                                    
30 
Swelling 0 2 0 0 0 0 
  
81 
Swelling 0 0 0 0 0 0 
  
Duration swelling 0 1 0 0 0 0 Duration swelling 0 0 0 0 2 0 
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 0 0 0 0 1 1 
Axial alignment 0 1 0 0   Axial alignment 0 0 0 0   
Crepitus on motion 0 2 0 0 0 0 Crepitus on motion 0 0 0 0 1 0 
Flexion loss 0 1 0 0 0 0 Flexion loss 0 2 0 0 3 2 
Extension loss 0 1 0 1 0 0 Extension loss 0 0 0 0 3 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 2 0 0 0 0 Joint pain 1 1 0 0 1 0 
Strength 0 4 0 0 0 0 Strength 1 1 0 0 3 0 
Gait 1 2 1 1   Gait 1 2 1 1     
Joint total 1 16 1 3 0 0 21+2=23 Joint total 3 6 1 1 14 3 28+2=30 
                                    
31 
Swelling 0 0 1 1 0 1 
  
82 
Swelling 0 0 3 2 0 1 
  
Duration swelling 0 0 0 0 0 1 Duration swelling 0 0 0 0 0 1 
Muscle atrophy 0 0 1 1 1 1 Muscle atrophy 1 1 2 2 0 0 
Axial alignment 0 0 1 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 1 0 0 1 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 1 0 3 3 N 1 Flexion loss 0 0 2 2 3 0 
Extension loss 1 1 1 1 N 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 1 0 1 0 Instability 0 0 0 0 0 0 
Joint pain 1 1 1 1 1 1 Joint pain 1 1 0 0 1 1 
Strength 1 1 1 2 2 3 Strength 2 1 3 3 3 2 
Gait 2 2 2 1   Gait 1 1 1 2   
Joint total 6 5 13 11 5 9 49+3=52 Joint total 5 4 11 11 7 5 43+2=45 
                                    
32 
Swelling 0 0 2 0 0 0 
  83 
Swelling 1 1 1 2 0 0 
  
Duration swelling 0 0 1 0 0 0 Duration swelling 0 1 0 0 0 0 
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 1 1 2 2 1 2 
Axial alignment 0 0 1 1 0 0 Axial alignment 1 1 1 1   
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 1 1 3 3 0 1 Flexion loss 0 0 3 3 1 0 
Extension loss 0 0 0 3 0 0 Extension loss 0 0 2 0 0 0 
Instability 0 0 1 1 0 0 Instability 0 0 0 0 0 0 
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Joint pain 0 0 2 2 0 1 Joint pain 1 1 1 1 1 1 
Strength 1 1 4 4 1 1 Strength 2 2 2 3 2 3 
Gait 2 2 2 4 1 1 Gait 1 0 2 3   
Joint total 4 4 17 19 2 4 50+3=53 Joint total 7 6 14 15 5 6 53+3=56 
                                    
33 
Swelling 0 0 2 0 0 0 
  
84 
Swelling 1 1 1 1 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 1 0 1 1 Muscle atrophy 1 1 1 0 2 2 
Axial alignment 0 0 1 1   Axial alignment 1 1 1 1   
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 1 1 3 1 2 2 Flexion loss 0 0 3 3 3 1 
Extension loss 0 0 3 0 0 0 Extension loss 0 0 2 0 2 0 
Instability 0 0 1 1 O O Instability 0 0 0 0 0 0 
Joint pain 0 0 2 1 1 1 Joint pain 0 0 1 1 1 1 
Strength 1 1 4 3 3 3 Strength 1 2 2 1 2 3 
Gait 1 1 3 2   Gait 1 2 3 3   
Joint total 3 3 21 9 7 7 50+3=53 Joint total 5 7 14 10 10 7 53+3=56 
                                    
34 
Swelling 0 0 0 0 0 0 
  
85 
Swelling 0 0 1 1 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 1 0 0 0 0 Muscle atrophy 1 0 2 1 0 0 
Axial alignment 0 0 0 0   Axial alignment 0 0 1 1   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 1 0 3 3 0 1 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 1 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 1 1 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 1 1 1 1 1 1 
Strength 0 1 0 0 0 0 Strength 1 1 2 3 1 0 
Gait 0 0 0 0   Gait 1 2 1 3   
Joint total 0 2 0 0 0 0 2 Joint total 5 4 13 14 2 2 40+3=43 
                                    
35 
Swelling 0 0 0 0 0 0   
86 
Swelling 0 0 1 0 0 0 
  
Duration swelling 0 0 0 0 0 0   Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 0 0 0 0   Muscle atrophy 0 0 1 0 0 0 
Axial alignment             Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0   Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0   Flexion loss 0 0 1 0 0 0 
Extension loss 0 0 0 0 0 0   Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0   Instability 0 0 0 0 0 0 
Joint pain 0 0 0 0 0 0   Joint pain 0 0 1 0 0 0 
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Strength 0 0 0 0 0 0   Strength 0 0 2 0 0 1 
Gait 0 0 0 0       Gait 0 0 1 1   
Joint total 0 0 0 0 0 0 0 Joint total 0 0 7 1 0 1 9+1=10 
                                    
36
 Inhib
 
Swelling 0 0 1 2 0 0 
  
87 
Swelling 0 0 0 1 0 0 
  
Duration swelling 0 0 1 1 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 1 1 1 0 0 Muscle atrophy 0 0 0 1 0 0 
Axial alignment 1 0 0 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 1 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 1 1 2 2 1 1 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 3 3 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 1 1 1 2 0 0 Joint pain 0 0 1 1 0 0 
Strength 1 1 3 4 0 0 Strength 0 0 0 1 1 1 
Gait 1 1 2 3   Gait 1 1 1 2   
Joint total 5 5 14 20 1 1 46+3=49 Joint total 1 1 2 6 1 1 12+2=14 
                                    
37 
Swelling 0 0 0 1 0 0 
  
88 
Swelling 0 0 1 0 0 1 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 0 1 0 0 Muscle atrophy 0 0 1 1 0 2 
Axial alignment 0 0 1 1   Axial alignment 0 0 1 1   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 1 2 1 1 Flexion loss 0 0 2 1 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 1 0 0 1 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 1 1 0 0 Joint pain 0 0 1 1 0 1 
Strength 0 0 1 2 0 0 Strength 0 0 2 1 0 2 
Gait 0 0 1 1   Gait 0 1 2 2   
Joint total 0 0 5 9 1 1 16+1=17 Joint total 0 1 11 7 0 7 26+2=28 
                                    
38 
Swelling 0 0 0 0 0 0 
  89 
Swelling 0 0 1 0 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 1 0 0 0 
Muscle atrophy 1 0 0 0 1 0 Muscle atrophy 1 0 1 0 0 0 
Axial alignment 0 0 1 1   Axial alignment 1 0 1 1   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 0 0 0 
Flexion loss 0 0 0 2 0 0 Flexion loss 0 0 1 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 1 0 0 0 
Joint pain 1 1 0 0 1 0 Joint pain 0 0 1 1 0 0 
Strength 1 1 2 1 2 0 Strength 1 1 1 0 0 0 
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Gait 1 1 1 1   Gait 0 1 1 1   
Joint total 4 3 4 5 4 0 20+2=22 Joint total 3 2 10 3 0 0 18+1=19 
                                    
39 
Swelling 0 0 0 0 0 0 
  
90 
Swelling 0 0 2 0 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 1 0 0 0 
Muscle atrophy 0 0 0 0 0 0 Muscle atrophy 0 0 1 0 0 0 
Axial alignment 0 0 0 0   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 2 0 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 0 0 0 0 Joint pain 0 0 2 0 1 1 
Strength 0 0 0 0 0 0 Strength 0 0 1 0 1 1 
Gait 0 0 0 0   Gait 0 0 0 0   
Joint total 0 0 0 0 0 0 0 Joint total 0 0 10 0 2 2 14 
                                    
40 
Swelling 0 0 1 0 0 0 
  
91 
Swelling 0 0 0 0 0 0 
  
Duration swelling 0 0 1 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 1 0 0 0 0 0 Muscle atrophy 0 0 0 0 0 0 
Axial alignment 1 1 1 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 1 1 0 1 0 0 Flexion loss 0 0 0 0 0 0 
Extension loss 0 0 1 0 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 1 0 1 0 0 0 Joint pain 0 0 1 0 0 0 
Strength 2 0 3 0 0 0 Strength 0 0 1 0 0 0 
Gait 1 1 2 1   Gait 0 0 1 0   
Joint total 7 3 11 3 0 0 24+2=26 Joint total 0 0 3 0 0 0 3+1=4 
                                    
41 
Swelling 0 0 1 0 0 0 
  92 
Swelling 0 0 0 2 1 0 
  
Duration swelling 0 0 1 0 0 0 Duration swelling 0 0 0 1 0 0 
Muscle atrophy 0 0 2 0 2 0 Muscle atrophy 0 1 0 1 2 0 
Axial alignment 0 0 1 1   Axial alignment 1 1 1 1   
Crepitus on motion 0 0 1 0 0 0 Crepitus on motion 0 0 0 1 1 0 
Flexion loss 0 0 3 0 2 0 Flexion loss 0 0 0 3 1 0 
Extension loss 0 0 1 0 2 0 Extension loss 1 0 0 0 2 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 1 0 1 0 1 0 Joint pain 0 1 0 2 1 0 
Strength 1 0 3 0 4 0 Strength 1 1 0 2 3 1 
Gait 1 1 2 2   Gait 1 0 1 1   
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Joint total 3 1 16 3 9 0 32+2=34 Joint total 4 4 2 14 11 1 36+1=37 
                                    
  Swelling 0 0 1 0 0 0 
  
93 
Swelling 0 0 0 0 0 0 
  
  Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
  Muscle atrophy 0 0 1 0 0 0 Muscle atrophy 0 0 0 0 0 0 
  Axial alignment 1 1 0 0   Axial alignment 0 0 0 0   
42 Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
  Flexion loss 1 0 0 0 0 0 Flexion loss 0 0 0 0 0 0 
  Extension loss 1 0 1 0 0 0 Extension loss 0 0 0 0 0 0 
  Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
  Joint pain 1 0 1 0 0 0 Joint pain 0 0 1 0 0 0 
  Strength 1 0 2 0 0 0 Strength 0 0 1 0 0   
  Gait 1 1 2 2   Gait 0 0 1 0   
  Joint total 6 2 8 2 0 0 18+2=20 Joint total 0 0 3 0 0 0 3+1=4 
43 
Swelling 0 0 0 0 0 0 
  
94 
Swelling 1 1 2 1 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 1 0 0 0 
Muscle atrophy 0 0 1 0 0 0 Muscle atrophy 1 1 2 2 0 0 
Axial alignment 0 0 0 0   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 1 0 0 0 
Flexion loss 0 0 0 0 1 0 Flexion loss 1 1 3 3 0 2 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 3 3 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 0 0 1 1 Joint pain 1 0 1 1 0 0 
Strength 0 0 0 0 1 1 Strength 1 1 3 3 0 0 
Gait 0 0 0 0   Gait 1 1 3 3   
Joint total 0 0 1 0 3 2 6 Joint total 6 5 19 16 0 2 48+4=52 
44 
Swelling 0 0 1 1 0 0 
  
95 
Swelling 1 1 1 2 0 2 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 1 0 0 1 0 1 
Muscle atrophy 0 0 1 1 0 1 Muscle atrophy 1 0 1 1 1 0 
Axial alignment 0 0 1 1   Axial alignment 0 0 0 0   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 1 0 0 
Flexion loss 0 0 1 1 3 3 Flexion loss 1 1 3 3 1 Ne 
Extension loss 0 0 0 0 0 2 Extension loss 0 0 0 0 0 Ne 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 2 2 0 1 Joint pain 1 0 1 2 0 0 
Strength 0 0 4 4 0 3 Strength 1 1 2 2 1 0 
Gait 1 1 3 3   Gait 1 1 2 3     
Joint total 1 1 13 13 3 10 41+3=44 Joint total 7 4 10 15 3 3 42+2=44 
45 
Swelling 0 0 0 1 0 0 
  96 
Swelling 1 1 1 2 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 1 1 1 1 0 0 
Page 174 of 197 
 
Muscle atrophy 1 1 1 1 0 0 Muscle atrophy 1 1 1 2 0 1 
Axial alignment 0 0 1 1   Axial alignment 0 1 1 1   
Crepitus on motion 0 0 1 1 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 3 0 0 0 Flexion loss 0 0 1 2 0 0 
Extension loss 0 0 3 0 0 0 Extension loss 1 1 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 0 1 0 0 Joint pain 0 0 1 1 0 1 
Strength 1 1 3 4 0 0 Strength 1 2 3 2 1 1 
Gait 2 2 3 2   Gait 1 2 2 3   
Joint total 4 4 14 11 0 0 33+4=37 Joint total 6 9 11 14 1 3 54+4=58 
46
 Inhib
 
Swelling 0 0 0 0 0 0 
  
97 
Swelling 0 0 1 1 0 0 
  
Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 0 0 0 0 
Muscle atrophy 0 0 0 1 0 1 Muscle atrophy 0 0 1 1 0 0 
Axial alignment 0 0 0 0   Axial alignment 0 0 1 1   
Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 3 2 0 0 
Extension loss 0 0 0 0 0 0 Extension loss 0 0 0 0 0 0 
Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
Joint pain 0 0 0 1 O 1 Joint pain 0 0 0 0 0 0 
Strength 0 0 1 1 0 1 Strength 0 0 1 2 1 1 
Gait 1 1 1 1   Gait 1 1 2 2   
Joint total 1 1 2 4 0 3 11+1=12 Joint total 1 1 9 9 1 1 22+2=24 
                                    
  Swelling 0 0 0 0 0 0 
  
98 
Swelling 1 1 1 0 0 0 
  
  Duration swelling 0 0 0 0 0 0 Duration swelling 0 0 1 0 0 0 
  Muscle atrophy 0 0 0 0 1 1 Muscle atrophy 1 0 1 0 1 1 
  Axial alignment 0 0 0 0   Axial alignment 0 0 1 1   
47 Crepitus on motion 0 0 0 0 0 0 Crepitus on motion 0 0 0 0 0 0 
  Flexion loss 0 0 0 0 0 0 Flexion loss 0 0 1 1 0 0 
  Extension loss 0 0 0 0 1 1 Extension loss 1 0 0 0 1 0 
  Instability 0 0 0 0 0 0 Instability 0 0 0 0 0 0 
  Joint pain 0 0 0 0 1 1 Joint pain 1 1 1 0 0 0 
  Strength 0 0 0 0 1 1 Strength 1 1 3 0 2 1 
  Gait 0 0 0 0   Gait 1 1 2 3   
  Joint total 0 0 0 0 4 4 8 Joint total 6 4 11 5 4 2 32+3=35 
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Table A3 
Thrombin Generation data at different concentration of tissue factor trigger 
 
    Thrombin generation at 1 pmol/L of tissue factor Thrombin generation at 3 pmol/L of tissue factor Thrombin generation at 5 pmol/L of tissue factor 
  Lagtime  
(min) 
ETP 
(nM.min) 
Peak      
(nM) 
ttpeak   
(min) 
Velocity Index 
(nM/min) 
Lagtime  
(min) 
ETP 
(nM.min) 
Peak      
(nM) 
ttpeak   
(min) 
Velocity 
Index 
(nM/min) 
Lagtime  
(min) 
ETP 
(nM.min) 
Peak      
(nM) 
ttpeak   
(min) 
Velocity 
Index 
(nM/min) 
  
  
Normal 
range 
0-31.11 0-566 0-44.41 0-101.22 0.17-1.83 2-13.33 0-1570 
17.15-
109.57 
5.11-
102.51 
0.37-26.70 1.67-5.17 0-1988 
29.17-
221.35 
3.83-51.00 1-55.41 
  
  Individual 
               
  1 8.33 215 6.99 27.67 0.36 2.67 576 39.22 9.33 5.89 2.11 707 79.63 5.67 22.37 
  2 13.67 238 12.73 28.17 0.88 2.67 664 48.31 11.89 5.24 2.11 967 84.77 9.44 11.56 
  3 17.75 0 12.97 41.17 0.55 3.67 561 30.45 15.67 2.54 3.08 0 80.99 9.92 11.84 
  4 5.75 0 23.53 23.33 1.34 2.75 845 62.85 10.42 8.19 2.25 978 112.02 7.08 23.19 
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5 12.11 378 15.30 28.44 0.94 4.11 779 54.07 14.22 5.35 2.89 814 74.26 10.44 9.84 
  6 5.42 0 24.43 39.50 0.72 3.17 910 95.39 8.50 17.90 2.50 859 166.22 5.50 55.41 
  7 12.83 171 5.24 34.00 0.25 3.78 578 28.32 16.33 2.26 3.00 682 40.84 11.83 4.63 
  8 5.56 223 11.26 19.33 0.82 2.78 820 70.25 9.22 10.91 2.33 1013 151.11 5.89 42.45 
  9 12.67 152 4.65 31.00 0.25 3.56 510 30.32 12.78 3.29 2.78 800 69.22 7.78 13.84 
  10 10.00 0 16.62 49.83 0.42 3.22 891 55.68 11.33 6.87 2.56 1015 96.56 8.33 16.73 
  11 7.22 256 12.32 20.22 0.95 2.89 624 48.16 10.11 6.67 2.44 738 75.09 7.67 14.36 
  12 5.67 284 11.11 22.00 0.68 2.78 694 42.62 12.11 4.57 2.11 972 92.95 7.56 17.06 
          13
 Inhib
 5.83 450 13.55 24.67 0.72 3.78 785 41.47 18.11 2.89 3.11 835 55.45 14.33 4.94 
  14 9.50 0 44.41 89.00 0.56 3.00 0 77.68 17.67 5.30 2.33 0 104.02 11.00 12.00 
  15 13.17 0 13.10 42.00 0.45 3.33 593 37.60 12.42 4.14 2.67 850 73.23 7.83 14.19 
  16 13.80 0 17.99 62.23 0.37 4.50 700 45.46 14.18 4.70 3.44 1005 94.77 9.20 16.45 
  17 9.00 0 17.90 72.49 0.28 3.44 0 52.93 48.61 1.17 2.67 1128 104.74 7.28 22.72 
  18 7.85 0 22.56 70.67 0.36 3.25 0 46.45 101.94 0.47 2.87 1043 106.66 7.28 24.19 
  19 12.65 0 20.13 94.36 0.25 3.54 0 64.82 102.51 0.65 2.48 715 75.85 7.56 14.93 
  21 14.18 0 13.87 49.00 0.40 4.40 786 38.04 18.11 2.77 3.34 1162 65.96 12.84 6.94 
  22 8.81 0 21.85 33.84 0.87 3.54 985 67.55 10.92 9.15 2.96 1129 120.36 7.37 27.29 
  23 17.35 0 21.20 53.41 0.59 3.82 803 45.91 12.84 5.09 3.25 0 118.74 8.62 22.11 
  24 11.00 0 21.74 80.78 0.31 2.67 716 44.27 11.33 5.11 2.50 955 82.99 8.00 15.09 
  25 4.33 0 30.25 47.33 0.70 2.33 828 45.68 12.33 4.57 1.83 874 89.55 7.00 17.32 
  26 8.00 0 25.64 98.33 0.28 3.00 490 28.17 14.89 2.37 2.44 734 42.93 12.67 4.20 
  27 6.00 0 18.66 45.67 0.47 3.44 413 17.15 19.33 1.08 2.89 852 51.06 11.33 6.05 
  28 5.33 0 33.24 96.67 0.36 2.33 0 64.46 20.67 3.51 2.00 747 68.85 7.56 12.38 
  29 9.17 0 19.94 54.33 0.44 3.50 0 56.09 22.17 3.00 2.50 981 122.16 6.50 30.54 
  30 10.17 0 12.31 49.67 0.31 3.67 840 35.96 17.67 2.57 3.33 1094 51.97 14.78 4.54 
  31 0.00 0 0.00 0.00 
 
3.17 519 27.05 16.00 2.11 2.56 746 45.94 13.56 4.18 
  32 9.56 0 14.49 70.22 0.24 2.78 554 30.07 13.78 2.73 2.44 619 47.42 10.44 5.93 
  33 4.67 0 31.10 44.83 0.77 2.22 858 67.57 10.00 8.69 2.00 841 120.90 5.89 31.08 
  34 4.50 0 29.67 45.67 0.72 2.33 1030 83.83 8.67 13.22 2.00 1075 166.50 5.56 46.77 
  35 5.33 0 38.80 35.33 1.29 2.67 875 104.50 8.22 18.83 2.00 807 150.90 5.33 45.32 
         36
 Inhib
 11.17 0 6.98 53.33 0.17 4.00 462 17.97 18.56 1.23 3.33 665 31.01 14.33 2.82 
  37 6.50 0 14.08 43.50 0.38 2.78 813 46.99 10.00 6.51 2.22 1085 90.13 6.22 22.53 
  38 6.33 259 10.82 22.67 0.66 2.67 855 47.27 13.00 4.58 2.33 1086 74.60 10.00 9.73 
  39 9.33 0 17.35 46.00 0.47 2.83 445 25.01 14.33 2.17 2.33 811 61.13 9.67 8.33 
  40 6.89 273 11.45 23.00 0.71 2.78 705 42.59 13.56 3.95 2.33 962 78.61 9.11 11.59 
  41 5.50 290 12.78 21.00 0.82 2.89 993 66.98 11.11 8.15 2.33 1058 91.95 8.56 14.76 
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42 6.63 0 21.28 70.00 0.34 3.45 0 51.30 23.52 2.56 2.62 0 98.62 19.34 5.90 
  43 10.14 0 11.72 55.62 0.26 4.12 0 25.24 40.41 0.70 2.95 836 35.10 14.82 2.96 
  44 15.32 0 13.32 56.62 0.32 4.29 539 25.94 19.84 1.67 3.95 893 39.80 17.50 2.94 
  45 10.34 0 16.52 45.86 0.47 2.32 0 37.55 47.42 0.83 2.09 975 119.73 6.55 26.85 
       46
 Inhib
 7.17 0 25.56 95.83 0.29 2.83 0 54.59 14.17 4.81 2.17 929 103.07 5.83 28.16 
  47 6.17 0 21.82 84.67 0.28 4.17 0 45.19 20.17 2.82 2.17 0 84.36 9.50 11.51 
  48 7.67 0 10.21 36.83 0.35 3.17 542 27.32 13.33 2.69 2.67 0 37.30 12.83 3.67 
  49 13.00 0 18.44 87.67 0.25 4.50 0 49.30 43.50 1.26 3.00 0 80.44 22.33 4.16 
  50 19.83 0 16.37 85.50 0.25 13.33 0 27.90 59.33 0.61 5.17 0 45.61 51.00 1.00 
  51 8.50 0 25.92 50.93 0.61 3.49 1032 54.84 14.68 4.90 2.82 1237 112.28 8.50 19.77 
  52 6.67 363 13.87 23.33 0.83 3.67 1442 48.95 14.00 4.74 2.67 1533 106.93 8.17 19.44 
  53 6.67 261 8.38 27.17 0.41 4.11 582 25.42 21.67 1.45 2.83 815 52.28 15.00 4.30 
  54 6.67 127 4.62 25.67 0.24 2.89 462 22.85 15.00 1.89 2.33 437 29.17 11.44 3.20 
  55 10.67 0 14.66 54.50 0.33 3.67 557 31.64 15.67 2.64 2.67 892 61.42 10.33 8.02 
  56 15.89 303 10.26 39.67 0.43 3.89 513 26.13 19.11 1.72 3.00 653 51.37 11.44 6.09 
  57 8.67 228 6.21 33.83 0.25 4.00 876 37.09 14.17 3.65 3.00 1318 83.58 7.50 18.57 
  58 5.50 0 44.37 47.00 1.07 2.44 1570 93.35 12.67 9.13 2.00 1884 175.41 8.78 25.87 
  59 7.00 0 23.98 51.50 0.54 3.17 1007 69.68 9.17 11.61 2.50 995 122.53 6.67 29.38 
  60 11.00 0 9.97 57.83 0.21 3.33 659 30.50 12.50 3.33 2.67 1016 63.98 7.50 13.25 
  61 8.00 0 28.09 80.00 0.39 2.83 0 49.47 34.67 1.55 2.33 0 115.98 7.33 23.20 
  62 8.83 0 11.73 42.83 0.35 3.33 744 29.40 17.00 2.15 2.83 849 53.28 10.83 6.66 
  65 14.18 0 13.87 49.00 0.40 4.40 786 38.04 18.11 2.77 3.34 1162 65.96 12.84 6.94 
  66 7.93 490 24.46 21.29 1.83 3.14 887 83.14 10.15 11.86 2.36 1056 136.23 7.48 26.61 
  70 16.83 0 21.12 90.83 0.29 5.67 0 41.60 40.17 1.21 4.17 0 60.66 37.33 1.83 
  71 5.26 268 11.81 22.62 0.68 2.81 690 40.83 15.28 3.27 2.70 667 51.29 13.38 4.80 
  72 6.09 0 26.08 40.49 0.76 2.75 0 52.30 33.31 1.71 1.92 798 60.06 11.82 6.07 
         73
 Inhib
 9.04 0 16.05 68.60 0.27 4.03 613 29.58 15.16 2.66 3.42 1481 42.42 13.77 4.10 
  74 6.59 0 25.26 90.42 0.30 2.81 0 58.00 32.42 1.96 2.25 848 64.24 11.60 6.87 
  75 7.71 360 12.72 26.41 0.68 3.59 779 39.85 16.39 3.11 2.92 978 62.70 12.94 6.26 
  76 12.33 0 13.20 75.00 0.21 3.33 572 23.32 17.33 1.67 2.78 809 54.05 10.33 7.16 
  77 14.67 0 14.97 79.00 0.23 4.17 0 45.91 55.83 0.89 3.00 0 76.14 24.00 3.63 
  78 11.33 0 18.51 77.50 0.28 4.00 0 46.97 76.00 0.65 2.67 0 71.23 20.17 4.07 
  79 4.17 0 43.02 94.50 0.48 2.00 606 83.04 5.11 26.70 1.83 0 80.05 3.83 40.03 
  80 31.11 0 11.40 73.11 0.27 2.50 1447 109.57 8.83 17.31 2.33 1988 221.35 6.67 51.00 
  81 24.83 0 10.61 79.83 0.19 8.50 0 29.09 46.00 0.78 5.00 0 49.61 38.17 1.50 
  82 20.78 0 18.34 70.89 0.37 7.22 0 34.96 101.00 0.37 4.33 0 47.34 32.33 1.69 
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83 5.33 0 14.64 35.89 0.48 2.67 567 29.83 15.33 2.36 2.33 697 44.04 13.22 4.04 
  84 14.67 0 24.82 58.44 0.57 2.00 612 40.14 10.33 4.82 1.67 750 69.73 7.22 12.56 
  85 5.33 0 25.78 35.00 0.87 3.11 863 45.29 14.78 3.88 2.78 1003 49.11 13.78 4.46 
  86 8.11 0 21.50 47.44 0.55 3.78 952 45.72 15.56 3.88 2.89 1065 85.59 8.56 15.10 
  87 3.89 0 19.05 40.00 0.53 2.33 850 57.89 6.56 13.69 1.78 534 91.45 4.44 34.38 
  88 6.33 0 11.71 37.44 0.38 2.33 444 24.40 12.11 2.49 2.11 639 45.90 9.11 6.56 
  89 7.67 0 20.76 101.22 0.22 3.11 0 42.85 31.56 1.51 2.67 0 90.32 9.33 13.56 
  90 5.78 0 22.90 30.33 0.93 3.33 416 24.92 16.50 1.89 2.00 889 72.76 11.00 8.08 
  91 10.33 0 13.17 52.11 0.32 4.17 0 28.38 42.17 0.75 2.89 659 45.33 14.33 3.96 
  92 7.89 0 26.04 60.22 0.50 3.00 491 27.66 15.33 2.24 2.33 930 82.79 9.33 11.83 
  93 4.50 566 24.66 19.50 1.64 2.67 1005 65.80 10.17 8.77 2.50 1042 113.89 7.00 25.31 
  94 9.50 0 44.41 89.00 0.56 3.00 0 77.68 17.67 5.30 2.33 0 104.02 11.00 12.00 
  95 7.33 0 24.05 35.67 0.85 3.00 897 50.66 13.50 4.82 2.67 878 89.63 8.33 15.84 
  96 6.56 383 15.15 24.67 0.84 3.00 872 57.05 14.33 5.04 2.33 895 92.29 9.11 13.61 
  97 4.78 488 19.79 18.67 1.42 3.00 991 101.84 7.33 23.52 3.33 1045 161.38 6.44 51.89 
  98 11.56 0 9.76 41.78 0.32 5.67 0 49.30 24.67 2.59 3.56 0 84.54 16.44 6.56 
   
 
“0” is an assignment when no ETP was obtained, as described in the text (Chapter 6, section 6.1.2) 
Page 179 of 197 
 
 
 
 
 
